,PageNo,Text
0,page_1,"['2017N330177 0', 'CONFIDENTIAL', 'GlaxoSmithKline group of companies', '205678', 'TITLE PAGE', 'Protocol Title: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the', 'Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in', 'Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are', 'Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed', 'an Anti-CD38 Antibody (DREAMM 2)', 'Protocol Number: 205678 Amendment 03', 'Short Title: Open-label, randomized study of two doses of GSK2857916 in participants', 'with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-', 'CD38 antibody', 'Compound Number: GSK2857916', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information: This information will be provided', 'in the Study Reference Manual (SRM).', 'Regulatory Agency Identifying Number(s): IND 119333, EudraCT number 2017-', '004810-25', 'Approval Date: 17-DEC-2018', 'Copyright 2018 The GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorized copying or use of this information is prohibited.', '1']"
1,page_2,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'SPONSOR SIGNATORY', 'Joanna Opalinska, MD', 'Date', 'Director, Clinical Development', '2']"
2,page_3,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 3-2017N330177_04', '17-DEC-2018', 'Amendment 2- (Republishing)- 2017N330177_03', '04-SEP-2018', '30-AUG-2018', 'Amendment 2- 2017N330177_02', 'Amendment 1 2017N330177_01', '02-APR-2018', 'Original Protocol-2017N330177_00', '18-Jan-2018', 'Amendment 3: 17-DEC-2018', 'Overall Rationale for the Amendment:', 'The protocol has been amended to address over-enrollment in the frozen liquid solution', 'portion of the study.', 'Due to the over-enrollment, the primary analysis will be based on all randomized', 'participants (anticipated ~200) enrolled into the frozen liquid solution arms. In addition, a', 'sensitivity analysis based on the first 130 participants will be performed to account for', 'the original design.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'All Sections', 'Removed references of precise number', 'To align with actual enrollment', 'of participants for enrollment', 'Section 2 Schedule of', 'Table 1, footnote 14 Correction of FISH', 'Typographical error', 'Activities', 'testing', 'To allow greater flexibility for', 'Table 2, Footnote 29 and Table 3', 'interview to occur', 'Footnote 19 window added for patient', 'interviews', 'Clarification of ocular assessment', 'Table 4, Footnote 5 clarified', 'timing', 'Section 4 Objectives', 'Addition of Investigator assessed ORR', 'The primary analysis for the', 'and Endpoints', 'as a secondary objective and endpoint.', 'endpoint ORR is based on IRC', 'Section 1 Protocol', 'Removed the specification that clinical', 'assessment. Therefore, a', 'Synopsis Objectives', 'benefit rate (CBR) will be performed by', 'secondary analysis for ORR', 'and Endpoints', 'IRC assessment', 'based on investigator', 'assessment is added and are', 'described in Section 10.5.1,', '3']"
3,page_4,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Efficacy Analyses', 'Section 5 Study', 'Figure 1 - Study 205678 Schematic', 'To account for possible', 'Design', 'revised to remove enrollment references', 'under/over enrollment.', 'Additional clarification that IA for futility', 'Clarification of ORR analysis at', 'is planned for ORR based on', 'IA and final analysis', ""investigator's assessment"", 'Clarification that lyophilized cohort will', 'be analyzed separately from participants', 'randomized to the frozen solution', 'Clarification that the final analysis of the', 'primary endpoint (ORR) will be', 'performed 6 months after the last', 'participant is randomized', 'Section 6.1 Inclusion', 'Changed e.g. to i.e. for the IMiD listed', 'The Latin abbreviation of e.g.', 'Criteria', 'under Inclusion criteria 4b', 'which translates to ""for example""', 'and is commonly confused with', 'Section 1 Protocol', 'the Latin abbreviation of i.e.', 'Synopsis Inclusion', 'which translates to ""in other', 'Criteria', 'words"". The intent was that', 'participants need to be refractory', ""to the IMiD's lenalidomide or"", 'Pomalidomide ONLY (not', 'thalidomide) and therefore the', 'correct abbreviation is ""i.e.""', 'Section 7 Treatments', 'Added Infusion Time', 'To address regulatory comments', 'Removed text to specify the lyophilized', 'cohort will be initiated when enrollment', 'has completed in the frozen arms', 'To more accurately reflect study', 'conduct', 'Section 9 Study', 'Table 14 Correction of FISH testing', 'Typographical error to align with', 'Assessments and', 'results', 'Section 7.3, method of treatment', 'Procedures', 'assignment', 'Section 9.11.3', 'Window added for patient interviews', 'Updated to align with Section 2,', 'Schedule of Activities', 'Qualitative Telephone', 'Interview (Patient', 'Interviews)', 'To reflect shortened enrolment', 'Section 10.1', 'Update the timing of final ORR analysis', '4']"
4,page_5,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name Description of Change', 'Brief Rationale', 'Hypothesis Testing', 'Clarification that lyophilized cohort will', 'period', 'be analyzed separately from participants', 'randomized to the frozen solution', 'Clarification of ORR analysis at', 'IA and final analysis', 'Section 10.2 Sample', 'Provide updated language on IA and', 'Size Determination', 'final analysis based on sample size of', 'To reflect actual enrollment onto', '100 participants per arm.', 'the frozen liquid solution arms of', 'the study', 'Section 10.3 Sample', 'Update Table 15 to include power', 'Size Sensitivity', 'scenarios for sample size of 100', 'To accommodate increase in', 'participants per arm.', 'sample size due to over', 'enrolment.', 'Section 10.4', 'Add a new analysis population', 'To evaluate the effect of over-', 'Populations for', '(Efficacy), which consist of the first 130', 'enrollment with respect to the', 'Analysis', 'randomized patients', 'original planned sample size for', 'primary and key secondary', 'endpoints.', 'Section 10.5.1', 'Clarifying the analysis population for', 'Efficacy Analyses', 'efficacy endpoints at Final analysis', 'To accommodate increase in', 'sample size due to over', 'enrolment.', 'Clarification that IA for futility is planned', ""for ORR based on investigator's"", 'assessment.', 'ORR based on IRC assessment', 'is planned for the final primary', 'analysis and the IA will be', 'performed based on investigator', 'assessment.', 'Section 10.5.9 Interim', 'Provide updated language on stopping', 'Analyses', 'rule/boundary crossing probability for IA', 'To accommodate increase in', 'and final analysis based on sample size', 'sample size due to over', 'of 100 participants per arm.', 'enrolment.', '5']"
5,page_6,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '3', '1. SYNOPSIS', '11', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '20', '3.', 'INTRODUCTION', '33', '3.1.', 'Study Rationale', '33', '3.2.', 'Background - BCMA and Multiple Myeloma', '34', '3.3.', 'Antibody-Drug Conjugate GSK2857916', '34', '3.4.', 'Human Experience with GSK2857916', '35', '3.4.1.', 'Thrombocytopenia', '36', '3.4.2.', 'Corneal Events', '36', '3.4.3.', 'Pharmacokinetics', '37', '3.4.4.', 'Clinical Activity', '37', '3.5.', 'Benefit / Risk Assessment', '38', '3.5.1.', 'Risk Assessment', '38', '3.5.2.', 'Benefit Assessment', '40', '3.5.3.', 'Overall Benefit-Risk Conclusions', '41', '4.', 'OBJECTIVES AND ENDPOINTS', '41', '5.', 'STUDY DESIGN', '43', '5.1.', 'Overall Design', '43', '5.2.', 'Number of Participants', '46', '5.3.', 'Participant and Study Completion', '47', '5.4.', 'Scientific Rationale for Study Design', '47', '5.5.', 'Dose Justification', '48', '6.', 'STUDY POPULATION', '51', '6.1.', 'Inclusion Criteria', '51', '6.2.', 'Exclusion Criteria', '54', '6.3.', 'Lifestyle Restrictions', '55', '6.4.', 'Screen Failures', '55', '7.', 'TREATMENTS', '56', '7.1.', 'GSK2857916 Treatments Administered', '56', '7.2.', 'Dose Modification', '57', '7.2.1.', 'Adjustments Due to Body Weight', '57', '7.2.2.', 'Dose Reductions for Toxicity', '57', '7.2.3.', 'Corneal Supportive Care Guidelines', '62', '7.3.', 'Method of Treatment Assignment', '62', '7.4.', 'Blinding', '63', '7.5.', 'reparation/Handling/Storage/Accountability', '63', '7.6.', 'Treatment Compliance', '64', '7.7.', 'Concomitant Therapy', '64', '7.7.1.', 'Permitted Medication(s)', '65', '7.7.2.', 'Prohibited Medication(s', '65', '7.7.3.', 'Prohibited Device(s)', '65', '6']"
6,page_7,"['2017N330177_04', 'CONFIDENTIAL', '205678', '7.8.', 'Treatment after the End of the Study', '66', '8.', 'DISCONTINUATION CRITERIA', '66', '8.1.', 'Discontinuation of Study Treatment', '66', '8.2.', 'Safety Stopping Criteria', '67', '8.2.1.', 'Liver Chemistry Stopping Criteria', '67', '8.2.2.', 'Study Treatment Restart or Rechallenge', '68', '8.2.3.', 'QTc Interval Stopping Criteria', '68', '8.2.4.', 'Left Ventricular Ejection Fraction (LVEF) Stopping Criteria', '69', '8.2.5.', 'Corneal Event Stopping Criteria', '69', '8.2.6.', 'Infusion-Related Reaction Management and Stopping', 'Criteria', '70', '8.2.7.', 'Allergic and Anaphylactic Reaction Stopping Criteria', '70', '8.3.', 'Withdrawal from the Study', '70', '8.4.', 'Lost to Follow Up', '70', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', '71', '9.1.', 'Efficacy Assessments', '74', '9.1.1.', 'Independent Review Committee', '76', '9.2.', 'Adverse Events', '76', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '76', '9.2.2.', 'Method of Detecting AEs and SAEs', '77', '9.2.3.', 'Follow-up of AEs and SAEs', '77', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '77', '9.2.5.', 'Cardiovascular and Death Events', '77', '9.2.6.', 'Disease-Related Events and/or Disease-Related', '78', '9.2.7.', 'Adverse Events of Special Interest', '78', '9.2.8.', 'Pregnancy', '78', '9.2.9.', 'Ocular Examinations and Procedures', '79', '9.2.10.', 'Ocular Sub-Study Examinations', '79', '9.2.10.1.', 'Monocular prophylaxis', '80', '9.2.10.2. Monocular treatment', '81', '9.2.10.3.', 'Sub-Study Exams', '81', '9.3.', 'Treatment of Overdose', '82', '9.4.', 'Safety Assessments', '82', '9.4.1.', 'Physical Examinations', '82', '9.4.2.', 'ECOG Performance Status', '82', '9.4.3.', 'Vital Signs', '82', '9.4.3.1.', 'First Infusion', '83', '9.4.3.2.', 'Subsequent Infusions', '83', '9.4.4.', 'Electrocardiogram', '83', '9.4.5.', 'Echocardiogram', '83', '9.4.6.', 'Laboratory Assessments', '83', '9.4.7.', 'Patient-Reported Outcome Version of the Common Term', 'Criteria for Adverse Events (PRO-CTCAE)', '84', '9.4.8.', 'Visual Function Questionnaires', '84', '9.4.8.1.', 'National Eye Institute Visual Function', 'Questionnaire-25', '85', '9.4.8.2.', 'The Ocular Surface Disease Index', '85', '9.5.', 'Pharmacokinetics', '85', '9.5.1.', 'Blood Sample Collection for Pharmacokinetics', '85', '7']"
7,page_8,"['2017N330177_04', 'CONFIDENTIAL', '205678', '9.5.2.', 'Pharmacokinetic Sample Analysis', '85', '9.6.', 'Immunogenicity', '86', '9.7.', 'Translational Research', '86', '9.8.', 'Genetics', '86', '9.9.', 'Tumor Biomarker Analysis', '86', '9.9.1.', 'sBCMA Sample Analysis', '86', '9.9.2.', 'Potential Tumor Related Biomarkers', '87', '9.10.', 'Evaluation of Anti-Cancer Activity', '87', '9.11.', 'Health-Related Quality-of-Life', '88', '9.11.1.', 'European Organization for Research and Treatment of', 'Cancer Quality of Life Questionnaire 30-item Core module', '(EORTC QLQ-C30)', '88', '9.11.2.', 'European Organization for Research and Treatment of', 'Cancer Quality of Life Questionnaire 20-item Multiple', 'Myeloma module (EORTC QLQ-MY20)', '88', '9.11.3. Qualitative Telephone Interviews (Patient Interviews)', '89', '10. STATISTICAL CONSIDERATIONS', '89', '10.1. Hypothesis Testing', '89', '10.2.', 'Sample Size Determination', '90', '10.3.', 'Sample Size Sensitivity', '90', '10.4.', 'Populations for Analysis', '91', '10.5.', 'Statistical Analyses', '91', '10.5.1.', 'Efficacy Analyses', '92', '10.5.2.', 'Safety Analyses', '94', '10.5.3.', 'Analyses of Health-Related Quality of Life Data', '95', '10.5.4.', 'Pharmacokinetic Analyses', '95', '10.5.4.1. Pharmacokinetic Data Analyses', '95', '10.5.4.2. Statistical Analysis of Pharmacokinetic Data', '96', '10.5.5.', 'Pharmacokinetic/Pharmacodynamic Analyses', '96', '10.5.6.', 'Translational Research Analyses', '96', '10.5.6.1. Analysis of Novel Biomarker Data', '96', '10.5.6.2.', 'Analysis of Genetic Data', '96', '10.5.6.3.', 'Exploratory Analyses of DNA and Protein Data', '96', '10.5.7.', 'Analyses of Immunogenicity Data', '97', '10.5.8.', 'Other Analyses', '97', '10.5.9.', 'Interim Analyses', '97', '10.5.9.1. Futility Stopping Rule Based on Group', 'Sequential Design', '97', '10.5.9.2.', 'Additional Comparative Futility Stopping Rule', 'Based on Bayesian Approach', '98', '11. REFERENCES', '100', '12. APPENDICES', '105', '12.1.', 'Appendix 1: Abbreviations and Trademarks', '105', '12.2.', 'Appendix 2: Clinical Laboratory Tests', '110', '12.3.', 'Appendix 3: Study Governance Considerations', '111', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '116', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', '122', '8']"
8,page_9,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', '12.6. Appendix 6: Genetics', '125', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments and Study Treatment Rechallenge Guidelines', '126', '12.7.1. Liver Safety Drug Restart or Re-Challenge Guidelines', '128', '12.7.1.1. Re-challenge Following Liver Stopping Events', 'that are Possibly Related to Study Treatment', '128', '12.7.1.2.', 'Re-challenge Following Transient Liver', 'Stopping Events Not Related to Study', 'Treatment', '130', '12.7.2. References', '131', '12.8. Appendix 8: ECOG Performance Status', '132', '12.9.', 'Appendix 9: GSK Corneal Event Severity Scale and Mitigation', 'Strategy for GSK2857916 Treatment-Related Corneal Events', '133', '12.10. Appendix 10: Modified Diet in Renal Disease (MDRD) Formula', '136', '12.11. Appendix 11: Protocol Amendment History', '137', '12.12. Appendix 12: Statistical Considerations for Section 10.5.9.2', 'Additional Comparative Futility Stopping Rule Based on Bayesian', 'Approach', '152', 'LIST OF TABLES', 'PAGE', 'Table 1', 'Schedule of Activities - Screening Assessments', '21', 'Table 2', 'Schedule of Activities - On Study Assessments', '23', 'Table 3', 'Schedule of Activities: End of Treatment (EOT) and Follow-Up', 'Assessments', '29', 'Table 4', 'Ocular Sub-Study Schedule of Activities (Selected Sites Only)', '32', 'Table 5', 'Risk Assessment and Mitigation Strategy', '38', 'Table 6', 'Objectives and Endpoints for Study 205678 - GSK2857916 in', 'RRMM Participants Previously Treated with an Anti-CD38', 'Antibody', '41', 'Table 7', 'Summary of Investigator-Assessed Best Response (with', 'Confirmation; Study BMA117159 Part 1)', '49', 'Table 8', 'Summary of Predicted Mean Response and Mean >Grade 2', 'Corneal Event* and 95% Credible Intervals (Parts 1 and 2, Study', 'BMA117159)', '51', 'Table 9', 'Criteria for Determining Adequate Organ System Function', '52', 'Table 10', 'Permitted Dose Reductions', '57', 'Table 11', 'Dose Modification Guidelines for GSK2857916-Related Adverse', 'Events', '59', '9']"
9,page_10,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 12', 'General Dose Modification and Management Guidelines for', 'Drug- related Adverse Events Not Otherwise Specifieda', '60', 'Table 13', 'Dose Modification Guidelines for GSK2857916 Treatment-', 'Related Corneal Events', '61', 'Table 14', 'List of Clinical Laboratory Tests', '73', 'Table 15', 'Statistical Power Scenarios', '91', 'Table 16', 'Analysis Populations Defined for the Study', '91', 'Table 17', 'Statistical Analysis Methods for Efficacy Endpoints', '92', 'Table 18', 'Statistical Analysis Methods for Safety Endpoints', '94', 'Table 19', 'Probabilities of Crossing Boundaries at the Interim or Final ORR', 'Analysis based on Group Sequential Design', '98', 'Table 20', 'Probabilities of Stopping for Futility at the Interim or Claiming', 'Efficacy at the Final ORR Analysis based on Both Futility Rules', '98', 'Table 21', 'Prophylactic Measures for Corneal Events Associated with', 'GSK2857916 a, b', '134', 'Table 22', 'GSK Scale for Corneal Events Associated with GSK2857916a', '134', 'Table 23', 'Guidance on GSK Scale Grading Based on Changes in Visual', 'Acuity', '135', 'Table 24', 'Posterior Probabilities of (Arm 1 Response Rate > Arm 2', 'Response Rate) at Interim Analyses', '153', 'Table 25', 'Scenarios of Simulation Studies to Evaluate Probabilities of', 'Stopping for Futility', '154', 'LIST OF FIGURES', 'PAGE', 'Figure 1', 'Study 205678 Schematic', '44', 'Figure 2', 'Fitted Dose-Response Plot for ORR and Grade 2 Corneal', 'Event Rate', '50', 'Figure 3', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'Algorithm', '68', 'Figure 4', 'Ocular prophylaxis schematic', '81', '10']"
10,page_11,"['2017N330177_04', 'CONFIDENTIAL', '205678', '1.', 'SYNOPSIS', 'Protocol Title: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the', 'Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in', 'Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are', 'Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed', 'an Anti-CD38 Antibody (DREAMM 2)', 'Short Title: Open-label, randomized study of two doses of GSK2857916 in participants', 'with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-', 'CD38 antibody.', 'Rationale: Multiple myeloma (MM) is an incurable malignancy and accounts for 1% of', 'all cancers and for 10% of all hematologic malignancies. Worldwide, approximately', '103,000 new cases are diagnosed annually, and an estimated 30,330 new cases and', '12,650 deaths will occur in the US in 2016. Despite significant advances in treatment', 'options, including hematopoietic stem cell transplant (HSCT), and novel therapies like', 'second- and third-generation proteasome inhibitors (PIs), immunomodulatory drugs', '(IMiDs), and recent addition of monoclonal antibodies (mAbs), most MM patients will', 'ultimately develop resistance to existing therapies and die of relapse.', 'One such novel therapy, daratumumab, is a human IgGk monoclonal antibody that was', 'granted first approval in the US in November 2015. Daratumumab binds with high', 'affinity to the CD38 molecule, which is highly expressed on the surface of MM cells. It', 'is believed to induce rapid tumor cell death through apoptosis, and multiple immune-', 'mediated mechanisms, including complement-dependent cytotoxicity, antibody-', 'dependent cellular phagocytosis and antibody-dependen cellular cytotoxicity.', 'Daratumumab is approved by the FDA for the treatment of MM in combination with', 'lenalidomide and dexamethasone, or bortezomib and dexamethasone in patients who', 'have received at least one prior therapy, in combination with pomalidomide and', 'dexamethasone in patients who have received at least two prior therapies including', 'lenalidomide and a proteasome inhibitor (PI), and as monotherapy for the treatment of', 'patients who have received at least three prior lines of therapy, including a PI and an', 'IMiD, or who are double-refractory to a PI and an IMiD.', 'In Europe, daratumumab is approved for the treatment of MM in combination with', 'lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of', 'patients who have received at least one prior therapy and as monotherapy for the', 'treatment of patients with relapsed and refractory MM, whose prior therapy included a PI', 'and an immunomodulatory agent and who have demonstrated disease progression on the', 'last therapy. Patients with MM who have proven refractory to daratumumab mono- and', 'combination therapy, have few treatment options available, and could benefit', 'significantly from treatment with a next-generation regimen, such as GSK2857916.', 'GSK2857916 is a humanized (IgG1) antibody-drug conjugate (ADC) which binds to', 'BCMA, a target widely expressed on malignant plasma cells in MM. The parent anti-', 'BCMA antibody is conjugated to the microtubule inhibitor, MMAF, which is released', '11']"
11,page_12,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'inside the malignant cell after binding and internalization of the antibody. The normal', 'function of BCMA is to promote cell survival by transduction of signals from two known', 'ligands: B-cell activating factor from the tumor necrosis factor (TNF) family', '(BAFF/BLyS), and APRIL, a proliferation-inducing ligand.', 'In addition, preclinical experiments indicate that GSK2857916 has the potential to induce', 'immunogenic cell death (ICD) in a BCMA-expressing multiple myeloma cell line.', 'Exposure of dendritic cells to tumor cells undergoing ICD induces an antigen-specific T', 'cell response, which may help to exert anti-tumor effects.', 'Preliminary clinical data from the ongoing BMA117159 study as of 26 June 2017 (n=35', 'participants treated at 3.4 mg/kg) has demonstrated an ORR of 60% [95% CI: 42.1%,', '76.1%], (complete response: 6%, very good partial response [VGPR 43%, partial', 'response [PR] 9%), with 51% of participants (N = 18/35) having deep responses of', 'VGPR or better, in heavily pretreated participants with relapsed/refractory multiple', 'myeloma (RRMM). The median duration of response (DoR) has not been achieved, the', '25th percentile for DoR is 6.7 months; the median PFS in this population was 7.9 months', '[95% CI: 3.1, NA]. The number of prior therapies ranged from 1-13 with 71% of', 'participants reporting greater than or equal to 4 prior therapies. For the 14 (40%)', 'participants who had received prior daratumumab, the ORR was 43%, (95% CI: 17.7%,', '71.1%; CR: 0, VGPR: 21%; PR: 14%).', 'In Study BMA117159, the maximum clinical benefit (ORR) was observed at the', '3.4 mg/kg dose level, but a significant number of participants required dose delays and', 'dose reductions to manage adverse events. In order to generate additional safety and', 'efficacy data at a lower dose while providing participants a chance of deriving clinical', 'benefit, the dose of 2.5 mg/kg has been selected for testing in an additional arm in this', 'study. The two-arm design with two dose levels and a futility analysis is justified for this', 'population because there is no approved comparator for the proposed treatment setting.', 'Objectives and Enppoints', 'Objectives', 'Enppoints', 'Primary Objective', 'To evaluate the clinical efficacy of 2', 'ORR, defined as the percentage of participants with a confirmed', 'doses of GSK2857916 in participants', 'partial response (PR) or better (i.e., PR, very good partial', 'with relapsed/refractory multiple', 'response [VGPR], complete response [CR] and stringent', 'myeloma.', 'complete response [sCR]), according to the 2016 International', 'Myeloma Working Group (IMWG) Response Criteria by', 'Independent Review Committee (IRC).', 'Secondary Objectives', 'To further evaluate the clinical', 'ORR, defined as the percentage of participants with a confirmed', 'measures of efficacy of GSK2857916', 'partial response (PR) or better, according to the 2016', 'in participants with RRMM', 'International Myeloma Working Group (IMWG) Response Criteria', 'by investigator assessment', 'Clinical benefit rate (CBR), defined as the percentage of', 'participants with a confirmed minimal response (MR) or better', 'according to the 2016 International Myeloma Working Group', '12']"
12,page_13,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Objectives', 'Enpoints', '(IMWG) Response Criteria', 'Duration of response (DoR), defined as: the time from first', 'documented evidence of PR or better until the earliest date of', 'documented disease progression (PD) per IMWG; or death due to', 'PD occurs among participants who achieve an overall response,', 'i.e., confirmed PR or better.', 'Time to response, defined as the time between the date of', 'randomization and the first documented evidence of response', '(PR or better).', 'Progression-free survival, defined as the time from randomization', 'until the earliest date of documented disease progression (PD)', 'per IMWG, or death due to any cause.', 'Time to progression, defined as the time from randomization until', 'the earliest date of documented PD per IMWG, or death due to', 'PD.', 'Overall survival, defined as the time from randomization until', 'death due to any cause.', 'To evaluate the safety of GSK2857916', 'The safety profile of GSK2857916 will be evaluated in participants', 'in participants with RRMM.', 'with RRMM as assessed through:', 'standard clinical and laboratory tests (hematology and chemistry,', 'physical examination, vital sign measurements, and diagnostic', 'tests)', 'through the collection of adverse events (AEs) and serious', 'adverse events (SAEs)', 'AEs of special interest', 'ocular findings on ophthalmic exam', 'To evaluate the pharmacokinetic profile', 'Plasma concentrations of GSK2857916 (ADC, total mAb, and', 'of GSK2857916', 'cys-mcMMAF)', 'Derived pharmacokinetic parameter values (e.g., AUC, Cmax,', 'tmax, t1/2), as data permit.', 'To assess anti-drug antibodies (ADAs)', 'Incidence and titers of ADAs against GSK2857916', 'against GSK2857916', 'Participant self-reported symptomatic', 'Symptomatic adverse effects and related impacts as measured', 'adverse effects by evaluation of', 'by the PRO-CTCAE, NEI-VFQ-25 and OSDI', 'tolerability of GSK2857916', 'To evaluate disease and treatment', 'Health-related quality-of-life as measured by the EORTC QLQ-', 'related symptoms and impact on', 'C30 and EORTC QLQ-MY20', 'function and health-related quality-of-', 'life', 'Exploratory Objectives', 'To explore the relationship between', 'Determine BCMA expression levels and other markers on', 'clinical response and other biologic', 'malignant cells, serum sBCMA levels, and evaluate the', 'characteristics including BCMA', 'relationship of these factors to clinical response', 'expression on tumor cells and sBCMA', 'concentrations', 'To investigate the relationship between', 'Possible relationship between host genetic variation and', '13']"
13,page_14,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Objectives', 'Enpoints', 'genetic variants in the host and', 'response to GSK2857916', 'response to GSK2857916', 'To evaluate disease and treatment', 'Qualitative telephone interview(s)', 'related symptoms and impact on', 'function and health-related quality-of-', 'life', 'To explore exposure-response', 'Explore relationships between GSK2857916 exposure (e.g.,', 'relationships between GSK2857916', 'dose, dose intensity, concentration, Cmax, or AUC) and clinical', 'exposure and clinical endpoints', 'endpoints (e.g., response, corneal event), if data permit', 'To assess Minimal Residual Disease', 'Minimal Residual Disease (MRD) negativity rate, defined as: the', '(MRD) in participants who achieve', 'percentage of participants who are MRD negative by Next', '>VGPR or better', 'Generation Sequencing (NGS).', 'To assess the safety, efficacy,', 'AEs, clinical and laboratory assessments; Descriptive analyses of', 'immunogenicity, and pharmacokinetics', 'ORR, duration of response, time to response, time to progression,', 'of GSK2857916 in a lyophilized', 'overall response; incidence and titers against GSK2857916;', 'configuration (n= Approximately 25', 'plasma concentrations of GSK2857916 (ADC, total mAb, and', 'participants)', 'cys-mcMMAF) and derived pharmacokinetic parameters, if data', 'permit', 'Ocular sub-study objective', 'To evaluate the effect of topical', 'Description of differences in corneal findings in each eye based', 'corticosteroids on corneal findings in', 'on ophthalmic examinations (participant-level).', 'approximately 30 participants who will', 'receive monocular topical', 'corticosteroids for the first 4 cycles', 'Abbreviations: IV = intravenous; Q3W: once every 3 weeks; RRMM = relapsed refractory multiple myeloma; BCMA =', 'B-cell maturation antigen; MMAF = monomethyl auristatin-F; MRD = minimal residual disease; NGS = Next Generation', 'Sequencing; ORR = overall response rate; CI = confidence interval; CR = complete response; VGPR = very good', 'partial response; PR = partial response; PFS = progression free survival; AUC = area under the curve; Cmax =', 'maximum concentration; tmax = time to maximum; t¹/² = half-life; PRO-CTCAE = Patient Reported Outcomes-Common', 'Terminology Criteria for Adverse Events; NEI-VFQ-25 = National Eye Institute Visual Functioning Questionnaire 25;', 'OSDI = Ocular Surface Disease Index; EORTC = European Organisation for Research and Treatment of Cancer;', 'QLQ-C30 = Quality of Life Questionnaire 30-item Core module; FLC = free light chain; SCT = stem cell transplant;', ""QLQ-MY20 = ; Quality of Life Questionnaire 20-item module for MM; QTcF = QT interval corrected by Fridericia's"", 'formula; HIV = human immune deficiency virus; RNA = ribose nucleic acid.', 'Overall Study Design: This is a Phase II, open-label, two-arm, randomized, multicenter', 'study to evaluate the efficacy and safety of GSK2857916 monotherapy at the dose levels', 'of 2.5 mg/kg and 3.4 mg/kg administered intravenously (IV), Q3W, in participants with', 'RRMM. Participants will be treated until disease progression or unacceptable toxicity.', 'The study consists of a screening/baseline period, a treatment period, and a post-', 'treatment follow-up period.', 'The design includes an independent cohort of approximately 25 additional participants', 'who will receive a lyophilized configuration of GSK2857916. Participants in the main', 'study will receive a frozen liquid solution of GSK2857916. Assessments will be', 'performed during Screening, prior to the first dose of Cycle 1, and during each cycle of', 'treatment as illustrated in the Schedule of Activities.', 'The study will include 1 interim analysis for futility. If one arm is discontinued as a', 'result of the interim analysis, participants will be offered the opportunity to receive', 'treatment at the dose that is continuing, or at the original dose upon re-consenting.', '14']"
14,page_15,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'As part of an ocular sub-study, approximately 30 participants (~15 per dose level) will', 'be evaluated to study the effect of ophthalmic topical corticosteroids on', 'GSK2857916-associated corneal findings and to further characterize these findings.', 'Number of Participants: The sample size calculation was performed using East 6.4', 'software as a starting point, based on the ORR comparison between the GSK2857916', 'arm and the historical control. Based on the simulation results with the planned sample', 'size of 65 participants there is 86.90% power to reject the null hypothesis within each', 'arm with a 1-sided type I error of 1.23%.', 'Approximately 170 participants were initially planned to be screened to enroll a', 'minimum of 155 participants at approximately 60 investigational sites globally. A', 'minimum of 130 participants (65/arm) were planned to be enrolled to 2 arms receiving', 'frozen liquid solution of GSK2857916, which includes ~30 participants from the ocular', 'sub-study. Approximately 200 participants will be enrolled onto the frozen liquid portion', 'of the study.', 'Approximately, twenty-five additional participants will be enrolled into the independent', 'lyophilized drug product cohort.', 'Treatment Groups and Duration: In this two-arm randomized study, GSK2857916 will', 'be administered at 2 dose levels (2.5 mg/kg or 3.4 mg/kg) to participants by IV infusion', 'on the Q3W schedule at the study site. The dose will be based on actual body weight', 'calculated at baseline and may be reduced to address toxicities according to protocol', 'guidelines.', 'GSK2857916 will be administered on Day 1 of each cycle. Premedication is not required', 'unless deemed medically necessary by the investigator, in which case it should be', 'administered according to institutional recommendations. If an infusion-related reaction', '(IRR) occurs during administration, the infusion rate may be reduced or halted at the', 'discretion of the investigator depending on the severity of the symptoms.', 'Participants will be treated until disease progression or until unacceptable toxicity.', 'Inclusion Criteria: Participants are eligible to be included in the study only if all the', 'following criteria apply:', '1. Provide signed written informed consent, which includes compliance with the', 'requirements and restrictions listed in the consent form', '2.', 'Male or female, 18 years or older (at the time consent is obtained)', '3.', 'Eastern Cooperative Oncology Group (ECOG) performance status of 0-2', '4. Histologically or cytologically confirmed diagnosis of MM as defined in IMWG,', '2014 criteria, and', 'a. Has undergone stem cell transplant or is considered transplant ineligible, and', 'b. Has failed at least 3 prior lines of anti-myeloma treatments, including an anti-', 'CD38 antibody (e.g., daratumumab) alone or in combination, and is refractory', '15']"
15,page_16,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'to an IMiD (i.e., lenalidomide or pomalidomide), and to a proteasome', 'inhibitor (e.g., bortezomib, ixazomib or carfilzomib).', 'Refractory myeloma is defined as disease that is nonresponsive while on', 'primary or salvage therapy, or progresses within 60 days of last therapy.', 'Nonresponsive disease is defined as either failure to achieve at least minimal', 'response or development of progressive disease (PD) while on therapy.', '5.', 'Has measurable disease with at least one of the following:', 'a.', 'Serum M-protein >0.5 g/dL (>5 g/L)', 'b. Urine M-protein >200 mg/24h', 'c. Serum FLC assay: Involved FLC level >10 mg/dL (100 mg/L) and an', 'abnormal serum free light chain ratio (<0.26 or >1.65)', '6. Participants with a history of autologous stem cell transplant are eligible for study', 'participation provided the following eligibility criteria are met:', 'a.', 'transplant was > >100 days prior to study enrolment', 'b. no active infection(s)', 'c. participant meets the remainder of the eligibility criteria outlined in this', 'protocol', '7.', 'Adequate organ system function.', '8.', 'Female Participants: Contraceptive use by men or women should be consistent with', 'local regulations regarding the methods of contraception for those participating in', 'clinical studies.', 'A female participant is eligible to participate if she is not pregnant or breastfeeding,', 'and at least one of the following conditions applies:', 'Is not a woman of childbearing potential (WOCBP)', 'OR', 'Is a WOCBP and using a contraceptive method that is highly effective (with a', 'failure rate of <1% per year), preferably with low user dependency, during the', 'intervention period and for at least 80 days after the last dose of study', 'intervention and agrees not to donate eggs (ova, oocytes) for the purpose of', 'reproduction during this period. The investigator should evaluate the', 'effectiveness of the contraceptive method in relationship to the first dose of', 'study intervention.', 'A WOCBP must have a negative highly sensitive serum pregnancy test (as', 'required by local regulations) within 72 hours before the first dose of study', 'intervention.', 'The investigator is responsible for review of medical history, menstrual history,', 'and recent sexual activity to decrease the risk for inclusion of a woman with an', 'early undetected pregnancy.', '16']"
16,page_17,"['2017N330177_04', 'CONFIDENTIAL', '205678', '9. Male Participants: Contraceptive use by men or women should be consistent with', 'local regulations regarding the methods of contraception for those participating in', 'clinical studies.', 'Male participants are eligible to participate if they agree to the following during the', 'intervention period and for at least 140 days:', 'Refrain from donating sperm', 'PLUS either:', 'Be abstinent from heterosexual intercourse as their preferred and usual lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent.', 'OR', 'Must agree to use contraception/barrier as detailed below:', 'Agree to use a male condom and female partner to use an additional highly', 'effective contraceptive method with a failure rate of <1% per year as when', 'having sexual intercourse with a woman of childbearing potential who is not', 'currently pregnant.', '10. All prior treatment-related toxicities (defined by National Cancer Institute- Common', 'Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.03 must be <Grade', '1', 'at the time of enrolment except for alopecia and Grade 2 peripheral neuropathy.', '11. In France, a participant will be eligible for inclusion in this study only if either', 'affiliated to or a beneficiary of a social security category.', 'Exclusion Criteria: Participants satisfying any of these criteria are not eligible for', 'assignment to treatment:', '1. Systemic anti-myeloma therapy within <14 days or 5 half-lives, whichever is shorter,', 'or plasmapheresis within 7 days prior to the first dose of study drug', '2. Systemic treatment with high dose steroids (equivalent to >60 mg prednisone daily', 'for >4 days) within the past 14 days if administered to treat MM or non- MM disease', '3.', 'Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy,', 'organomegaly, endocrinopathy, myeloma protein, and skin changes), active plasma', 'cell leukemia at the time of screening.', '4.', 'Prior allogeneic stem cell transplant (SCT)', '5.', 'Current corneal epithelial disease except mild punctate keratopathy', '6.', 'Use of an investigational drug within 14 days or five half-lives, whichever is shorter,', 'preceding the first dose of study drug. Prior treatment with a monoclonal antibody', 'within 30 days of receiving the first dose of study drugs. Prior BCMA targeted', 'therapy.', '7.', 'Evidence of active mucosal or internal bleeding', '17']"
17,page_18,"['2017N330177_04', 'CONFIDENTIAL', '205678', '8.', 'Any major surgery within the last four weeks', '9.', 'Presence of active renal condition (infection, requirement for dialysis or any other', ""condition that could affect participant's safety). Participants with isolated"", 'proteinuria resulting from MM are eligible, provided they fulfil entry criteria.', '10. Any serious and/or unstable pre-existing medical, psychiatric disorder or other', ""conditions (including lab abnormalities) that could interfere with participant's safety,"", 'obtaining informed consent or compliance to the study procedures.', '11. Current unstable liver or biliary disease per investigator assessment defined by the', 'presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or', 'gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease', ""(including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary"", 'involvement of malignancy is acceptable if participant otherwise meets entry criteria.', '12. Malignancies other than disease under study are excluded, except for any other', 'malignancy from which the participant has been disease-free for more than 2 years', 'and, in the opinion of the principal investigators and GSK Medical Monitor, will not', 'affect the evaluation of the effects of this clinical trial treatment on the currently', 'targeted malignancy (MM). Participants with curatively treated non-melanoma skin', 'cancer may be enrolled.', '13. Evidence of cardiovascular risk including any of the following:', 'a.', 'QTcF interval QTcF > 480 msec (the QT interval values must be corrected', ""for heart rate by Fridericia's formula [QTcF])"", 'b.', 'Evidence of current clinically significant uncontrolled arrhythmias, including', 'clinically significant ECG abnormalities such as 2nd degree (Type II) or 3rd', 'degree atrioventricular (AV) block.', 'c.', 'History of myocardial infarction, acute coronary syndromes (including', 'unstable angina), coronary angioplasty, or stenting or bypass grafting within', 'six months of Screening.', 'd. Class III or IV heart failure as defined by the New York Heart Association', 'functional classification system', 'e.', 'Uncontrolled hypertension', '14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs', 'chemically related to GSK2857916, or any of the components of the study treatment.', '15. Pregnant or lactating female.', '16. Active infection requiring antibiotic, antiviral, or antifungal treatment.', '17. Known HIV infection.', '18. Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody', '(HBcAb at screening or within 3 months prior to first dose of study treatment)', '19. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at', 'screening or within 3 months prior to first dose of study treatment.', 'Note: Participants with positive Hepatitis C antibody due to prior resolved disease', 'can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.', '18']"
18,page_19,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C', 'antibody test are not required to also undergo Hepatitis C RNA testing.', '19']"
19,page_20,"['2017N330177_04', 'CONFIDENTIAL', '205678', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', 'All assessments planned for participants in Study 205678 are shown in Table 1', '(Screening), Table 2 (On Study Assessments), and Table 3 (End of Treatment and Follow', 'Up Assessments).', 'Assessments for participants in the ocular sub-study are shown in Table 4. Participants', 'who are enrolled into the lyophilized configuration cohort of GSK2857916 (Figure 1)', 'will follow the same assessments and procedures as the main study.', 'The details of these assessments are provided in footnotes to the table, with more details', 'provided in Section 9.', '20']"
20,page_21,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 1', 'Schedule of Activities - Screening Assessments', 'Study Assessments¹', 'Screen¹', 'Notes', 'Informed Consent', '1.', 'All Screening assessments must be performed within 21 days prior to first dose unless otherwise specified. Informed Consent', 'Baseline Demographics', 'must be signed before any study-specific assessments are performed. Screening Assessment do not need to be repeated on Day', 'Medical History including', '1 of Cycle 1 (C1D1) unless otherwise specified.', 'disease history and', 'characteristics', '2.', 'All related SAEs are to be collected from consent through os follow-up', 'Physical Exam', '3.', 'Screening examination to be performed within 21 days prior to first dose. See Section 9.2.9 for the list of screening ophthalmic', 'Concomitant Medications', 'exam procedures.', 'Adverse Events 2', 'Safety', '4. Refer to Table 14 for a comprehensive list of clinical laboratory tests that must be collected for all participants. If labs are', 'Ocular Exam³', 'completed within 72 hours prior to the first dose, this assessment need not be repeated on C1D1', 'ECOG Performance Status', '5. Albumin/Creatinine ratios (spot urine from first void) at screening, C1, and every other cycle thereafter (C3, C5, C7) (local labs or', 'Vital Signs (BP, HR, Body', 'central if local not available)', 'Temperature)', 'Weight and Height', '6. Hepatitis: If the participant is hepatitis C virus (HCV) positive by serology, an additional Hep C RNA testing may be done to', 'Hematology4', 'determine participant eligibility (if Hep C RNA is negative, participant is eligible).', 'Clinical chemistry4', '7.', 'Troponin I will be measured at the local lab, or by central laboratory if not available locally. If cardiac workup is required due to', 'Urine Dipstick4', 'safety concerns during the study, troponin I should be measured as clinically indicated.', 'eGFR (by MDRD formula- see', 'X', '8.', 'Appendix 10)', 'B-type natriuretic peptide (BNP) to be measured locally, or by a central laboratory if not available locally, at screening; if cardiac', 'Spot Urine (albumin/creatinine', 'workup is required due to safety concerns during the study, BNP should be measured as clinically indicated.', 'ratio)4 5', '9.', 'Perform only in women of child-bearing potential. A serum pregnancy test must be performed', 'CRP', 'at screening, and subsequent pregnancy tests may be either serum or urine. If test is completed within 72 hours prior to the first', 'HBsAg, HBcAb, and hepatitis C', 'dose, this assessment need not be repeated on Day 1 of Cycle 1. For questionable cases of whether a participant is of non-child', 'Ab. 6', 'bearing potential, obtain follicle stimulating hormone (FSH) and estradiol. See Section 6.1, Section 9.2.8, and Appendix 5 for', 'more details.', 'Troponin 17', '10. Echocardiography for LVEF performed within 35 days prior to first dose is acceptable as screening value.', 'BNP8', 'X', '11. Skeletal Survey: Imaging of bones for lytic lesions by a method aligned with the institutional guidance (ex: X-ray, CT, or MRI).', 'Skeletal survey results within 30 days prior to C1D1 are acceptable. For sites in Germany: Only MRI is allowed to be used as', 'Pregnancy Test 9', 'X', 'imaging modality for participants.', 'ECHO10', 'X', '12. Imaging is only required for participants with extramedullary disease (CT, MRI, or PET/CT can be applied per local guidance).', '12-lead ECG', 'Screening assessment may be performed up to 30 days prior to C1D1. The same modality should be used throughout the study', '21']"
21,page_22,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Study Assessments¹', 'Screen¹', 'Notes', 'Disease Evaluation', '(i.e., if CT scan was used as baseline, participant needs to be followed by CT scans). Plasmacytoma measurements should be', 'Beta2 microglobulin', 'taken from the CT portion of the PET/CT, or MRI scans, or dedicated CT scans where applicable. For participants with skin only', 'Skeletal survey11', 'involvement, skin lesions should be measured with a ruler. Measurement of tumor size will be determined by the Sum of the', 'Imaging for Extramedullary', 'Products of the maximal perpendicular diameters of measured lesions (SPD). Imaging will be collected for independent review.', 'X', 'disease12', 'For sites in Germany: Only MRI is allowed to be used as imaging modality for participants with extramedullary disease.', 'UPEP (Urine Protein', '13. Only required for participants with IgD/E myeloma, where serum m-component cannot be followed otherwise.', 'Electrophoresis) 24 hr. urine', 'X', 'collection', '14. FISH testing at least for: t (4;14), t (14;16), and 17p13del. FISH results from samples taken within 60 days prior to first dose are', 'Urine immunofixation', 'X', 'acceptable. If testing cannot be performed at a local lab, a bone marrow aspirate can be sent to central lab for analysis. If the', 'SPEP (Serum Protein', 'patient is known to have high risk disease from previous FISH tests regardless of timing (i.e.: t(4;14), or t(14;16) they should be', 'Electrophoresis)', 'stratified as High Risk for the purpose of enrollment.', 'Serum Immunofixation', '15. Minimal residual disease (MRD) to be performed by the central lab at screening, at the time of first achieving VGPR or CR,', 'repeat', 'Serum Kappa, Lambda free', 'MRD testing 6 mo and 12 mo after achieving VGPR or CR (provided VGPR/CR is maintained).', 'Light chain, FLC ratio', 'Calcium corrected for albumin', '16. Bone Marrow (aspirate preferred) for disease assessment performed within the screening period prior to first dose is acceptable.', '(serum)', 'lgG, IgM, IgA', 'X', 'lgD/E13', 'X', 'Bone Marrow (BM) Aspiration/Biopsy', 'BM for FISH 14', 'BM aspirate for BCMA IHC', 'assessment', 'BM for MRD testing15', 'X', 'BM for disease assessment16', 'Health Outcomes', 'PRO-CTCAE', 'NEI-VFQ-25', 'OSDI', 'X', 'BM = bone marrow; BNP = B-type natriuretic peptide; BP = blood pressure; C1D1 = Cycle 1 Day 1, etc. CRP = C-reactive protein; FISH = fluorescence in situ hybridization; FLC = free', 'light chain; HR= heart rate; lg = immunoglobulin; NEI-VFQ-25 = National Eye Institute Visual Functioning Questionnaire 25; OSDI = Ocular Surface Disease Index; PRO-CTCAE =', 'Patient Reported Outcome version of the Common Term Criteria for Adverse Events; PD = Progressive Disease; SPEP = serum protein electrophoresis; UPEP = urine protein', 'electrophoresis.', '22']"
22,page_23,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 2', 'Schedule of Activities - On Study Assessments', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Wk 42 to be', 'Cycle 2-', 'Cycle 1,', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 1¹', '3 Day', '3, Day', 'performed', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'Physical Exam', 'X', 'X', '(Important: Every participant will complete Cycle 1 Day 1 on study assessments. Then, they', ""will complete 'Q3W' assessments starting at week 4' AND the 'Cycle 2-CX with dosing'"", 'Adverse Events3', 'Ongoing', 'Ongoing', 'Ongoing', 'assessments during the treatment phase). If dosing is not completed only perform the', 'Concomitant', 'Medications', 'Ongoing', 'Ongoing', 'Ongoing', '""Q3W starting at Week 4"" assessments at the scheduled visit.', 'Safety', '1. Assessments scheduled on days of dosing must be done prior to drug administration, unless', 'Ocular Exam4', 'X', 'otherwise specified. All other assessments can be done +3 days unless otherwise specified.', 'ECOG Performance', 'X', '2.', 'GSK2857916 will be administered intravenously on Day 1 (D1) of every 21-day cycle (Q3W)', 'Status', 'until disease progression, unacceptable toxicity, death or withdrawal of consent.', 'Vital Signs (BP, HR,', 'Body', 'X', 'X', '3.', 'All related SAEs are to be collected from consent through os follow-up', 'Temperature)5,', '4.', 'On-study ophthalmic exams to be performed by an ophthalmologist (or an optometrist if an', 'Weight', 'Weight', 'Weight5', 'ophthalmologist is not available) predose every 3 weeks. See Section 9.2.9 for the list of', 'Only', 'Only', 'ophthalmic exam procedures. If there are no corneal signs per the GSK Scale for corneal', 'Hematology7', 'X', 'X', 'events at time of the cycle 4 exam, participants may have their ophthalmologic exams', 'Clinical chemistry7', 'X', 'X', 'decreased to once every 3 months. If a participant subsequently develops ocular symptoms,', 'the participant should be evaluated by an ophthalmologist (an optometrist if an ophthalmologist', 'Urine Dipstick 7', 'X', 'X', 'is', 'not available). Intraocular pressure must be monitored if steroid eye drops are used', 'eGFR (by MDRD', 'continuously for more than 7 days. Additional exams may be performed by the', 'formula- see', 'X', 'X', 'ophthalmologist (an optometrist if an ophthalmologist is not available), as clinically indicated. At', 'Appendix 10)', 'selected sites, participants will undergo additional ophthalmic exams. If you are a selected site,', 'Spot urine for', 'see Section 9.2.9 for full list of ocular sub-study exam procedures.', 'albumin/creatinine', 'X', 'X', 'ratio5, 7,8', '5.', ""If a participant's GSK2857916 dose is not administered at a given visit, the following activities"", 'CRP', 'X', 'do not need to be performed at that visit unless clinically indicated: Vitals, weight, spot urine,', 'Pregnancy Test 5, 9', 'X', 'pregnancy test, ECG, PK sample, ADA sample, and soluble BCMA sample.', 'ECHO', 'As clinically', '6.', 'On initial (first infusion) dosing day, vital signs must be assessed at pre-dose (within 30', 'indicated', 'minutes prior to start of infusion(SOI)) +10 minutes after SOI, within +5 minutes of end of', '12-lead ECG 5,10', 'X', 'X', 'X', '23']"
23,page_24,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Cycle 1,', 'Wk 4² (to be', 'Cycle 2-', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 11', '3 Day', 'performed', '3, Day', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'Pharmacokinetics', 'X11', 'X12', 'X13', 'X14', 'infusion (EOI), and 1-hour (+5 minutes) post EOI. On subsequent dosing days, vital signs', 'PK5,', 'must be assessed at pre-dose (within 30 minutes prior to SOI), within +5 minutes of EOI. On', 'Anti-drug', 'days where vital sign time points align with PK sampling time points, vital signs must be', 'X', 'X', 'antibodies5, 15', 'assessed prior to PK samples being drawn. On days where vital signs are measured multiple', 'Disease Evaluation', 'times, temperature does not need to be repeated unless clinically indicated.', 'Response', 'X', '7.', 'Refer to Table 14 for a comprehensive list of lab tests that must be collected for all', 'assessment16', 'participants. If labs are completed within 72 hours prior to the first dose, this assessment need', 'Skeletal Survey 17', 'As clinically', 'not be repeated on C1D1.', 'indicated', 'Week 13, 25,', '8.', 'Albumin / creatinine ratios (spot urine from first void) at, C1, and every other cycle thereafter', '37, 49, and', '(C3, C5, C7, etc.) (use local labs; use central labs if local not available)', 'then every', '9.', 'Perform only in women of child-bearing potential. A serum pregnancy test must be performed', '12 weeks', 'at screening, and subsequent pregnancy tests may be either serum or urine. If test is', 'Imaging for', 'within the', 'completed within 72 hours prior to the first dose, this assessment need not be repeated on', 'Extramedullary', 'first 12', 'C1D1. For questionable cases of whether a participant is of non-child bearing potential, obtain', 'disease¹ 18', 'months;', 'follicle stimulating hormone (FSH) and estradiol. See Section 6.1, Section 9.2.8, and', 'thereafter', 'Appendix 5 for more details.', 'only if', 'clinically', '10. ECGs on dosing days: Triplicate ECGs to be performed at predose (within 30 minutes prior to', 'indicated', 'SOI) and EOI (within 5 minutes prior to EOI) at cycles 1, 2, 3, 6, 9 and 12. Additional triplicate', 'PET/CT upon', 'ECGS to be performed at 24 h + 2h after SOI on Day 1 of Cycle 1 and Cycle 3 and on Day 4', 'Once after', 'achieving CR or', 'CR or sCR', '(+1 day) and on any day from Day 8 to Day 15 in Cycle 1 and Cycle 3. Single ECGs predose', 'sCR19', 'at all other cycles.', 'UPEP (Urine', 'ECG recordings should be made after at least 10 minutes rest and collected 2 minutes apart.', 'Protein', 'X', 'On days where ECG time points align with PK sampling time points, ECGs must be performed', 'Electrophoresis) 24', 'prior to PK samples being drawn. ECGs on Day 4 and Day 8-15 in Cycle 1 and Cycle 3 should', 'hr. urine collection', '24']"
24,page_25,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Cycle 1,', 'Wk 4² (to be', 'Cycle 2-', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 11', '3 Day', 'performed', '3, Day', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'By central', 'be collected at a similar time of day as the SOI on Cycle 1 Day 1 (+2 h). ECGs will be collected', 'lab if UPEP', 'and stored centrally and may be reviewed by an independent central reviewer. See SRM for', 'is negative,', 'details on collection regarding ECGs.', 'at the time of', 'first', '11. PK samples to be taken in all participants for GSK2857916 measurement during Cycle 1, Day', 'Urine', 'achieving CR', '1 and Cycle 3, Day 1 at the following study times: predose (within 30 minutes prior to SOI), at', 'Immunofixation', 'then perform', 'EOI (+5 min), at 2 h (+15 min) after SOI, and at 24 h (2 hrs) after SOI.', 'every 3', '12. PK samples to be taken for GSK2857916 measurement C1D4 and C3D4 (+1 day): one', 'weeks until', 'sample after ECG collection.', 'suspected', 'PD after CR', '13. One PK sample to be taken for GSK2857916 measurement in Cycle 1 and Cycle 3 after ECG', 'or sCR.', 'collection on any day from Day 8 to Day 15. If dosing is delayed at Cycle 2 or Cycle 4, a PK', 'SPEP (Serum', 'sample should be drawn 21 days post dose (Day 22 +2 days) in Cycle 1 and Cycle 3.', 'Protein', 'X', '14. PK samples to be taken on Cycle 3, Day 1 at the following study times: predose (within 30', 'Electrophoresis)', 'minutes prior to SOI), at EOI (+5 min), at 2 h (+15 min) after SOI, and at 24 h (2 hrs) after', 'By central', 'SOI. At C2, C4, C6, C9, and C12, PK samples to be taken at predose (within 30 minutes prior', 'lab if SPEP', 'to SOI) and at EOI (+5 min). Every 6 subsequent cycles (e.g., C18, C24, etc.) at predose', 'is negative at', '(within 30 minutes prior to SOI).', 'the time of', 'first', '15. Anti-drug antibodies should be collected prior to the dose at C2, C6, C9, C12, and every 6', 'Serum', 'achieving CR', 'cycles thereafter (C18, C24, etc.) until end of treatment (dosing days only) with the PK sample', 'Immunofixation', 'then perform', '16. Response assessment must be conducted every 3 weeks based on disease laboratory tests', 'every 3', 'and imaging (if applicable) as outlined in this table. Response evaluation will be performed', 'weeks until', 'according to the IMWG (Uniform Response Criteria for Multiple Myeloma 2016). Central', 'suspected', 'laboratory results for all disease response assessments will be shared with the Independent', 'PD after CR', 'Review Committee (IRC)', 'or sCR.', 'Serum Kappa,', '17. Only if clinically indicated or if worsening clinical symptoms suggest skeletal PD.', 'Lambda free Light', 'X', '18. Imaging is only required for participants with extramedullary disease (CT, MRI, or PET/CT can', 'chain, FLC ratio', '25']"
25,page_26,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Cycle 1,', 'Wk 42 (to be', 'Cycle 2-', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 11', '3 Day', 'performed', '3, Day', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'Calcium corrected', 'X', 'be applied per local guidance). The same modality should be used throughout the study (i.e.,', 'for albumin (serum)', 'if CT scan was used as baseline, participant needs to be followed by CT scans).', 'lgG, IgM, IgA', 'X', 'Plasmacytoma measurements should be taken from the CT portion of the PET/CT, or MRI', 'lgD/E20', 'X', 'scans, or dedicated CT scans where applicable. For participants with skin only involvement,', 'Bone Marrow (BM) Aspiration/Biopsy', 'skin lesions should be measured with a ruler. Measurement of tumor size will be determined', 'BM for MRD', 'by the Sum of the Products of the maximal perpendicular diameters of measured lesions', 'X', 'testing21', '(SPD). Imaging will be collected for independent review. For sites in Germany: Only MRI is', 'At the time of', 'allowed to be used as imaging modality for participants with extramedullary disease.', 'CR (always)', '19. Germany: no PET/CT to confirm CR or sCR will be performed until approval by the German', 'BM for disease', 'or at time of', 'Federal Office for Radiation Protection until further notice.', 'assessment', 'suspected', '(aspirate, preferred)', 'PD (only if', '20. Only required for participants with lgD/E myeloma, where serum m-component cannot be', 'not evident', 'followed otherwise', 'otherwise)', '21. Minimal residual disease (MRD) to be performed by the central lab at the time of first achieving', 'Only if CR', 'Bone marrow biopsy', 'VGPR or CR, repeat MRD testing 6 mo and 12 mo after achieving VGPR or CR (provided', 'have been', 'to assess sCR by', 'VGPR/CR is maintained).', 'achieved on', 'IHC22', 'this visit', '22. In participants achieving a CR, bone marrow biopsy to confirm sCR by IHC.', 'Biomarker', '23. sBCMA samples to be taken in all participants for GSK2857916 measurement during Cycle 1,', 'Soluble BCMA', 'X', 'X', 'X', 'X', 'Day 1 and Cycle 3, Day 1 at the following study times: predose (within 30 minutes prior to', '(serum)5, 23', 'SOI), at EOI (+5 min), at 2 h (+15 min) after SOI, and at 24 h (2 hrs) after SOI, on Cycle 1', 'cfDNA (plasma)', 'X', 'Day 4 (+1 days) and one sample at any time between Cycle 1 Day 8 & Day 15, with the PK', 'Optional', 'samples. Pre-infusion sBCMA samples are collected prior to GSK2857916 infusion during', 'Optional tissue', 'each of the first 18 cycles: after which, sBCMA sample should be collected every 3 cycles, i.e.', 'sample at PD for', 'X', 'pre-infusion C18D1, C21D1, C24D1, etc.', 'BCMA24', 'Genetics sample', '24. Upon PD- Optional tumor sample (BM aspirate clot, or fresh tissue, or tissue block from', '(optional)', 'extramedullary tumor) for BCMA expression analysis by IHC. To be submitted to central lab for', 'X', 'analysis.', '26']"
26,page_27,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Cycle 1,', 'Wk 42 (to be', 'Cycle 2-', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 11', '3 Day', 'performed', '3, Day', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'Treatment', 'Premedication if', '25. GSK2857916 administration: Study drug administration +3-day window. In case a dose is', 'X', 'X', 'needed', 'delayed, the participant should wait for the next scheduled dose to resume treatment. Please', 'refer to Section 7.2.2', 'GSK2857916', 'X', 'X', 'administration25', '26. Corneal management information:', 'Steroid eye drops26', 'X', 'a) Steroid eye drops administered as prophylaxis (such as: prednisolone acetate 1.0%,', 'Preservative-free', 'prednisolone phosphate 1%, dexamethasone 0.1% or equivalent) 1 drop QID starting 1 day', 'X', 'X', 'artificial tears 26', 'prior to each GSK2857916 infusion, and continuing for a total of 7 consecutive days. If dosing', 'Health Outcomes', 'delayed for a non-corneal event, the prophylactic drops can be stopped.', 'PRO-CTCAE', 'X', 'b) Prophylactic preservative-free artificial tears must be administered in each eye at least 4-8', 'NEI-VFQ-2527', 'X', 'X', 'times daily beginning on Cycle 1 Day 1 until end of treatment.', 'OSDI27', 'X', 'X', 'c) At the start of each infusion, participants may apply cooling eye masks to their eyes for', 'EORTC QLQ-C3028', 'X', 'every 6', 'approximately 1 hour or as long as tolerated.', 'weeks', 'd) Selected sites will participate in an ocular sub-study.', 'EORTC QLQ-', 'X', 'every 6', '27. NEI-VFQ-25 and OSDI will be administered every 3 weeks even if dose is delayed. Additional', 'MY2028', 'weeks', 'assessments may be conducted for those participants who are experience a worsening in', 'Patient Interview', 'X', 'visual function. Participants who discontinue participation in the study will continue to be', '(PRO) 29', '(within 21', 'assessed during follow-up until resolution of visual symptoms. Continue to follow up with', 'days after', 'participants via telephone who are still experiencing visual symptoms even after', 'C4 Day', 'discontinuation', '1)', '28. EORTC- QLQ-C30 and EORTC QLQ-MY20 should start at week 7 and continue every 6', 'weeks.', '29. Patient Interview (PRO) must be conducted via telephone within 21 days (+7 days) following', 'Day 1 of the fourth treatment cycle (C4D1). The second patient Interview must be completed', 'within 21 days (+7 days) of the participants end of treatment visit, unless the participant has', 'already completed their interview following C4D1 within the prior 30 days', '27']"
27,page_28,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'ADA = Anti-drug Antibody; ALP = alkaline phosphatase BM = bone marrow; BP = blood pressure; C1D1 = Cycle 1 Day 1, etc.; cfDNA = Circulating free DNA; CK = creatine kinase;', 'CRP = C-reactive protein; EM = extramedullary; EOI = End of Infusion; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life', 'Questionnaire 30-item Core module; EORTC QLQ-MY20 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 20-item Multiple Myeloma', 'module; FISH = fluorescence in situ hybridization; FLC = free light chain; ; HR= heart rate; Ig = immunoglobulin; NEI-VFQ-25 = National Eye Institute Visual Functioning Questionnaire', '25; OSDI = Ocular Surface Disease Index; PRO-CTCAE = Patient Reported Outcome version of the Common Term Criteria for Adverse Events; PD = Progressive Disease PK =', 'Pharmacokinetics; QID = 4 times a day; SOI = start of infusion; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis.', '28']"
28,page_29,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 3', 'Schedule of Activities: End of Treatment (EOT) and Follow-Up Assessments', 'os', 'PFS', 'Study Assessments', 'EOT Visit¹', 'Follow-', 'Notes', 'Follow-up²', 'Up³', 'Physical Exam', 'X', 'X', '1.', 'The EOT visit is to assess any residual AEs or toxicities associated with', 'Safety', 'treatment. The visit should occur within 45 days after last dose or before', 'Related', 'the start of any new anti-cancer therapy.', 'Related', 'Adverse Events4', 'X', 'SAEs', 'SAEs only', '2.', 'PFS follow-up every 21 days (+7 days) for participants who discontinue', 'only', 'IP for a reason other than PD. Disease evaluations will continue until', 'Concomitant', 'X', 'X', 'confirmed PD, death, start of a new anticancer treatment, withdrawal of', 'Medications', 'consent, or end of the study whichever occurs first.', 'Ocular Exam', 'X5', 'X6', 'X6', 'ECOG Performance', '3.', 'Survival follow-up every 3 months (+14-day window): After PD is', 'X', 'Status', 'documented, participants will be followed for survival and subsequent', 'Vital Signs (BP, HR,', 'anticancer therapy by chart review, phone call, or any form of', 'X', 'Body Temperature)', ""communication every 3 months. Record participant's survival status and"", 'Weight and Height', 'Weight only', 'whether subsequent treatment for disease was given. Participant does', 'Hematology7', 'X', 'not need to come in for visit unless they are being followed for corneal', 'Clinical chemistry7', 'X', 'signs that are present at the end of study treatment.', 'Urine Dipstick', 'X', '4.', 'All related SAEs are to be collected from consent through os follow-up.', 'eGFR (by MDRD', '5.', 'formula- see Appendix', 'X', 'End of treatment ophthalmic exam to be performed by an ophthalmologist', '10)', '(or an optometrist if an ophthalmologist is not available). See Section', 'Spot urine for', '9.2.9 for the list of ophthalmic exam procedures.', 'X', 'albumin/creatinine ratio', '6.', 'Participants with corneal signs per the GSK Scale for corneal events at', 'CRP', 'X', 'the end of study treatment visit will have a follow-up ophthalmic exam 3', 'Pregnancy Test 8', 'X', 'X', 'weeks after the last dose of study treatment, 6 weeks after the last dose', ""12-lead ECG' 9"", 'of study treatment and then every 6 weeks (7 days) until deemed', 'Pharmacokinetics PK', 'clinically stable by ophthalmologist (an optometrist if an ophthalmologist', 'Anti-drug antibodies', 'is not available), or up to 1 year (whichever comes first). Corneal exams', 'Disease Evaluation', 'to be performed by an ophthalmologist (an optometrist if an', 'Response', 'X', 'ophthalmologist is not available). See Section 9.2.9 for the list of', 'X', 'Assessment10', 'ophthalmic exam procedures).', '29']"
29,page_30,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'os', 'PFS', 'Study Assessments', 'EOT Visit¹', 'Follow-', 'Notes', 'Follow-up²', 'Up³', 'Imaging for', 'Every 12 weeks if clinically', '7.', 'Extramedullary', 'X 12', 'Refer to Table 14 for a comprehensive list of lab tests that must be', 'indicated', 'disease¹', 'collected for all participants. Only serum creatinine is required at PFS', 'PET/CT upon achieving', 'Once after CR or sCR', 'visits (not a full chemistry)', 'Once after CR or sCR', 'CR or sCR1 13', 'declared', 'declared', '8.', 'Perform only in women of child-bearing potential. For questionable cases', 'UPEP (Urine Protein', 'X', 'of whether a participant is of non-child bearing potential, obtain follicle', 'Electrophoresis) 24 hr.', 'X', 'stimulating hormone (FSH) and estradiol. See Section 6.1, Section 9.2.8,', 'urine collection', 'and Appendix 5 for more details.', 'By central lab if UPEP is', 'By central if UPEP is', 'Final pregnancy test (serum or urine) must be performed in women of', 'negative, at the time of first', 'negative, at the time of first', 'childbearing potential 80 days (+7 days) after last study treatment.', 'Urine immunofixation', 'achieving CR then perform', 'achieving CR then perform', '9.', 'Single ECG required at End of Study. On days where ECG time points', '(Central lab)', 'every 21 days ( 7 days) until', 'every 21 days ( 7 days) until', 'align with PK sampling time points, ECGs must be performed prior to PK', 'suspected PD after CR or', 'suspected PD after CR or', 'samples being drawn. ECGS will be collected and stored centrally.', 'sCR.', 'sCR.', 'SPEP (Serum Protein', 'X', '10. For participants who are discontinuing IP due to PD the confirmation must', 'X', 'Electrophoresis)', 'be performed from a different blood collection within 14 days of the', 'By central lab if SPEP is', 'By central lab if SPEP is', 'original disease progression, preferably before institution of any new anti-', 'negative, at the time of first', 'negative, at the time of first', 'myeloma therapy. This may be performed at the EOT visit.', 'Serum Immunofixation', 'achieving CR then perform', 'achieving CR then perform', '11. Imaging is only required for participants with extramedullary disease (CT,', 'every 21 days ( 7 days) until', 'every 21 days ( 7 days) until', 'MRI, or PET/CT can be applied per local guidance). The same modality', 'suspected PD after CR or', 'suspected PD after CR or', 'should be used throughout the study (i.e., if CT scan was used as', 'sCR.', 'sCR.', 'baseline, participant needs to be followed by CT scans). Plasmacytoma', 'Serum Kappa, lambda', 'X', 'measurements should be taken from the CT portion of the PET/CT, or', 'free LC, FLC ratio', 'MRI scans, or dedicated CT scans where applicable. For participants', 'Calcium corrected for', 'X', 'X', 'with skin only involvement, skin lesions should be measured with a ruler.', 'albumin (serum)', 'Measurement of tumor size will be determined by the Sum of the', 'lgG, IgM, IgA', 'X', 'X', 'Products of the maximal perpendicular diameters of measured lesions', 'lgD/E14', '(SPD). Imaging will be collected for independent review.', 'Bone Marrow (BM) Aspiration/Biopsy', '12. If the last radiographic assessment occurred >8 weeks prior to the', 'BM for MRD testing15', 'X', ""participant's withdrawal from study treatment, and PD has NOT been"", 'BM for disease', 'Only if CR has been achieved', 'Only if CR has been achieved', 'documented, -a new assessment for extramedullary disease should be', 'by this visit, or suspected PD', 'assessment', 'by this visit, or suspected PD', 'obtained at EOT. If participant continues in PFS follow-up, perform scans', 'not evident otherwise', 'not evident otherwise', '30']"
30,page_31,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'os', 'PFS', 'Study Assessments', 'EOT Visit¹', 'Follow-', 'Notes', 'Follow-up²', 'Up³', 'Bone marrow biopsy to', 'Only if CR has been achieved', 'Only if CR have been', 'for extramedullary disease as clinically indicated.', 'assess sCR by IHC16', 'on this visit', 'achieved on this visit', 'Biomarkers', '13. Germany: no PET/CT to confirm CR or sCR will be performed until', 'approved by the German Federal Office of Radiation Protection until', 'Soluble BCMA (serum)', 'X', 'further notice.', 'cfDNA (plasma)', 'X', 'Optional', '14. Only required for participants with lgD/E myeloma, where serum m-', 'Optional tissue sample', 'component cannot be followed otherwise.', 'At time of PD', 'At time of PD', 'at PD for BCMA17', '15. Performed by a central lab at the time of first achieving VGPR or CR. And', 'Health Outcomes', 'repeated at 6 months and 12 months after achieving the VGPR or CR', 'PRO-CTCAE', 'X', '(provided VGPR/CR is maintained).', 'NEI-VFQ-2518', 'X', 'X', 'X', '16. In participants achieving a CR, bone marrow biopsy to confirm sCR by', 'OSDI18', 'X', 'X', 'IHC.', 'EORTC-QLQ-C30', 'X', 'EORTC-QLQ-MY20', '17. Upon PD- Optional tumor sample (BM aspirate clot, or fresh tissue, or', 'Patient Interview (PRO)', 'tissue block from extramedullary tumor) for BCMA expression analysis by', '19', 'IHC. To be submitted to central lab for analysis', 'Survival Status phone', 'X', '18. Participants who discontinue participation in the study will continue to be', 'call', 'assessed during follow-up until resolution of visual symptoms. Continue', 'to follow up with participants via telephone who are still experiencing', 'visual symptoms even after discontinuation', 'Subsequent Treatment', 'X', 'X', '19. Patient Interview (PRO) must be conducted via telephone within 21 days', 'Information', '(+7 days) of the end of treatment visit, unless the participant has already', 'completed their interview following C4D1 within the prior 30 days.', 'Abbreviations:', 'BM = bone marrow; BP = blood pressure; cfDNA = Circulating free DNA; CRP = C-reactive protein; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer', 'Quality of Life Questionnaire 30-item Core module; EORTC QLQ-MY20 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 20-item Multiple', 'Myeloma module; FISH = fluorescence in situ hybridization; FLC = free light chain; ; HR= heart rate; Ig = immunoglobulin; NEI-VFQ-25 = National Eye Institute Visual Functioning', 'Questionnaire 25; OSDI = Ocular Surface Disease Index; PRO-CTCAE = Patient Reported Outcome version of the Common Term Criteria for Adverse Events; PD = Progressive', 'Disease; PK = Pharmacokinetics; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis.', '31']"
31,page_32,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 4', 'Ocular Sub-Study Schedule of Activities (Selected Sites Only)', 'C1-C4', '10 days', 'Cycle 1-', 'Every 3 weeks starting at week 4 (to be completed', 'C5-', 'End of', 'PFS', 'os Follow-', 'Study Assessments', 'Screen', 'post', 'Cycle 4', 'regardless of dose given)', 'CX', 'Treatment', 'Follow-up', 'up', 'Dose', 'exam', 'Informed Consent', '1', 'X', 'Steroid eye drops 2', 'X', 'X6', 'Preservative-free artificial', 'X3', 'X3', 'X3', 'X3', 'tears 3', 'Full Ocular exams 1,4', 'X', 'X', 'X', 'X6', 'X', 'X6', 'X6', 'Specialty Ocular Exams1,', 'X', 'X', 'X', 'X', '5,6', '1.', 'Informed consent obtained for inclusion into the ocular sub-study population. Consent must be obtained prior to performing any sub-study protocol-related procedures. All', 'Screening assessments must be performed within 21 days prior to first dose unless otherwise specified. There is no need to repeat screening ocular', 'assessments', 'at', 'C1D1', 'if', 'they', 'have been done within 21 days of first dose.', '2.', 'Steroid eye drops administered as prophylaxis (such as: prednisolone acetate 1.0%, prednisolone phosphate 1%, dexamethasone 0.1%, or equivalent) 1 drop QID starting 1 day', 'prior to each GSK2857916 infusion, and continuing for a total of 7 consecutive days. Steroid eye drops are to be administered in only one eye as assigned (randomized) centrally', 'by the Sponsor and the site staff will instruct the participant which eye will be treated. The ophthalmologist will remain blinded to this decision. The treating ophthalmologist has', 'discretion to begin steroid drops in the both eyes should the participant develop symptoms requiring intervention as clinically indicated. Intraocular pressure should be monitored', 'if', 'steroid eye drops are used for more than 7 consecutive days.', '3.', 'Prophylactic preservative-free artificial tears will be administered starting 1 day prior to C1D1 according to Section 9.2.10.1. Outside of the 7-day prophylaxis period they should', 'be administered at least 4-8 times daily as needed, at least one drop in each eye, until end of treatment or as clinically indicated.', '4.', 'Participants will undergo ""full\' ocular exams as outlined in Section 9.2.9 within 3 days prior to day 1 and on day 10 (+3 days) of Treatment Cycles 1, 2, 3 and 4 (4 doses of study', 'medication). Day 10 exam is only necessary after participant receives study medication.', ""5. Participants could undergo 'specialty' ocular exams as outlined in Section 9.2.10 on Day 10 (+3 days) of Treatment Cycles 1, 2, 3 and 4 (4 doses of study medication) and within 3"", 'days prior to day 1 of cycles 2,3, and 4. A Day 10 exam is only necessary if participant receives study medication.', '6.', 'After Cycle 4 Day 10, participants who have no signs/symptoms should revert to the ocular activities of the general participant population (see main SOA tables), treatment with', 'steroid eye drops, and specialty ocular exams should continue at the discretion of the treating ophthalmologist. If a participant subsequently develops ocular signs/symptoms, or', 'they require additional treatment, participant must be evaluated by an ophthalmologist (an optometrist if an ophthalmologist is not available), and treated as clinically indicated.', '32']"
32,page_33,"['2017N330177_04', 'CONFIDENTIAL', '205678', '3.', 'INTRODUCTION', 'Multiple myeloma (MM) is an incurable malignancy and accounts for 1% of all cancers', 'and for 10% of all hematologic malignancies. Worldwide, approximately 103,000 new', 'cases are diagnosed annually, and an estimated 30,330 new cases and 12,650 deaths will', 'occur in the US in 2016 [Siegel, 2016]. There have been significant advances in', 'treatment for MM, including novel therapies like second and third -generation', 'proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and recent addition of', 'monoclonal antibodies (mAbs). Those advances have contributed to incremental gains in', 'PFS and OS, but most MM patients still relapse and ultimately develop resistance to', 'existing therapies. Therefore, there is an urgent need to develop treatments with novel', 'MOA which could potentially prevent the cross resistance to existing therapies [Kumar,', '2004]. Details of the characteristics of GSK2857916, nonclinical, and clinical activity', ""are provided in the Investigator's Brochure (IB) [GSK2857916 GlaxoSmithKline"", 'Document Number 2013N175128_04]', '3.1.', 'Study Rationale', 'Before the introduction of daratumumab, patients with disease that is refractory to both', 'immunomodulatory drugs and proteasome inhibitors (PIs) had a median overall survival', '(OS) ranging from 9 months [Kumar, 2012] to 12 months [Kumar, 2004; Kumar, 2003].', 'Daratumumab [DARZALEX, 2017], is a human IgGk monoclonal antibody that was', 'granted accelerated approval as monotherapy for the treatment of RRMM in the US in', 'November 2015 [Afifi, 2016] on the basis of the results from a Phase II monotherapy', 'study (n=106) which reported 29.2% ORR and mPFS 3.7 months in patients with', 'relapsed or refractory multiple myeloma. The median number of prior lines of treatment', 'reported in this study was 5.', 'Later, daratumumab has been approved in combination with', 'lenalidomide/dexamethasone, bortezomib/dexamethasone for patients who were', 'previously treated with at least one prior line, and in combination with pomalidomide and', 'dexamethasone for patients previously treated with at least 2 prior lines [DARZALEX,', '2017; Janssen-Cilag International NV, 2016].', 'While the data with daratumumab indicate that further prolongation of PFS can been', 'achieved, it is also increasingly recognized that patients continue to relapse after', 'treatment with daratumumab, and will need additional treatment options to control the', 'disease. Patients with MM who relapse after daratumumab therapy, have few treatment', 'options available and could benefit from treatment with a novel drug such as', 'GSK2857916.', 'GSK2857916 is a first in class, ADCC enhanced, humanized immunoglobulin G1 (IgG1)', 'antibody-drug conjugate (ADC) that binds specifically to B-cell maturation antigen', '(BCMA), a target present on mature B cells and on tumor cells in patients with MM [Tai,', '2015; Tai, 2006]. The antibody is conjugated to the microtubule inhibitor monomethyl', 'auristatin-F (MMAF), and is produced as an afucosylated form that generates an', 'enhanced antibody-dependent cellular cytotoxicity (ADCC) response. As demonstrated', '33']"
33,page_34,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'in the FTIH study this novel mechanism of action can be reasonably expected to', 'overcome cross resistance to existing therapies.', 'GSK2857916 has shown strong single-agent activity in the currently ongoing FTIH', 'study BMA117159.', 'Among the 35 participants receiving GSK2857916 at the RP2D of 3.4 mg/kg IV,', 'Q3W, the following results were observed:', 'Overall response rate (ORR) of 60% (95% CI: 42.1%, 76.1%)', 'Median progression-free survival (PFS) was 7.9 months (95% CI:3.1, -', 'months).', 'The ORR in 14 participants who failed prior daratumumab treatment was', '43% (95% CI: 17.7%, 71.1%), and the PFS in this subgroup was 6.8 mo.', 'Overall, GSK2857916 was well tolerated and adverse events were', 'manageable.', 'This data supports further development of GSK2857916 as monotherapy in patients', 'who failed an anti-CD38 antibody and are refractory to PI and IMiD.', '3.2.', 'Background - BCMA and Multiple Myeloma', 'B-cell maturation antigen (BCMA also referred to as TNFRSF17 or CD269) is a member', 'of the tumor necrosis factor (TNF) receptor superfamily and regulates a variety of', 'cellular functions. BCMA is expressed in mature B lymphocytes and binds to two TNF', 'family ligands BAFF (B-cell-activating factor belonging to the TNF family) and APRIL', '(a proliferation-inducing ligand) which promotes B-cell survival and proliferation. Mice', 'deficient for BCMA are viable, have normal B-cell development, and exhibit normal', 'humoral responses [Belnoue, 2008; Varfolomeev, 2004; Jiang, 2011]. BCMA is', 'expressed on malignant plasma cells in all MM patients [Tai, 2015; Tai, 2006]. The', 'restricted expression profile of BCMA in normal tissue, combined with its up-regulation', 'and recognized survival function in MM [Tai, 2006; Sanchez, 2012; Novak, 2004] makes', 'BCMA an attractive target for a therapeutic antibody with direct cell killing activity and', 'with minimal off target effects [Tai, 2015]. BCMA has been validated as a therapeutic', 'target in MM [Tai, 2015]. The BMA117159 study was the first time in human (FTIH)', 'study demonstrating single-agent activity of GSK2857916 in heavily pre-treated MM', 'participants. Chimeric Antigen Receptor T-Cells (CAR-T) based therapies targeting', 'BCMA have also demonstrated powerful activity against MM, with substantial albeit', 'reversible risks [Cohen, 2016]. Other approaches utilizing bispecific antibodies (BiTe)', 'have also entered development, but clinical results have not been reported at the time of', 'writing this protocol.', '3.3.', 'Antibody-Drug Conjugate GSK2857916', 'GSK2857916 is a first in class, ADCC-enhanced, humanized immunoglobulin G1 (IgG1)', 'antibody drug conjugate (ADC) that binds specifically to B-cell maturation antigen', '(BCMA), a target restricted to B cells at later stages of differentiation and expressed on', 'tumor cells of all patients with MM [Tai, 2015; Tai, 2006]. The antibody moiety of', 'GSK2857916 is produced as an afucosylated form that generates an enhanced antibody-', '34']"
34,page_35,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'dependent cellular cytotoxicity (ADCC) response upon binding to FcyRIIIa receptors on', 'the surface of human immune effector cells. The antibody is conjugated to the', 'microtubule inhibitor monomethyl auristatin-F (MMAF).', 'Upon binding to the cell surface, GSK2857916 is rapidly internalized and the active drug', '(cys-mcMMAF) is released inside the cell. The cys-mcMMAF moiety disrupts', 'microtubule networks, leading to cell cycle arrest and apoptosis (ADC mechanism)', '[Alley, 2009; Pettit, 1998]. This dual mechanism of action of GSK2857916 (ADCC and', 'microtubule disruption) enables anti-tumor activity on both dividing and non-dividing', 'cells. In addition, when MM cell lines expressing BCMA are exposed to GSK2857916,', 'it may act as an inducer of immunogenic cell death (ICD) [Kroemer, 2013; Krysko,', '2012], representing a potential third mechanism of action. Exposure of dendritic cells to', 'tumor cells undergoing ICD induces an antigen-specific T-cell response, and if it acts', ""similarly in humans could induce the patient's own immune response against the MM"", 'tumor. Expression of the target of GSK2857916 (BCMA) is restricted to B cells at later', 'stages of differentiation. The target is also present on tumor cells of all patients with MM', '[Tai, 2015; Tai, 2006].', '3.4.', 'Human Experience with GSK2857916', 'GSK2857916 is currently being evaluated in a First Time in Human (FTIH) trial in', 'participants with RRMM (Study BMA117159 on Q3W schedule via IV administration).', 'As of data cut off from 26 June 2017 a total of 73 participants with RRMM have been', 'treated with at least one dose of GSK2857916.', 'The Part 1 dose-escalation phase enrolled 38 participants at doses ranging from 0.03', 'mg/kg IV up to 4.6 mg/kg IV.', 'The Part 2 dose expansion phase has enrolled 35 participants with MM at 3.4 mg/kg', 'IV, Q3W.', 'In the Part 2 population, 57% of all participants (20/35) had 5 or more prior treatment', 'lines. The most frequently-reported AEs (15.0%) in the All Treated Population', 'included: vision blurred (37%), nausea (36%), fatigue (33%), anemia (29%), dry eye', '(29%), thrombocytopenia (26%), aspartate aminotransferase increased (25%), chills', '(23%), platelet count decreased (23%) pyrexia (22%), cough (18%), photophobia (16%),', 'back pain (15%), headache (15%), and upper respiratory tract infection (15%).', 'Among the participants in Part 2 (N=35), the most frequently reported AEs included:', 'vision blurred (46%), platelet count decreased (37%), dry eye (34%), anemia (29%),', 'aspartate aminotransferase increased (29%), cough (26%), chills (23%), nausea (23%),', 'photophobia (23%), pyrexia (23%), fatigue (20%), thrombocytopenia (20%), back pain', '(17%), and diarrhea (17%). A total of 14 (40%) participants in Part2 had an SAE. There', 'were no fatal SAEs, and 5 participants (14%) had SAEs considered related, as follows:', 'Infusion-related reaction (IRR): Two participants experienced serious, Grade 3', 'infusion-related reactions (preferred term) during Cycle 1 that were characterized by', 'tachycardia, hypertension and pyrexia.', '35']"
35,page_36,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Intracranial hemorrhage: A participant with a history of intracranial bleeding', 'experienced a Grade 2 intracranial hemorrhage with concomitant Grade 4,', ""thrombocytopenia after Cycle 1. At the same time, the participant's disease was"", 'starting to progress; the participant was taken off study and salvage chemotherapy', 'was started.', 'Pericardial effusion: A Grade 4 pericardial effusion consistent with tamponade was', 'found prior to Cycle 9 during a routine study echocardiogram in an asymptomatic', 'participant who had a concurrent upper respiratory tract infection. The fluid was', 'evacuated, and the effusion was resolving at the time of data cut-off. The participant', 'received three more cycles of treatment after this event. This SAE is listed as ""not', 'resolved"" at the time of data cut, however a subsequent echocardiogram has', 'confirmed no evidence of a pericardial effusion.', 'Lung infection and Pyrexia: A participant experienced a Grade 2 lung infection', 'resulting in a dose delay at Cycle 1. Approximately three months later, the', 'participant developed a Grade 2 fever resulting in hospitalization. The fever', 'resolved the same day; the participant was not neutropenic. This participant remains', 'on study treatment.', 'In the Part 2 population, 57% of all participants (20/35) had 5 or more prior treatment', 'lines. Overall, GSK2857916 has a manageable safety profile with thrombocytopenia', 'and/or platelet count decreased and corneal events as the most commonly reported', 'events, as described in the following subsections.', '3.4.1.', 'Thrombocytopenia', 'A total of 36 participants (49%) in the All treated population, and 20 participants (57%)', 'in Part 2 have experienced thrombocytopenia/platelet count decreased. GSK2857916', 'may cause transient worsening of thrombocytopenia in some participants, but in most', 'cases these events are resolved during between-dosing intervals. In the Part 2 MM', 'population, two serious bleeding events were reported: intracranial hemorrhage in a', 'participant with a history of an intracranial bleeding in the setting of disease progression,', 'and hematuria in a participant with a large bladder mass in the setting of progressive', 'disease.', '3.4.2.', 'Corneal Events', 'Corneal AEs have been observed with various ADC drugs and represent the most', 'commonly reported types of AEs associated with GSK2857916. As there is no single', ""term which appropriately captures these events, the term 'corneal events' includes"", 'reported preferred terms (from Eye Disorders System Organ Class) describing events', 'associated with the corneal events related to GSK2857916. The FTIH study', '(BMA117159) utilized the NCI-CTCAE scale Version 4.03 for all AEs. The most', 'commonly reported corneal events included vision blurred, dry eye, photophobia, and', 'lacrimation increased. A total of 42 participants (58%) in the all treated population, and', '22 participants (63%) in Part 2 have experienced corneal events which were', 'predominantly low-grade. In Part 2, there were three participants with > Grade 3 corneal', 'events: one with Grade 3 keratitis resulting in a delay and a dose reduction, one with', 'Grade 3 eye pain resulting in a delay; and one Grade 3 dry eye resulting in a dose delay.', '36']"
36,page_37,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'In Part 2, there were no serious corneal events and no participants permanently', 'discontinued study treatment due to a corneal event. In Part 1, there was one SAE of', 'Grade 3 limbal stem cell deficiency (in a participant at the 1.92 mg/kg dose) that was', 'characterized by blurred vision and dry eyes. The events resolved after treatment was', ""discontinued, and the participant's vision returned to baseline. Another participant in"", 'Part 1 (4.6 mg/kg) discontinued treatment due to the feeling of a foreign object in the eye', '(Grade 2). The mean time to onset of corneal AEs was 28 days after first dose for Part 2', 'MM; most participants developed events within 42 days of first dose though 20% of', 'those who reported these events developed them after Day 43.', 'In addition to the AEs describing corneal events, 89% of participants in Part 2 had', 'corneal findings upon examination. These findings were generally characterized by a', 'superficial punctate keratopathy/keratitis which was often associated with epithelial', '(microcystic) edema and occasional stromal edema or opacities. Visual acuity declined', 'during treatment in most participants experiencing these clinical findings, but improved', 'on average to near baseline in participants completing end of study treatment visits', '(n=13). Eleven of these 13 participants (84.6%) had corneal clinical signs at the end of', 'study treatment visit, with most cases (9/11 or 81.8%) considered as having ""mild""', 'changes.', '3.4.3.', 'Pharmacokinetics', 'The pharmacokinetics of GSK2857916 (antibody-drug conjugate), the parent antibody,', 'total antibody (including the complex), and cys-mcMMAF were investigated in', '70 participants after IV administration at doses of 0.03 to 4.60 mg/kg in a preliminary', 'analysis. Maximum concentrations of GSK2857916, parent antibody, and total antibody', 'were observed at end of infusion (EOI), whereas maximum cys-mcMMAF', 'concentrations peaked approximately 24 hours after dosing. There was limited', 'accumulation of GSK2857916 or cys-mcMMAF during subsequent cycles.', 'The pharmacokinetics of GSK2857916 were linear over the range of doses tested, with', 'exposure of all analytes increasing proportionately with increasing dose, and were well-', 'described in a preliminary population PK analysis using conventional allometry. Total', 'plasma clearance of GSK2857916 was 0.37 L/day, and the mean steady-state volume of', 'distribution was 4.2 L. The model-predicted terminal phase elimination half-life of', 'GSK2857916 was 8.2 days (95% CI: 6.4 to 10.1), in keeping with the log-linear model', 'estimate (8.7 days). On a molar basis, the levels of cys-mcMMAF were <1% of', 'GSK2857916, and the half-life of free cys-mcMMAF was <2 hours.', '3.4.4.', 'Clinical Activity', 'Preliminary clinical data from the ongoing BMA117159 study as of 26 June 2017 (n=35', 'participants treated at 3.4 mg/kg) has demonstrated an ORR of 60% [95% CI: 42.1%,', '76.1%], (complete response: 6%, very good partial response [VGPR] 43%, partial', 'response [PR] 9%), with 51% of participants (N = 18/35) having deep responses of', 'VGPR or better, in heavily pretreated participants with relapsed/refractory multiple', 'myeloma (RRMM). The median duration of response (DoR) has not been achieved, the', '25th percentile for DoR is 6.7 months; the median PFS in this population was 7.9 months', '[95% CI: 3.1, NA]. Although no responses were observed at the 2.5 mg/kg dose in Study', '37']"
37,page_38,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'BMA117159 (0 in 8 participants), one response was noted at each of the lower doses of', '0.96 mg/kg (1 in 3 participants) and 1.92 mg/kg, and (1 in 4 participants). In addition,', 'estimated receptor binding saturation was seen at doses 1.92 mg/kg.', '3.5.', 'Benefit / Risk Assessment', '3.5.1.', 'Risk Assessment', 'Additional information about the known and expected benefits and risks, detailed', 'information of nonclinical and clinical findings information regarding warnings,', 'precautions, contraindications, adverse events, and other pertinent information on', ""GSK2857916 that may impact participant eligibility is provided in the Investigator's"", 'Brochure [GSK2857916 (IB) GlaxoSmithKline Document Number 2013N175128_04].', 'Table 5', 'Risk Assessment and Mitigation Strategy', 'Potential Risk of', 'Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Investigational Product (GSK2857916)', 'Corneal events', 'Reversible corneal events have been', 'Active monitoring for corneal events', 'observed with various ADCs (specific', 'according to the Schedule of Activities', 'corneal changes with ADCs conjugated to', '(Table 1).', 'MMAF).', 'Cornea-related AEs such as blurred vision,', 'Preventive use of steroid eye drops as', 'dry/watery eyes, decreased visual acuity,', 'outlined in Table 21 in Appendix 9.', 'and photophobia are among the most', 'common AEs associated with GSK2857916', 'Timely evaluation and management by an', 'in the clinic. The majority of events have', 'ophthalmologist (an optometrist if an', 'been non-serious and transient, some', 'ophthalmologist is not available) upon', 'requiring dose delays/reductions. Time to', 'developing corneal related events.', 'recovery is variable, and in some instances', 'Recommendations for dose', 'the resolution may take several weeks.', 'delays/reductions are provided in Section', '9.4.8 and Appendix 9.', 'Infusion related', 'Without pre-medication, the majority of IRRs', 'Participants will be closely monitored for', 'reaction', 'observed in the clinic to date have been G1-', 'signs of IRR.', '2 and non-serious; however, there have also', 'been serious IRRs. Overall, participants', 'Premedication prior to first infusion of', 'who experienced an IRR during the initial', 'GSK2857916 is not mandatory but may be', 'infusion were pre-medicated prior to', 'considered based on investigator', 'subsequent infusions and IRRs did not', 'judgment.', 'recur.', 'If an infusion-related reaction occurs during', 'GSK2857916 administration, the infusion', 'rate may be reduced or halted depending', 'on the severity of the symptoms. The', 'participant will receive appropriate medical', ""treatment. When the participant's"", 'condition is stable, the infusion may be', 'restarted. Upon restart, the infusion rate', 'must be half of the infusion rate at the time', 'the infusion was paused.', 'Thrombocytopenia', 'Thrombocytopenic events of all grades (1-4)', 'A hematologic panel is assessed', 'are among the most common AEs', 'frequently. Supportive therapy (including', '38']"
38,page_39,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Potential Risk of', 'Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'associated with GSK2857916 in the clinic.', 'transfusions) is provided according to', 'standard medical practice, and dose', 'reductions or treatment discontinuations', 'are outlined in Section 7.2.', 'Neutropenia', 'Non-serious and serious neutropenia has', 'A hematologic panel is assessed', 'been observed in the clinic with', 'frequently. Supportive therapy (growth', 'GSK2857916.', 'factors, antibiotics, and treatment of active', 'infections) is provided according to', 'standard medical practice, and dose', 'reductions or treatment discontinuations', 'are outlined in Section 7.2.', 'Potential for', 'Preclinical inflammatory findings were seen', 'Monitoring of ECG. Treatment as', 'cardiotoxicity related', 'in the rat mandibular and mesenteric lymph', 'medically indicated. Monitoring of other', 'to an inflammatory', 'nodes, brachial/sciatic nerves, epididymides,', 'cardiac parameters as clinically indicated.', 'response', 'lung, thymus, and atrial epicardium. In the', 'monkey, microscopic effects in spleen and', 'bone marrow at >3 mg/kg/week were', 'reflective of a systemic inflammatory', 'response. Electrocardiograms (ECG) were', 'monitored in monkeys for up to 24 hours', 'following repeat dosing and did not produce', 'any evidence of test-article induced', 'electrocardiographic waveform', 'abnormalities, arrhythmias or QTc changes.', 'Serum cardiac troponin I was also measured', 'in the rat and monkey 3-week studies and', 'no treatment-related effects were observed.', 'This potential risk was based on described', 'preclinical findings, however to date there is', 'no evidence of systemic inflammatory', 'response or cardiotoxicity in the clinic.', 'Laboratory', 'Report of non-serious, asymptomatic', 'Monitoring of LDH and CK levels will be', 'abnormalities', 'elevations in LDH / CK levels have been', 'performed.', 'observed in the clinic.', 'Hepatotoxicity', 'Non-clinical safety experiments', 'Only participants with well-preserved liver', 'demonstrated increased liver weight and', 'function per the inclusion/exclusion criteria', 'elevated liver enzymes in rats. Elevations in', 'will be allowed on study. Participants with', 'liver enzymes, and increased mitotic figures', 'Hepatitis B (HBV) and C will be excluded', 'in Kupffer cells were observed in monkeys.', 'from the trial. Liver function tests will be', 'All of these changes were dose dependent', 'monitored in all participants on study and', 'and reversible.', 'in case of liver abnormalities management', 'will be implemented according to clinical', 'Non-serious elevations in ALT, AST have', 'practice. Participants that meet liver', 'been observed in the clinic.', 'stopping criteria (Section 8.2.1) will be', 'withdrawn from the study.', 'Nephrotoxicity', 'Non-clinical safety experiments have', 'During the study, participants will be', 'demonstrated primary glomerular injury and', 'monitored for kidney function by assessing', 'tubular degeneration (in rat and monkey).', 'creatinine, epidermal growth factor', 'The morphologic changes were', 'receptor (eGFR), electrolytes, and albumin', 'accompanied by large molecular proteinuria', '/ creatinine ratios (spot urine). Participants', '(albuminuria). The renal changes were', 'will be educated about the need of', 'dose dependent and reversible.', 'maintaining adequate urinary output.', 'Management will be implemented', 'according to clinical practice. Dose', '39']"
39,page_40,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Potential Risk of', 'Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'reductions and treatment stopping criteria', 'will be applied according to Section 7.2', 'and Section 8.2', 'Pulmonary toxicity', 'Preliminary nonclinical safety experiments', 'Monitoring for clinical signs and symptoms', '(pneumonitis)', 'have demonstrated the presence of', 'potentially related to pulmonary toxicity.', 'microscopic changes in the lungs (prominent', 'Further diagnostic tests and management', 'alveolar macrophages associated with', 'will be implemented immediately according', 'flocculent eosinophilic material; mixed', 'to recommendations provided in Section', 'perivascular inflammation) in rats at all', '7.2.2.', 'doses tested. To date no pneumonitis has', 'been observed in the clinic.', 'Immunosuppression', 'In nonclinical studies GSK2857916 has', 'Participants will be monitored for', 'been associated with decrease in', 'infections. Participants will receive', 'immunoglobulins in monkeys. An increase', 'immediate treatment according to standard', 'in immunoglobulins was seen in rats (rats', 'practice.', 'are not an antigen specific species for', 'GSK2857916).', 'Potential for overdose', 'A frozen liquid configuration of GSK2857916', 'Proactive communication and training will', 'specific to the', 'will be used to initiate this trial. An', 'be provided to the sites ahead and at the', 'preparation of study', 'independent cohort of approximately 25', 'time that the lyophilized configuration is', 'drug', 'additional participants will be enrolled and', 'introduced at the site.', 'administered a lyophilized configuration of', 'There is no specific antidote for overdose', 'compound (upon availability). A separate', 'with GSK2857916. In the event of a', 'set of preparation instructions will need to be', 'suspected overdose, it is recommended', 'followed in order to prevent potential', 'that the appropriate supportive clinical care', 'overdose.', 'should be instituted, as dictated by the', ""participant's clinical status."", 'Risks from Study Procedures', 'Bone marrow', 'Pain, infection, bleeding may occur after the', 'Participants will be treated according to', 'aspiration/biopsy', 'procedure', ""institution's practice"", 'Incidental findings', 'During the acquisition of imaging data (e.g..', 'All imaging scans will be reported to the', 'during imaging data', 'MRI, CT, PET, ECHO), non-MM disease or', 'site by an appropriate imaging clinician', 'acquisition:', 'drug related clinical abnormalities could be', '(non-anonymized) for non-MM Disease or', 'found by the radiographer or', 'drug related clinical abnormalities.', 'echocardiographer performing the exams.', 'TCR = T-cell receptor; mAb = Monoclonal antibody; AEs = Adverse Events', '3.5.2.', 'Benefit Assessment', 'The study population enrolled in this study has a high unmet medical need. Participants', 'failing multiple lines of prior treatments do not have many therapeutic options left, and if', 'response can be achieved with currently available drugs, it is usually of short duration.', 'This study is being performed to study efficacy and safety data in participants who have', 'been previously treated with multiple agents, including PI, IMiD, and an anti-CD38', 'antibody.', 'Data from single-agent study BMA117159 support further evaluation of participants with', 'MM failing currently available treatments.', '40']"
40,page_41,"['2017N330177_04', 'CONFIDENTIAL', '205678', '3.5.3.', 'Overall Benefit-Risk Conclusions', 'In the ongoing FTIH study, GSK2857916 has shown strong single-agent activity with an', 'ORR of 60% (95% CI: 42.1%, 76.1%) among the 35 participants in Part 2 who received', 'GSK2857916 at 3.4 mg/kg IV, Q3W. The ORR in the 14 participants who failed prior', 'daratumumab treatment was 43% (95% CI: 17.7%, 71.1%), and the PFS in this subgroup', 'was 7.8 months. Although maximum clinical benefit was observed at the 3.4 mg/kg dose', 'level, frequent dose delays and dose reductions were required to manage AEs including', 'thrombocytopenia/platelet count decreased and corneal events.', 'To generate additional safety and efficacy data at a lower dose while providing', 'participants a chance of deriving clinical benefit, two dose levels (2.5 mg/kg Q3W and', '3.4 mg/kg Q3W) will be evaluated in study 205678. Considering the potential benefit to', 'participants as well as the measures being taken to minimize risk, further development of', 'GSK2857916 as monotherapy in participants who failed an anti-CD38 antibody and are', 'refractory to PI and IMiD is warranted. Based on the recognized unmet medical need and', 'limited treatment options available for this population, this Phase II study has been', 'designed to evaluate the efficacy and safety of GSK2857916.', '4.', 'OBJECTIVES AND ENDPOINTS', 'The purpose of this Phase II study is to evaluate the safety and efficacy of GSK2857916', 'in participants with RRMM who have received at least 3 prior lines of anti-myeloma', 'therapy, have failed an anti-CD38 antibody, and are refractory to PI and IMiDs. See', 'Table 6 for the primary, secondary, exploratory, and other objectives, along with the', 'corresponding endpoints.', 'Table 6', 'Objectives and Enppoints for Study 205678 - GSK2857916 in RRMM', 'Participants Previously Treated with an Anti-CD38 Antibody', 'Objectives', 'Enppoints', 'Primary Objective', 'To evaluate the clinical efficacy of 2 doses', 'ORR, defined as the percentage of participants with a confirmed partial', 'of GSK2857916 in participants with', 'response (PR) or better (i.e., PR, very good partial response [VGPR],', 'relapsed/refractory multiple myeloma.', 'complete response [CR] and stringent complete response [sCR]),', 'according to the 2016 International Myeloma Working Group (IMWG)', 'Response Criteria by Independent Review Committee (IRC).', 'Secondary Objectives', 'To further evaluate the clinical measures of', 'ORR, defined as the percentage of participants with a confirmed partial', 'efficacy of GSK2857916 in participants with', 'response (PR) or better, according to the 2016 International Myeloma', 'RRMM', 'Working Group (IMWG) Response Criteria by investigator assessment.', 'Clinical benefit rate (CBR), defined as the percentage of participants', 'with a confirmed minimal response (MR) or better according to the', '2016 International Myeloma Working Group (IMWG) Response', 'Criteria).', 'Duration of response (DoR), defined as: the time from first documented', 'evidence of PR or better until the earliest date of documented disease', 'progression (PD) per IMWG; or death due to PD occurs among', 'participants who achieve an overall response, i.e., confirmed PR or', '41']"
41,page_42,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Objectives', 'Enppoints', 'better.', 'Time to response, defined as the time between the date of', 'randomization and the first documented evidence of response (PR or', 'better).', 'Progression-free survival, defined as the time from randomization until', 'the earliest date of documented disease progression (PD) per IMWG,', 'or death due to any cause.', 'Time to progression, defined as the time from randomization until the', 'earliest date of documented PD per IMWG, or death due to PD.', 'Overall survival, defined as the time from randomization until death due', 'to any cause.', 'To evaluate the safety of GSK2857916 in', 'The safety profile of GSK2857916 will be evaluated in participants with', 'participants with RRMM.', 'RRMM as assessed through:', 'standard clinical and laboratory tests (hematology and chemistry,', 'physical examination, vital sign measurements, and diagnostic tests)', 'through the collection of adverse events (AEs) and serious adverse', 'events (SAEs)', 'AEs of special interest', 'ocular findings on ophthalmic exam', 'To evaluate the pharmacokinetic profile of', 'Plasma concentrations of GSK2857916 (ADC, total mAb, and cys-', 'GSK2857916', 'mcMMAF)', 'Derived pharmacokinetic parameter values (e.g., AUC, Cmax, tmax,', 't1/2), as data permit.', 'To assess anti-drug antibodies (ADAs)', 'Incidence and titers of ADAs against GSK2857916', 'against GSK2857916', 'Participant self-reported symptomatic', 'Symptomatic adverse effects and related impacts as measured by the', 'adverse effects by evaluation of tolerability', 'PRO-CTCAE, NEI-VFQ-25 and OSDI', 'of GSK2857916', 'To evaluate disease and treatment related', 'Health-related quality-of-life as measured by the EORTC QLQ-C30 and', 'symptoms and impact on function and', 'EORTC QLQ-MY20', 'health-related quality-of-life', 'Exploratory Objectives', 'To explore the relationship between clinical', 'Determine BCMA expression levels and other markers on malignant', 'response and other biologic characteristics', 'cells, serum sBCMA levels, and evaluate the relationship of these', 'including BCMA expression on tumor cells', 'factors to clinical response', 'and sBCMA concentrations', 'To investigate the relationship between', 'Possible relationship between host genetic variation and response to', 'genetic variants in the host and response to', 'GSK2857916', 'GSK2857916', 'To evaluate disease and treatment related', 'Qualitative telephone interview(s)', 'symptoms and impact on function and', 'health-related quality-of-life', 'To explore exposure-response relationships', 'Explore relationships between GSK2857916 exposure (e.g., dose,', 'between GSK2857916 exposure and clinical', 'dose intensity, concentration, Cmax, or AUC) and clinical endpoints', 'endpoints', '(e.g., response, corneal event), if data permit', 'To assess Minimal Residual Disease (MRD)', 'Minimal Residual Disease (MRD) negativity rate, defined as: the', 'in participants who achieve >VGPR or', 'percentage of participants who are MRD negative by Next Generation', 'better', 'Sequencing (NGS).', 'To assess the safety, efficacy,', 'AEs, clinical and laboratory assessments; descriptive analyses of ORR,', 'immunogenicity, and pharmacokinetics of', 'duration of response, time to response, time to progression, overall', 'GSK2857916 in a lyophilized configuration', 'response; incidence and titers against GSK2857916; plasma', '(approximately 25 participants)', 'concentrations of GSK2857916 (ADC, total mAb, and cys-mcMMAF)', '42']"
42,page_43,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Objectives', 'Enppoints', 'and derived pharmacokinetic parameters, if data permit', 'Ocular sub-study objective', 'To evaluate the effect of topical', 'Description of differences in corneal findings in each eye based on', 'corticosteroids on corneal findings in', 'ophthalmic examinations (participant-level).', 'approximately 30 participants who will', 'receive monocular topical corticosteroids for', 'the first 4 cycles', 'Abbreviations: IV = intravenous; Q3W: once every 3 weeks; RRMM = relapsed refractory multiple myeloma; BCMA =', 'B-cell maturation antigen; MMAF = monomethyl auristatin-F; MRD = minimal residual disease; NGS = Next Generation', 'Sequencing; ORR = overall response rate; CI = confidence interval; CR = complete response; VGPR = very good', 'partial response; PR = partial response; PFS = progression free survival; AUC = area under the curve; Cmax =', 'maximum concentration; tmax = time to maximum; t¹/² = half-life; PRO-CTCAE = Patient Reported Outcomes-Common', 'Terminology Criteria for Adverse Events; NEI-VFQ-25 = National Eye Institute Visual Functioning Questionnaire 25;', 'OSDI = Ocular Surface Disease Index; EORTC = European Organisation for Research and Treatment of Cancer;', 'QLQ-C30 = Quality of Life Questionnaire 30-item Core module; FLC = free light chain; SCT = stem cell transplant;', ""QLQ-MY20 = ; Quality of Life Questionnaire 20-item module for MM; QTcF = QT interval corrected by Fridericia's"", 'formula; HIV = human immune deficiency virus; RNA = ribose nucleic acid.', '5.', 'STUDY DESIGN', '5.1.', 'Overall Design', 'This is a Phase II, open-label, two-arm, randomized, multicenter study to evaluate the', 'efficacy and safety of GSK2857916 monotherapy at the dose of 2.5 mg/kg or 3.4 mg/kg', 'IV, Q3W, in participants with RRMM. Participants will be treated until disease', 'progression or unacceptable toxicity and will be followed for PFS and OS. An ocular', 'sub-study will evaluate the effectiveness of steroid eye drops in approximately 30', 'participants (~15 on each dose arm) who sign an optional ICF.', 'The study will use frozen solution of GSK2857916 for those participants enrolled into 2', 'dose arms.', 'The design includes an independent cohort of approximately 25 participants who will', 'receive a lyophilized configuration of GSK2857916. Those participants will follow the', 'same assessments and procedures as the main study and will be analyzed separately from', 'participants randomized to the frozen solution.', 'The lyophilized cohort will be initiated when the lyophilized configuration becomes', 'available. It will evaluate the 3.4 mg/kg dose level, unless the results of the IA indicate', 'that it should not be continued. In that case, the lyophilized cohort will have a dose of 2.5', 'mg/kg.', 'The study consists of a screening/baseline period, a treatment period, and a post-', 'treatment follow-up period (schematic is displayed in Figure 1)', '43']"
43,page_44,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Figure 1', 'Study 205678 Schematic', 'Screening', 'Randomization Main Study &', 'Ocular Sub-Study', 'GSK2657916 Frozen', 'GSK2857916 Frozen', 'Configuration', 'Configuration', '2.5 mg/kg QSW', '3.4 mg/kg Q3W', 'Futility Analysis', '(""25 pts', 'evaluable/arm)', 'Discontinue 1 arm', 'if inferior', 'GSK2857916 LYO', 'I', 'Q3W', 'Participants le the', 'GSK2857916 Frozen', 'drapped arm will be', 'affownd to continue at', 'Configuration at dose Y or both', ""the dose ot I's discration"", 'PD or Discontinuation for Other Reasons', '(it Other)', '(if PD)', 'PFSF/U', 'OSF/U', 'every 3 wis', 'Every limos', 'WAY', 'Abbreviations: os = overall survival; PD = progressive disease; PFS = progression-free', 'survival; F/U = follow-up; lyo = lyophilized; DP = drug product; pts = participants.', '44']"
44,page_45,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Participants eligible for screening will be assigned a unique Participant Number by their', 'investigational site. Upon completion of all the required screening assessments, eligible', 'participants will be registered into the Registration and Medication Ordering System', ""(RAMOS), GSK's Interactive Response Technology (IRT) system, by the investigator or"", 'authorized site staff. Following randomization, eligible participants will begin Cycle 1', 'treatment in the assigned treatment arm. Assessments will be performed as illustrated in', 'the Schedule of Activities (Section 2).', 'Selected investigative sites will participate in the ocular sub-study and will conduct', 'additional ocular examinations on approximately 30 participants who sign an additional', 'consent to receive monocular treatment with corticosteroid eye drops. In this specific', 'subgroup, the ophthalmic examinations will occur pre-dose every 3 weeks and on Day 10', 'after a treatment dose for the first 4 cycles. Additional treatments and examinations will', 'be at the discretion of the treating ophthalmologist (an optometrist if an ophthalmologist', 'is not available). See the SOA for the scheduling (Section 2).', 'Additional details of the individual assessments are provided in Section 9.', ""An interim analysis (IA) for futility is planned for ORR based on investigator's"", 'assessment after approximately 25 participants per arm are evaluable for response', '(defined as having received at least 2 doses of study treatment and having completed at', 'least 1 disease assessment after the second dose, or progressed or died or discontinued', 'treatment due to reasons other than PD).', 'At the IA, given that 25 participants are evaluable for each arm, treatment arm/s will be', 'dropped from the study if there are <4 responses. If both arms have 5 or more responses', 'at IA, in addition to the futility rule described above, the posterior probability of', 'observing a better RR in one arm than the other will be calculated. If such a probability', 'is at least 97.5%, then the treatment arm with lower RR will be dropped due to lack of', 'efficacy.', 'The IA to assess futility will be performed by an Independent Data Monitoring', 'Committee (IDMC). Additional details of the IA are provided in Section 10.5.9 and will', 'be provided in an IDMC Charter. At the time of the IA, additional participants will', 'continue to be enrolled, treated, and followed as described in the SOA (Section 2).', 'Efficacy and safety results from the interim analysis will not be shared with investigators', 'or other site/study personnel.', 'If one arm is selected based on the results of the IA, enrollment to the futile arm will be', 'stopped and ongoing participants from the futile arm will have the possibility upon', 'additional consent to either continue at their current dose level or to have their dose', 'adjusted to the dose in the selected arm based on the following rules:', 'If the 2.5 mg/kg dose is discontinued, participants have the option to switch to', '3.4 mg/kg dose if they:', 'Did not experience an SAE, or a > Grade 3 non-corneal AE', 'Provide informed consent for the 3.4 mg/kg dose.', '45']"
45,page_46,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'If the 3.4 mg/kg dose is discontinued, participants who are currently treated at this', 'dose will have the option to switch to 2.5 mg/kg:', 'In cases when the participant has not achieved a maximum benefit of CR or sCR, did', 'not experience toxicity requiring a dose reduction, and is willing to continue at the', 'higher dose level, the participant will have the option to stay on their original dose', 'upon signing an additional informed consent informing them that a lower dose level', 'has been selected for the remaining participants.', 'The final analysis of the primary endpoint (ORR) will be performed 6 months after the', 'last participant is randomized. The study will continue and participants will remain on', 'treatment and continue to be followed.', 'For participants who discontinue study treatment for reasons other than PD, disease', 'evaluations will continue to be performed at 3-week intervals until confirmed PD, death,', 'start of a new anticancer treatment, withdrawal of consent, or end of the study whichever', 'occurs first. After PD is documented, participants will be followed for survival and', 'subsequent anticancer therapy every 3 months until study ends.', 'Pharmacokinetic samples will be collected from all participants. The collection of PK', 'samples for determination of GSK2857916 plasma (ADC and total antibody) and cys-', 'mcMMAF concentrations will allow characterization of the PK profile and support', 'investigation of its pharmacology.', 'Genetic testing (in consenting participants) and biomarker research samples will also be', 'conducted on samples from all participants prior to the first dose. Patient-Reported', 'Outcomes (PRO) data will be collected at each clinic visit.', 'Protocol waivers or exemptions are not allowed. Therefore, adherence to the study', 'design requirements, including those specified in the SOA (Table 1 to Table 4) is', 'essential.', 'Supplementary study conduct information not mandated to be present in this protocol is', 'provided in the accompanying Study Reference Manual (SRM). The SRM will provide', 'the site personnel with administrative and detailed technical information that does not', 'affect participant safety.', '5.2.', 'Number of Participants', 'Approximately 170 participants were initially planned to be screened to enroll a', 'minimum of 155 participants at approximately 60 investigational sites globally. A', 'minimum of 130 participants (65/arm) were planned to be enrolled to 2 arms receiving', 'frozen liquid solution of GSK2857916 which includes ~30 participants from the ocular', 'sub-study. Approximately 200 participants will be enrolled in the frozen liquid portion of', 'the study. Approximately twenty-five additional participants will be enrolled into the', 'independent lyophilized drug product cohort.', '46']"
46,page_47,"['2017N330177_04', 'CONFIDENTIAL', '205678', '5.3.', 'Participant and Study Completion', 'A participant will be considered to have completed the study if he or she has received at', 'least one dose of the study treatment and, has died or is still in follow-up when the study', 'is closed, and has not withdrawn consent from study participation.', 'The study will end when 60% of the participants have died, OR withdrawn consent, OR', 'are lost to follow-up, AND all participants with corneal events have been followed for up', 'to 12 months after last dose of treatment. At this time, end of study analyses will be', 'performed. If a participant remains on treatment at the time end of study is achieved, they', 'may be offered an option to extend treatment on another protocol. A participant will be', 'considered to have withdrawn from the study if:', '(a) the participant has not died and is lost to follow-up,', '(b) the participant has withdrawn consent,', ""(c) the participant is no longer being followed at the investigator's discretion, or"", '(d) the study is terminated prematurely.', 'Documentation of the cause of death in the electronic Case Report Form (eCRF) is', 'required for all participants who die in the study regardless of the cause of death.', '5.4.', 'Scientific Rationale for Study Design', 'Patients with RRMM who have relapsed after prior treatment with an anti-CD38 antibody', 'and are refractory to a PI and an IMiD represent a population of unmet medical need, for', 'whom there is no approved treatment option. Given the clinical activity demonstrated in', 'the BMA117159 study, treatment with GSK2857916 may offer a benefit to this patient', 'population. It is also expected that due to its unique mechanism of action, GSK2857916', 'may be able to overcome the resistance to previously used drugs in the MM population.', 'GSK2857916 is the first-in-class ADC targeting BCMA. Preliminary clinical data for', 'GSK2857916 monotherapy from Study BMA117159 among 35 participants indicate an', 'ORR of 60% [95% CI: 42.1%, 76.1%], with 51% of participants (n=18) having deep', 'responses of VGPR or better. The median DoR has not been achieved, the 25th percentile', 'for DoR is 6.7 months; the median PFS in this population was 7.9 months [95% CI: 3.1,', 'NA]. Of note, the ORR for participants previously treated with daratumumab (n=14) was', '43% (95% CI: 17.7, -71.1). Fifty nine percent of the treated population had 5 of more', 'prior treatments.', 'The response rate observed in this population is higher than response rates observed in', 'similarly defined patient populations treated with other recently approved drugs (ORR', 'ranging from 23.7% to 33.1% for Carfilzomib, pomalidomide and daratumumab)', '[Siegel, 2012; Usmani, 2016; Kumar, 2008]. Given the evidence of clinical activity and', 'manageable safety/tolerability profile demonstrated to date, the current evidence supports', 'further development.', '47']"
47,page_48,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'The two-arm design with two dose levels and a futility analysis is justified for this', 'population because there is no approved comparator for the proposed treatment setting.', 'In Study BMA117159, the maximum clinical benefit (ORR) was observed at the 3.4', 'mg/kg dose level, but a significant number of participants required dose delays and dose', 'reductions. At lower dose levels, the results were variable, with wide confidence', 'intervals. In order to generate additional safety and efficacy data at a lower dose while', 'providing participants a chance of deriving clinical benefit, the dose of 2.5 mg/kg has', 'been selected for additional testing (see Section 5.5 for dose justification).', 'This design is appropriate for the selected patient population, since there is no approved', 'standard of care in patients failing daratumumab. As shown in earlier studies on a similar', 'population, the response rate is low and the mPFS is short in those patients. For example,', 'in the pomalidomide + dexamethasone (PomDex) VS pomalidomide (Pom) study that', 'enrolled patients with median of 5 prior lines, among whom 61% have been refractory to', 'the mainstay of treatment, lenalidomide and bortezomib had an ORR of 18%, and mPFS', 'of 2.7 months on Pom monotherapy arm [Richardson, 2013]. A similar Phase3 study of', 'Pom with low dose dexamethasone (Pom/loDex) VS high dose dexamethasone (HiDex)', 'has demonstrated an ORR of 3.9%, mPFS of 1.8 months, and mOS of 8 months in the', 'HiDex arm where patients had a median of 5 prior lines, and 74% of them were double', 'refractory to lenalidomide and bortezomib [Weisel, 2013].', 'Further, a randomized, phase III study which compared carfilzomib monotherapy against', 'low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory', 'multiple myeloma has demonstrated an ORR of 11%, and OS of 10 months in', 'populations previously treated with 5 lines of therapy and 63% of patients were double', 'refractory to bortezomib and IMiD [Hájek, 2017]. In summary, these examples provide', 'indirect evidence that the prognosis of patients eligible for this protocol is poor, and that', 'selected threshold for claiming success (33%) is appropriate since it doubles the expected', 'ORR for those patients when treated with available agents.', '5.5.', 'Dose Justification', 'GSK2857916 is currently being studied in the Phase I FTIH study, BMA117159. As of', 'the clinical cut-off date of 26 June 2017, a total of 73 participants with RRMM have', 'received at least 1 dose of GSK2857916.', 'Participants in Study BMA117159 were enrolled into the dose-escalation phase of the', 'study (Part 1) at the following dose levels: 0.03 mg/kg (n=1), 0.06 mg/kg (n=1), 0.12', 'mg/kg (n=4), 0.24 mg/kg (n=4), 0.48 mg/kg (n=4), 0.96 mg/kg (n=3), 1.92 mg/kg (n=4),', '2.50 mg/kg (n=8), 3.40 mg/kg (n=3), and 4.60 mg/kg (n=6). Based on the data from Part', '1 of the study, 35 participants were treated in the Dose Expansion portion (Part 2) at 3.4', 'mg/kg Q3W.', 'Clinical activity in Study BMA117159', 'Clinical activity at the tested dose levels in Part 1 is summarized in Table 7. There were', 'no dose-limiting toxicities (DLTs) observed during dose escalation; however, there was', 'limited tolerability of the 4.6 mg/kg dose (prolonged fever, headache, severe fatigue).', '48']"
48,page_49,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 7', 'Summary of Investigator-Assessed Best Response (with', 'Confirmation; Study BMA117159 Part 1)', 'Dose level (mg/kg)', 'ORR (%)', '95%CI', '0.03', '0', '(0.0,97.5)', '0.06', '0', '(0.0,97.5)', '0.12', '0', '(0.0, 60.2)', '0.24', '0', '(0.0, 60.2)', '0.48', '0', '(0.0, 60.2)', '0.96', '33', '(0.8, 90.6)', '1.92', '25', '(0.6,80.6)', '2.5', '0', '(0.0, 36.9)', '3.4', '100', '(29.2, 100.0)', '4.6', '50', '(11.8, 88.2)', 'Preliminary clinical data from Part 2 of Study BMA117159 (3.4 mg/kg Q3W) indicated', 'an Overall Response Rate (ORR) of 60% (95% CI: 42.1, 76.1) in an RRMM population', '(57% of participants had 5 or more lines of prior therapy, n=35). The median', 'progression-free survival (mPFS) was 7.9 months (95% CI: 3.1, NA). The ORR was', '43% (95% CI: 17.7, 71.1) in the 14 participants who had received prior daratumumab.', 'Clinical safety and tolerability in Study BMA117159', 'In general, GSK2857916 has been well tolerated; the most frequent AEs were corneal', 'events and thrombocytopenia/platelet count decrease, which were manageable following', 'protocol-defined dose modification guidelines. Most participants in Study BMA117159', 'experienced dose reduction and/or dose delays; all events were graded using CTCAE', 'Version 4.03.', 'In the All Treated population (n=73), 35 participants (48%) had AEs that led to dose', 'reduction. The most common AEs (frequency 5%) that led to dose reductions were', 'vision blurred (18%), thrombocytopenia (8%), dry eye (5%), and keratitis (5%). In the', 'Part 2 group (n=35), 23 participants (66.%) had AEs that led to dose reduction. The', 'most common AEs (frequency 5%) that led to dose reductions were vision blurred', '(31%), thrombocytopenia (11%), keratitis (9%), photophobia (6%), platelet count', 'decreased (6%), and infusion-related reactions (6%).', 'Dose delays due to AEs were experienced by 38 participants (52%) in the All Treated', 'population. The most common AEs (5%) leading to dose delays were vision blurred', '(22%), thrombocytopenia (8%), dry eye (7%), and keratitis (5%). Dose delays due to', 'AEs were experienced by 25 participants (71%) in Part 2. The most common AEs', '(frequency 5%) leading to dose delays were vision blurred (34%), thrombocytopenia', '(11%), dry eye (9%), keratitis (9%), lung infections (6%), and photophobia (6%).', 'Rationale for evaluating 2.5 mg/kg in addition to 3.4 mg/kg in the current study', 'A substantial number of participants treated at 3.4 mg/kg dose required a dose delay', 'and/or dose reduction due to an AE. Responders in the 3.4 mg/kg dose group in Part 2', 'maintained their responses with dose reductions and delays. Based on the available data,', 'evaluation of a lower dose level in addition to the 3.4 mg/kg dose is being done to ensure', 'that the appropriate dose of GSK2857916 has been selected for monotherapy treatment.', '49']"
49,page_50,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Although no responses were observed at the 2.5 mg/kg dose in Study BMA117159, one', 'response was noted at each of the lower doses of 0.96 mg/kg (1 in 3 participants) and', '1.92 mg/kg, and (1 in 4 participants). In addition, estimated receptor binding saturation', 'was seen at doses >1.92 mg/kg.', 'The next highest dose level to 3.4 mg/kg is 2.5 mg/kg, a dose reduction of ~25%. The', 'preliminary population pharmacokinetic analysis estimated that the between-participant', 'variability in GSK2857916 clearance was ~50%, and the variability in Cmax values was', '~20%; therefore, some overlap in exposure is expected between the two dose levels.', 'Despite this pharmacokinetic overlap, the Bayesian logistic regression modeling based on', 'the full clinical dataset (see below) indicated that a dose level of 2.5 mg/kg had a lower', 'predicted response rate as well as a lower predicted rate of >Grade 2 corneal event. The', 'next lower dose level, 1.92 mg/kg, had a much lower predicted response rate and was not', 'considered suitable for further exploration. Therefore, 2.5 mg/kg was selected as the', 'second dose level for evaluation in this study. The interim analysis will help to minimize', 'exposure to a potentially less effective dose level.', 'Bayesian logistic regression model of dose-response for ORR and corneal event rate', 'To further explore the dose selection, Bayesian logistic regression model (BLRM) was', 'used to determine the dose-response relationships for both ORR and >Grade 2 corneal', 'event rate (as determined by NCI CTCAE grading) separately using all 73 participants', 'with RRMM in Study BMA117159 (Figure 2). Table 8 displays the predicted response', 'rate and predicted >Grade 2 corneal event rate at dose levels of 3.4, 2.5, and 1.92 mg/kg.', 'The model showed that the posterior probability of observing an ORR >30% is 100% in', 'the 3.4 mg/kg dose group, 83% in the 2.5 mg/kg dose group, and 29% in the 1.92 mg/kg', 'dose group. Similarly, the posterior probability of observing >Grade 2 corneal event rate', 'is also higher in the 3.4 mg/kg dose group.', 'Figure 2', 'Fitted Dose-Response Plot for ORR and Grade 2 Corneal Event', 'Rate', '25', '2.8', '31', '3.4', ',0', '0.8', '0.0', '0.4', '02', '0,0', 'o', '1', '2', '3', '4', 'Cose (mg/kg)', 'Fitted Response Rate', '95% Credible Interval (Response)', 'Observed Fesponsa Rate', 'Fittad Corneal Events Rate', '95% Credible Irterval (Corneal Events)', '*', 'Observed Correal Events Rate', '50']"
50,page_51,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 8', 'Summary of Predicted Mean Response and Mean >Grade 2 Corneal', 'Event* and 95% Credible Intervals (Parts 1 and 2, Study BMA117159)', 'Predicted response rate (%)', 'Predicted >G2 corneal AE rate', 'Dose (mg/kg)', '(95% credible interval)', '(%) (95% credible interval)', '1.92', '25.3 (9.4, 42.2)', '33.7 (18.3, 49.0)', '2.5', '37.0 (22.3, 51.6)', '43.4 (30.2, 56.9)', '3.4', '53.7 (40.3, 66.9)', '55.7 (42.3, 68.7)', '*Predicted values are based on the posterior distribution of response rate and corneal event rate per', 'CTCAE 4.03', 'In summary, based on the safety, tolerability, and clinical activity observed to date,', '2.5 mg/kg and 3.4 mg/kg were selected as the appropriate dose levels of GSK2857916 to', 'be further studied in this phase 2 study. The dose may be further individually adjusted in', 'participants experiencing adverse events, according to the guidance in the protocol.', '6.', 'STUDY POPULATION', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also', 'known as protocol waivers or exemptions, are not permitted.', '6.1.', 'Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria', 'apply:', '1. Provide signed written informed consent, which includes compliance with the', 'requirements and restrictions listed in the consent form', '2.', 'Male or female, 18 years or older (at the time consent is obtained)', '3.', 'Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Appendix', '8)', '4. Histologically or cytologically confirmed diagnosis of MM as defined according to', 'IMWG, [Rajkumar, 2014] criteria, and', 'a) Has undergone stem cell transplant or is considered transplant ineligible, and', 'b) Has failed at least 3 prior lines of anti-myeloma treatments, including an anti-', 'CD38 antibody (e.g., daratumumab) alone or in combination, and is refractory to', 'an IMiD (i.e., lenalidomide or pomalidomide), and to a proteasome inhibitor', '(e.g., bortezomib, ixazomib or carfilzomib). The number of prior lines of', 'therapy will be determined according to the guidelines in Rajkumar, 2015.', 'Refractory myeloma is defined as disease that is nonresponsive while on', 'primary or salvage therapy, or progresses within 60 days of last therapy.', 'Nonresponsive disease is defined as either failure to achieve at least minimal', 'response or development of progressive disease (PD) while on therapy', '[Rajkumar, 2011]', '51']"
51,page_52,"['2017N330177_04', 'CONFIDENTIAL', '205678', '5.', 'Has measurable disease with at least one of the following:', 'a.', 'Serum M-protein >0.5 g/dL(>5 g/L)', 'b.', 'Urine M-protein >200 mg/24h', 'c.', 'Serum FLC assay: Involved FLC level >10 mg/dL (>100 mg/L) and an', 'abnormal serum free light chain ratio (<0.26 or > -1.65)', '6. Participants with a history of autologous stem cell transplant are eligible for study', 'participation provided the following eligibility criteria are met:', 'a.', 'transplant was >100 days prior to study enrolment', 'b.', 'no active infection(s)', 'c. participant meets the remainder of the eligibility criteria outlined in this protocol', '7.', 'Adequate organ system functions as defined in Table 9.', 'Table 9', 'Criteria for Determining Adequate Organ System Function', 'System', 'Laboratory Values', 'Hematologic', 'Absolute neutrophil count (ANC)', '>1.0 X 10%/L', 'Hemoglobin', '>8.0 g/dL', 'Platelets', '>50 X 10%/L', 'Hepatic', 'Total bilirubin', '<1.5X ULN', '(Isolated bilirubin >1.5xULN is acceptable if bilirubin is', 'fractionated and direct bilirubin <35%)', 'ALT', '<2.5 X ULN', 'Renal', 'eGFRa', '>30 mL/min/ 1 1.73 m²', 'Spot urine (albumin/creatinine ratios (spot urine)', '<500 mg/g (56 mg/mmol)', 'Cardiac', 'LVEF (Echo)', '>45%', 'a.', 'As calculated MDRD equation (Appendix 10)', 'Note: Laboratory results obtained during Screening must be used to determine eligibility criteria. In situations', 'where laboratory results are outside the permitted range, the investigator may retest the participant and the', 'subsequent within range screening result may be used to confirm eligibility.', '8.', 'Female Participants: Contraceptive use by men or women should be consistent with', 'local regulations regarding the methods of contraception for those participating in', 'clinical studies.', 'A female participant is eligible to participate if she is not pregnant or breastfeeding,', 'and at least one of the following conditions applies:', 'Is not a woman of childbearing potential (WOCBP)', 'OR', 'Is a WOCBP and using a contraceptive method that is highly effective (with a', 'failure rate of <1% per year), preferably with low user dependency, during the', 'intervention period and for at least 80 days after the last dose of study', '52']"
52,page_53,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'intervention and agrees not to donate eggs (ova, oocytes) for the purpose of', 'reproduction during this period. The investigator should evaluate the', 'effectiveness of the contraceptive method in relationship to the first dose of', 'study intervention.', 'A WOCBP must have a negative highly sensitive serum pregnancy test (as', 'required by local regulations) within 72 hours before the first dose of study', 'intervention.', 'The investigator is responsible for review of medical history, menstrual history,', 'and recent sexual activity to decrease the risk for inclusion of a woman with an', 'early undetected pregnancy.', '9. Male Participants: Contraceptive use by men or women should be consistent with', 'local regulations regarding the methods of contraception for those participating in', 'clinical studies.', 'Male participants are eligible to participate if they agree to the following during the', 'intervention period and for at least 140 days:', 'Refrain from donating sperm', 'PLUS either:', 'Be abstinent from heterosexual intercourse as their preferred and usual lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent.', 'OR', 'Must agree to use contraception/barrier as detailed below:', 'Agree to use a male condom and female partner to use an additional highly', 'effective contraceptive method with a failure rate of <1% per year as when', 'having sexual intercourse with a woman of childbearing potential who is not', 'currently pregnant.', '10. All prior treatment-related toxicities (defined by National Cancer Institute- Common', 'Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.03, must be Grade 1', 'at the time of enrolment except for alopecia and Grade 2 peripheral neuropathy.', '11. (France only) A participant will be eligible for inclusion in this study only if either', 'affiliated to or a beneficiary of a social security category.', '53']"
53,page_54,"['2017N330177_04', 'CONFIDENTIAL', '205678', '6.2.', 'Exclusion Criteria', 'Participants satisfying any of these criteria are not eligible for assignment to treatment:', '1. Systemic anti-myeloma therapy within 14 days or 5 half-lives, whichever is', 'shorter, or plasmapheresis within 7 days prior to the first dose of study drug', '2. Systemic treatment with high dose steroids (equivalent to >60 mg prednisone', 'daily for >4 days) within the past 14 days if administered to treat MM or non-', 'MM disease', '3.', 'Symptomatic amyloidosis, active ""polyneuropathy, organomegaly,', ""endocrinopathy, myeloma protein, and skin changes' (POEMS) syndrome,"", 'active plasma cell leukemia at the time of screening.', '4.', 'Prior allogeneic stem cell transplant', '5.', 'Current corneal epithelial disease except mild punctate keratopathy', '6. Use of an investigational drug within 14 days or five half-lives, whichever is', 'shorter, preceding the first dose of study drug. Prior treatment with a', 'monoclonal antibody within 30 days of receiving the first dose of study drugs.', 'Prior BCMA targeted therapy.', '7.', 'Evidence of active mucosal or internal bleeding', '8. Any major surgery within the last four weeks', '9. Presence of active renal condition (infection, requirement for dialysis or any', ""other condition that could affect participant's safety). Participants with isolated"", 'proteinuria resulting from MM are eligible, provided they fulfil criteria given in', 'Table 9.', '10. Any serious and/or unstable pre-existing medical, psychiatric disorder or other', ""conditions (including lab abnormalities) that could interfere with participant's"", 'safety, obtaining informed consent or compliance to the study procedures.', '11. Current unstable liver or biliary disease per investigator assessment defined by', 'the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia,', 'esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable', ""chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones)"", 'or hepatobiliary involvement of malignancy is acceptable if participant', 'otherwise meets entry criteria.', '12. Malignancies other than disease under study are excluded, except for any other', 'malignancy from which the participant has been disease-free for more than 2', 'years and, in the opinion of the principal investigators and GSK Medical', 'Monitor, will not affect the evaluation of the effects of this clinical trial treatment', 'on the currently targeted malignancy (MM). Participants with curatively treated', 'non-melanoma skin cancer may be enrolled.', '13. Evidence of cardiovascular risk including any of the following:', 'a.', 'QTcF interval QTcF > 480 msec (the QT interval values must be corrected', ""for heart rate by Fridericia's formula [QTcF])"", '54']"
54,page_55,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'b.', 'Evidence of current clinically significant uncontrolled arrhythmias,', 'including clinically significant ECG abnormalities such as 2nd degree', '(Type II) or 3rd degree atrioventricular (AV) block.', 'c.', 'History of myocardial infarction, acute coronary syndromes (including', 'unstable angina), coronary angioplasty, or stenting or bypass grafting within', 'six months of Screening.', 'd.', 'Class III or IV heart failure as defined by the New York Heart Association', 'functional classification system [NYHA, 1994]', 'e.', 'Uncontrolled hypertension', '14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs', 'chemically related to GSK2857916, or any of the components of the study', 'treatment.', '15. Pregnant or lactating female.', '16. Active infection requiring antibiotic, antiviral, or antifungal treatment.', '17. Known HIV infection.', '18. Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody', '(HBcAb at screening or within 3 months prior to first dose of study treatment', '19. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at', 'screening or within 3 months prior to first dose of study treatment.', 'Note: Participants with positive Hepatitis C antibody due to prior resolved', 'disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is', 'obtained.', 'Note: Hepatitis RNA testing is optional and participants with negative Hepatitis', 'C antibody test are not required to also undergo Hepatitis C RNA testing.', '6.3.', 'Lifestyle Restrictions', 'Contact lenses are prohibited while the participant is on study.', '6.4.', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study', 'but are not subsequently enrolled. A minimal set of screen failure information is required', 'to ensure transparent reporting of screen failure participants to meet the Consolidated', 'Standards of Reporting Trials (CONSORT) publishing requirements and to respond to', 'queries from regulatory authorities. Minimal information to be entered into INFORM', 'includes demography, screen failure details, eligibility criteria, and any serious adverse', 'events (SAEs).', 'Individuals who do not meet the criteria for participation in this study (screen failure)', 'may be rescreened. Rescreened participants must be assigned a new unique participant', 'number that is different from the initial number.', '55']"
55,page_56,"['2017N330177_04', 'CONFIDENTIAL', '205678', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment intended to be administered to', 'a study participant according to the study protocol. GSK2857916 will be administered', 'intravenously.', 'GSK2857916 will be administered intravenously, at the study sites, as either 2.5 mg/kg or', '3.4 mg/kg calculated dose.', 'Product name:', 'GSK2857916', 'Frozen liquid, 30 mg/vial solution in single-use vial', 'or', 'Dosage form:', 'Lyophilized powder, 100 mg/vial in single-use vial for reconstitution', '(independent cohort with approximately 25 participants)', '30 mg/vial / 2.5 or 3.4 mg/kg (Frozen liquid)', 'Unit dose strength(s)/Dose Level(s):', 'or', '100 mg/vial / 2.5 or 3.4 mg/kg (Lyophilized powder)', 'Route of Administration', 'Delivered as IV solution over at least 30 minutes*.', 'Dilute GSK2857916 in normal 0.9% saline to the appropriate concentration for', 'the dose. Doses of GSK2857916 are to be administered as an IV infusion via', ""an infusion pump. See Investigator's Brochure for compatible administration"", 'Dosing instructions:', 'materials.', 'For lyophilized powder only: Reconstitute GSK2857916 lyophilized powder 100', 'mg/vial 2.0mL of water for injection (WFI); dilute with saline before use.', 'Manufacturer/ Source of', 'GSK/Baxter', 'Procurement:', '*Infusions may be prolonged in the event of an infusion reaction. If multiple participants experience clinically significant', 'infusion reactions, the infusion rate may be slowed for all future administrations of study treatment(s) for all', 'participants. Should this global change in infusion rate be required, it will be communicated to the sites in writing.', '7.1.', 'GSK2857916 Treatments Administered', 'GSK2857916 is to be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an', 'IV infusion, via an infusion pump. Administration of GSK2857916 will be documented', 'in the clinic source documents and reported in the electronic case report form (eCRF).', 'The time of start and end of infusion will be documented in eCRF.', 'GSK2857916 will be administered on Day 1 of each cycle. Premedication is not required', 'prior to infusion unless deemed medically necessary by the investigator, in which case it', 'should be administered according to institutional recommendations.', 'Any participant experiencing an IRR must receive appropriate medical treatment. When', ""the participant's condition is stable, the infusion may be restarted at a slower rate. For"", 'details on restarting the GSK2857916 infusion after interruption for IRR, please see', 'Table 11.', 'In general, upon restarting, the infusion rate must be decreased by half at the time the', 'infusion was interrupted.', 'Participants will be treated until disease progression, until unacceptable toxicity, or until', 'confirmed CR (Section 8).', '56']"
56,page_57,"['2017N330177_04', 'CONFIDENTIAL', '205678', '7.2.', 'Dose Modification', 'Dose modifications will be managed according to Dose Reduction Criteria and Guidance', 'provided in Table 11 and Table 12.', '7.2.1.', 'Adjustments Due to Body Weight', 'The actual body weight in kg at baseline (assessed on Cycle 1 Day 1 prior to dosing) will', 'be used for dose calculation of GSK2857916 in all participants during the treatment', 'period. However, if the change of body weight is greater than 10%, the dose must be', 'recalculated based on the actual body weight at the time of dosing.', '7.2.2.', 'Dose Reductions for Toxicity', 'After Cycle 1, participants may have their dose delayed or reduced for toxicities', 'according to the recommendations.', 'See Table 11 for dose modifications guidelines for GSK2857916 for specific toxicity', 'related AEs and Table 12 for guidelines for drug-related toxicities, not otherwise', 'specified AEs.', 'See Table 13 for dose modification guidelines for cornea-related AEs associated with', 'GSK2857916.', 'Permitted dose reductions for GSK2857916 are shown in Table 10.', 'Table 10', 'Permitted Dose Reductions', 'Starting dose', '1st reduction', '2nd reduction', '3.4 mg/kg', '2.5 mg/kg', '1.92 mg/kg', '2.5 mg/kg', '1.92 mg/kg', '--', 'If the participant cannot tolerate the drug after the allowed dose reductions, he or', 'she must be withdrawn from the study for lack of tolerability.', 'Only 1 dose reduction (to 1.92 mg/kg) is permitted for the lower starting dose of', '2.5 mg/kg.', 'In case of full resolution of symptoms which lead to dose reduction, further', 'treatment at the previous dose may be considered by the investigator.', 'Dosing delays are permitted in the case of medical/surgical events or for logistical', 'reasons not related to study therapy (e.g., elective surgery, unrelated medical events,', ""participant vacation, and/or holidays, but not for participants' decision to delay"", 'treatment). If a dose is delayed, the participant should wait for the next scheduled dose to', 'resume treatment. In individual cases where in the judgement of an investigator waiting', 'a full cycle to resume treatment after delay (skipping dose) related to toxicity which has', ""resolved would be detrimental to patient's health- the PI should contact Medical Monitor"", 'to discuss an earlier re-start. An earlier re-start may be considered only for patients who', 'have recovered from toxicity to at least G1 or less. The dosing with GSK2857916 cannot', '57']"
57,page_58,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'occur more frequently than every 21 days ( 3-day window). In such cases efficacy and', 'safety assessments must continue to be conducted every 3 weeks in line with initial', 'efficacy and safety assessments on study, which may result in 2 separate visits (1 for', 'dosing, 1 for disease assessments) (Table 2).', 'Evaluations associated with a Dose (Table 2) would be entered into the eCRF under the', 'next scheduled cycle.', ""The reason for any dose delay must be documented in the participant's eCRF and clinic"", 'record.', 'Resuming treatment with GSK2857916 will be possible with or without dose reduction', 'after the toxicity has resolved to Grade 1 or less.', '58']"
58,page_59,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 11', 'Dose Modification Guidelines for GSK2857916-Related Adverse', 'Events', 'Grade/description', 'Toxicity', 'Recommendations for GSK2857916', 'of toxicity', 'Elevated serum creatinine', 'If absolute serum', 'Repeat serum creatinine within 48 hours', 'which cannot be explained by', 'creatinine', 'If confirmed: withhold therapy, institute treatment and', 'concomitant sepsis, TLS, other', 'increases from', 'monitoring as clinically indicated, and follow for', 'severe condition with fever, or', 'baseline by >0.5', 'resolution', 'dehydration', 'mg/dL', 'Discuss any further dosing with Medical Monitora', '>3.0 mg/dL from', 'baseline', 'Serum creatinine >Grade 3', 'Provide appropriate medical treatment.', 'or', 'Permanently discontinue treatment with GSK2857916', '3.0-6.0xULN', 'Re-test (at least 7 days apart).', 'If not confirmed, continue GSK2857916 at 100% dose', 'If confirmed on re-test and no clear evidence of', 'disease progression', 'Interrupt treatment with GSK2857916', 'Repeat testing within 4 weeks', 'Spot urine (albumin / creatinine', '>2000 mg/g', 'i.', 'If spot urine <2000 mg/g (224 mg/mmol),', 'ratios)', '(or 224 mg/mmol)', 'may restart GSK2857916 with 25% dose', 'reduction', 'ii.', 'If spot urine remains >2000 mg/g', '(224 mg/mmol) after 4weeks, permanently', 'discontinue GSK2857916 and withdraw', 'participant from study; provide treatment as', 'clinically indicated and follow for resolution', 'No bleeding: continue treatment with 25% dose', 'reduction. Consider reverting to previous dose once', 'Thrombocytopenia', '3', 'thrombocytopenia recovered to G2 or less.', '(on days of dosing)', 'With bleeding: withhold the dose, continue treatment', 'after recovery with 25% dose reduction', 'Withhold the dose. Consider restarting with 25% dose', 'reduction if recovered, or transfused to <G3 only if', 'there is no active bleeding at time of treatment re-start', 'Thrombocytopenia', '4', '(On days of dosing)', 'If thrombocytopenia is considered disease related, is', 'not accompanied by bleeding, and recovers with', 'transfusion to >25x10%/L continuing treatment at 25-', '50% dose reduction may be considered after', 'discussion with the GSK Medical Monitor', 'Withhold the dose', '3-4', '(defined as: single', 'Implement treatment with antibiotics, antivirals and', 'temp of 38.3°C, or', 'antifungals, as clinically indicated, consider growth', 'Febrile neutropenia', 'factors', 'sustained 38°C for', '>1 hr. AND ANC', 'Continue treatment after resolution. Consider 25%', '<1000/mm³', 'dose reduction of GSK2857916, if neutropenia was', 'drug related', 'Stop the infusion, provide medical treatment and', '2', 'continue at half the original infusion rate after', 'resolution to Grade 0-1', 'Infusion Reaction', 'Further treatment with GSK2857916 needs to be', '3', 'discussed with Medical Monitor. Continuation only', 'allowed after recovery to <Grade 1 and with pre-', '59']"
59,page_60,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Grade/description', 'Toxicity', 'Recommendations for GSK2857916', 'of toxicity', 'medication, and extension of infusion time to 2-4 hours.', 'Any future infusion needs to be pre-medicated', '4', 'Permanently discontinue', '2', 'Continue treatment when toxicity resolves to Grade 0-1', 'Pneumonitis', 'Grade 3-4', 'Permanently discontinue', 'a.', ""Medical Monitor may consult GSK's nephrotoxicity panel about plans to continue therapy."", 'b.', 'If symptoms resolve within one hour of stopping infusion, the infusion may be restarted at 50% of the original', 'infusion rate (e.g., from 100 mL/hr. to 50 mL/hr.). Otherwise dosing will be held until symptoms resolve and the', 'participant must be pre-medicated for the next scheduled dose.', 'Table 12', 'General Dose Modification and Management Guidelines for Drug-', 'related Adverse Events Not Otherwise Specifieda', 'Severity', 'Management', 'Follow-up', 'Administer symptomatic', 'Grade 1', 'Provide close follow-up to evaluate for increased severity,', 'treatment as appropriate', 'no dose modification necessary', 'Continue study drug(s)a', 'Administer symptomatic', 'Symptoms resolved in 7 days:', 'Continue after resolution at the current dose', 'treatment', 'Symptoms ongoing >7 days or worsening:', 'Grade 2', 'Investigate etiology', 'Delay study drugb, or consider dose reduction by', 'Consider consulting', '25% If recovery takes >3 weeks- consult GSK MM', 'subspecialist, and/or', 'If symptoms continue or worsen to Grade 3-4, see', 'diagnostic procedure', 'below', 'Delay treatment till recovery to G1 or less. Consider dose', 'Provide appropriate medical', 'reduction. Consider consultation with GSK MM.', 'treatment', 'Grade 3', 'Exceptions: Participants who develop G3 toxicities which', 'Consider Consulting', 'respond to standard treatment and resolve to <G1 within 48', 'subspecialist', 'hours may continue treatment at scheduled or reduced', 'dose', 'Provide appropriate medical', 'treatment', 'Interrupt treatment. Further treatment with GSK2857916', 'Grade 4', 'Consider Consulting', 'only allowed on individual basis if in the discussion with MM', 'subspecialist', 'it is agreed that benefits outweigh the risks for a given', 'Discuss with', 'participant', 'Sponsor/Medical Monitor', 'a.', 'Treatment-related decisions can be made based on local laboratory results if central results are not available or', 'delayed.', 'b. In case a dose is delayed, the participant should wait for the next scheduled dose to resume treatment.', '60']"
60,page_61,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 13', 'Dose Modification Guidelines for GSK2857916 Treatment-Related', 'Corneal Events', 'Grade 1 per', 'Grade 2 per GSK', 'Grade 3 per GSK', 'Grade 4 per GSK', 'GSK Scale', 'Scale', 'Scale', 'Scale', 'GSK2857916', 'Continue', 'If either', 'Hold GSK2857916', 'Stop treatment with', 'Dosing', 'treatment with', 'ophthalmic exam', 'GSK2857916.', 'Actions', 'current dose', 'Upon', 'findings or visual', 'of', 'improvement of', 'Additional topical', 'acuity findings are', 'GSK2857916.', 'Grade 1, continue', 'either visual acuity', 'treatment may be', 'or ophthalmic', 'prescribed, as', 'dosing with', 'GSK2857916 at', 'exam findings to', 'recommended by', 'Grade 1 or', 'ophthalmologist*', 'current dose.', 'baseline, resume', 'with 25% dose', 'reduction*', 'Treatment re-start', 'If visual acuity', 'may be possible', 'and exam', '(* for participants', 'after discussion and', 'findings are both', 'receiving 1.92', 'agreement between', 'Grade 2, HOLD', 'mg/kg dose-', 'the treating', 'GSK2857916.', 'continue at 1.92', 'ophthalmologist*,', 'Upon', 'mg/kg)', 'treating physician,', 'improvement', 'the GSK Medical', 'of either visual', 'In case of recurring', 'Monitor and possibly', 'acuity or', 'a GSK', '>Gr3 events, consult', 'ophthalmic', 'GSK Medical', 'ophthalmologist', 'exam findings', 'monitor', '*or optometrist, if an', 'to Grade 1 or', 'ophthalmologist is', 'baseline,', 'not available', 'resume with', 'current dose', 'Corneal', 'Steroid Eye Drops:', 'Management', 'Care', 'If symptoms occur within the 7-day steroid eye drop prophylaxis window,', 'increase the frequency to 1 drop every 2-4 hours (6-12 times daily) and', 'Regardless', 'of Gradeb', 'continue until symptom resolution.', 'If symptoms occur after the 7-day prophylaxis window is complete, re-start', 'ocular steroid drops at 4x daily until symptom resolution.', 'Preservative-free artificial tears:', 'Increase to 1 drop as frequently as every 2 hours, as needed', 'a.', 'See Appendix 9 for GSK Scale for GSK2857916 Corneal Events', 'b.', 'In the sub-study of approximately 30 participants will receive monocular topical corticosteroids for the first 4', 'cycles, (or every 3 weeks in the case of dose delays) treatment of both eyes (in case of worsening', 'symptoms in the untreated eye) with topical corticosteroids will be at the discretion of the Investigator.', '61']"
61,page_62,"['2017N330177_04', 'CONFIDENTIAL', '205678', '7.2.3.', 'Corneal Supportive Care Guidelines', 'Corneal events, which commonly manifests as a superficial microcystic keratopathy, has', 'been observed with antibody drug conjugates, including those conjugated to MMAF.', 'Further information regarding corneal event associated with GSK2857916, including a', 'GSK corneal event scale and prophylactic measures are in Appendix 9.', 'Sites are required to establish a close collaboration with an ophthalmologist (or', 'optometrist, if an ophthalmologist is not available) who will be responsible for assessing', 'participants and managing those who develop a corneal event in close communication', 'with GSK Medical Monitor and possibly a GSK ophthalmologist.', 'Participants will be assessed by ophthalmologists (or optometrist, if an ophthalmologist is', 'not available) at baseline and every three weeks. If there are no corneal events at time of', 'the Cycle 4 exam, participants may have their ophthalmologic exams decreased to once', 'every 3 months. If a participant subsequently develops ocular symptoms, the participant', 'should be evaluated by an ophthalmologist (or optometrist, if an ophthalmologist is not', 'available). Intraocular pressure must be monitored if steroid eye drops are used', 'continuously for more than 7 days.', 'Participants who have corneal signs per the GSK Scale for corneal events present at end', 'of study will continue to be followed at 3 and 6 weeks after the EoT visit and then every', '6 weeks for up to 12 months, or until full resolution of ophthalmic changes, or deemed', 'clinically stable by an ophthalmologist/optometrist, whichever comes first.', 'At the selected sites, participants in the ocular sub-study will undergo additional', 'ophthalmic exams (see Section 9.2.10).', '7.3.', 'Method of Treatment Assignment', 'The Sponsor will supply a range of unique numbers to each site and participants eligible', 'for enrolment will be assigned a unique Participant Number by the site.', 'Before the study is initiated, log-in directions for the central Interactive Response', 'Technology (IRT) system will be provided to each site to be used to for study drug', 'supply.', 'Participant numbers are unique will not be reassigned to another participant if a', 'participant assigned a number is found to be a Screen Failure.', 'Participants will be assigned to study treatment in accordance with the randomization', 'schedule.', 'Participants will be identified by a unique participant number that will remain consistent', 'for the duration of the study.', 'Upon completion of all the required screening assessments, eligible participants will be', 'registered into the Registration and Medication Ordering System (RAMOS), the GSK', '62']"
62,page_63,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Interactive Response Technology (IRT, by the investigator or authorized site staff.', 'RAMOS allows study sites to register and randomize participants, and also records', 'stratification information.', 'The following information for stratification must be entered into the system to obtain the', 'treatment assignment:', 'number of prior lines of therapy', 'cytogenetic risk categories (high risk defined as t(4;14), t(14;16), and 17p13del vs', 'non-high risk - all others);', 'Randomization will be done centrally using a randomization schedule generated by the', 'GSK Clinical Statistics Department, which will assign participants in a 1:1 ratio to:', 'Arm 1: 3.4 mg/kg IV Q3W', 'Arm 2: 2.5 mg/kg IV Q3W', 'Once a randomization number has been assigned it must not be re-assigned even in cases', 'of errors.', 'In the lyophilized cohort participants will be assigned the 3.4 mg/kg dose level, unless the', 'results of the IA indicate that it should not be continued. In that case, the 2.5 mg/kg dose', 'level will be assigned to participants.', 'RAMOS Study Specific User Guide and Clinical Support Helpdesk contact information', 'will be provided to the study site in the SRM.', '7.4.', 'Blinding', 'This will be an open-label, 2-arm monotherapy study with an additional independent', 'cohort enrolled after lyophilized product is available. Therefore, sponsor will have', 'access to the participant level data throughout the study. However, there will be no', 'intention to summarize and interpret data from the ongoing study at any time point except', 'the pre-defined analyses.', 'In the ocular sub-study of participants (Section 9.2.10 and Appendix 9), the treating', 'ophthalmologist will remain blinded as to which eye receives the prophylactic', 'corticosteroid treatment.', '7.5.', 'Preparation/Handling/Storage/Accountability', 'The investigator or designee must confirm appropriate temperature conditions have been', 'maintained during transit for all study treatment received and any discrepancies are', 'reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only authorized', 'site staff may supply or administer study treatment. All study treatments must be stored', '63']"
63,page_64,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'in a secure, environmentally controlled, and monitored (manual or automated) area in', 'accordance with the labeled storage conditions with access limited to the investigator and', 'authorized site staff.', 'The investigator, institution, or the head of the medical institution (where applicable) is', 'responsible for study treatment accountability, reconciliation, and record maintenance', '(i.e., receipt, reconciliation, and final disposition records).', 'Further guidance and information for the final disposition of unused study treatment are', 'provided in the Study Reference Manual.', 'Under normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. Take adequate precautions to avoid direct eye', 'or skin contact and the generation of aerosols or mists. In the case of unintentional', 'occupational exposure notify the monitor, Medical Monitor, or GSK study contact.', 'A Material Safety Data Sheet (MSDS)/equivalent document describing occupational', 'hazards and recommended handling precautions either will be provided to the', 'investigator, where this is required by local laws, or is available upon request from GSK.', 'In the case of unintentional occupational exposure notify the monitor, Medical Monitor,', 'or GSK study contact.', '7.6.', 'Treatment Compliance', 'GSK2857916 will be administered intravenously to participants at the site.', 'Administration will be documented in the source documents and reported in the eCRF.', 'Study treatment is based on body weight calculation and may be reduced for toxicity for', 'individual participants according to protocol guidelines.', 'Participants will receive study treatment at the site directly from the investigator or', 'designee, under medical supervision. The date and time of each dose administered in the', 'clinic will be recorded in the source documents and reported in the eCRF. The dose of', 'study treatment and study participant identification will be confirmed at the time of', 'dosing by a member of the study site staff other than the person administering the study', 'treatment and documented in source.', '7.7.', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) that the participant is receiving at the time of', 'enrolment or receives during the study must be recorded along with:', 'reason for use', 'dates of administration including start and end dates', 'dosage information including dose and frequency', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', '64']"
64,page_65,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Participants will be instructed to inform the investigator prior to starting any new', 'medications from the time of first dose of study treatment until the end of the study (Final', 'Study Visit). Any concomitant medication(s) including non-prescription medication(s)', 'and herbal product(s), taken during the study will be recorded in the electronic case', 'report form (eCRF). Additionally, a complete list of all prior anti-cancer therapies will', 'be recorded in the eCRF.', 'If future changes are made to the list of permitted/prohibited medications, formal', 'documentation will be provided by GSK and stored in the study file. The SRM will be', 'updated to include this information. Any such changes will be communicated to the', 'investigative sites in the form of a letter.', '7.7.1.', 'Permitted Medication(s)', 'Participants should receive full supportive care during the study, including transfusions of', 'blood products, growth factors, and treatment with antibiotics, anti-emetics, antidiarrheal,', 'and analgesics, as appropriate. Concomitant therapy with bisphosphonates is allowed.', 'Participants may receive local irradiation for pain or stability control.', '7.7.2.', 'Prohibited Medication(s)', 'Chronic treatment with oral steroids is prohibited while the participant is on study, unless', 'for treatment of acute complications related to study treatment, or pre-medication prior to', 'GSK2857916 infusion. Steroids may be used to treat infusion-related reactions. Inhaled', 'steroids are allowed for management of asthma or COPD exacerbations. Chronic low', 'dose replacement therapy (less than or equal to 10 mg prednisolone) is allowed in', 'participants with adrenal insufficiency.', 'Concomitant administration of strong P-glycoprotein (P-gp) inhibitors with GSK2857916', 'should be avoided unless considered medically necessary. Please see the SRM for a list', 'of relevant P-gp inhibitors.', 'Elimination pathways for GSK2857916 or cys-mcMMAF in humans have not been', 'characterized, and care should be exercised when combined with potent cytochrome P450', '(CYP) inhibitors, CYP inducers, and transporter modulators.', 'Other prohibited therapies include:', 'Plasmapheresis: prohibited from 7 days prior to first dose through the end of', 'study.', 'Any other anti-cancer therapy not specified in this protocol, and any', 'investigational agents other than GSK2857916.', '7.7.3.', 'Prohibited Device(s)', 'Contact lenses are prohibited while the participant is on study.', '65']"
65,page_66,"['2017N330177_04', 'CONFIDENTIAL', '205678', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', ""study care of the participant's medical condition."", 'Refer to Section 9 and the SOA (Table 3) for follow-up assessments of participants who', 'are to be followed for disease progression and survival after they permanently', 'discontinue from study treatment.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', 'Participants will receive study treatment until disease progression, unacceptable toxicity,', 'or death (including but not restricted to meeting stopping criteria for significant toxicity', 'as outlined in Section 8.1).', 'Study treatment may be permanently discontinued for any of the following reasons:', 'disease progression or unacceptable toxicity.', 'participant has met any of the protocol defined safety stopping criteria', '(Section 7.2).', 'deviation(s) from the protocol', 'request of the participant or proxy (withdrawal of consent by participant or', 'proxy)', ""investigator's discretion"", 'concurrent illness that prevents further administration of study treatment(s)', 'pregnancy', 'participant is lost to follow-up', 'study is closed or terminated', 'The primary reason study treatment was permanently discontinued must be documented', ""in the participant's medical records and electronic case report form (eCRF)"", 'If the participant voluntarily discontinues from treatment due to toxicity, AE (adverse', 'event) must be recorded as the primary reason for permanently discontinuation on the', 'eCRF.', 'Once a participant has permanently discontinued from study treatment, the participant', 'will not be allowed to re-enter the study.', 'All participants who discontinue from study treatment for any reason other than', 'confirmed progression or death will complete safety assessments, and will be followed up', 'for PFS, OS, and subsequent anti-cancer therapy after study as specified in the SOA', '(Table 1).', '66']"
66,page_67,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'PFS Follow-up:', 'All participants who permanently discontinue study treatment in the absence of disease', 'progression will remain in the study and will be followed for progression according to the', 'protocol schedule until:', 'New anti-cancer therapy is initiated', 'Progression is documented, or', 'Death occurs', 'OS Follow-up:', 'All participants who permanently discontinue study treatment will be followed for', 'survival and new anti-cancer therapy until the end of study as described in Section 5.3.', 'Withdrawal from Study Treatment:', 'A participant may withdraw from study treatment at any time at his/her own request, or', 'may be withdrawn at any time at the discretion of the investigator for safety, behavioral', 'or administrative reasons. If a participant withdraws from the study, he/she may request', 'destruction of any samples taken, and the investigator must document this in the site', 'study records.', '8.2.', 'Safety Stopping Criteria', '8.2.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to', 'assure participant safety and evaluate liver event. The diagram below illustrates Liver', 'Stopping Event Algorithm (Figure : 3)', '67']"
67,page_68,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Figure 3', 'Liver Chemistry Stopping Criteria - Liver Stopping Event Algorithm', 'If subject to be monitored weeklymustreferto Liver Safety Required Actions and Follow up', 'Assessments section in the Appendix', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin22x', 'Yes', 'No', 'ULN (>35%', 'ALT23xULN', 'ALT>3xULN', 'ALT>3xULN', 'direct)', 'Plus', 'Yes', 'No', 'No', 'No', 'but able to', 'Yes', 'persist for', 'ALT23xULN', 'orplus', 'Symptoms of', 'ALT>5xULN', 'monitor', '4 weeks or', 'INR>1.5, if', 'liverinjury', 'weekly for', 'stopping', 'measured""', 'or', '4 weeks', 'criteria', 'Possible', 'hypersensitivity', 'met', ""Hy's Law"", 'Yes', 'Yes', 'No', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Mustrefer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', ""Reportas an SAE if possible Hy's Law case: AL Tz3xULN and Bilirubin22xULN (>35% direct) or"", 'INR>1.5 if measured*', '""INR valu e not applicable to subjects on anticoagulants', 'The details on follow up procedures are outlined in Appendix 7.', '8.2.2.', 'Study Treatment Restart or Rechallenge', 'If participant meets liver chemistry stopping criteria do not restart/rechallenge participant', 'with study treatment unless:', 'GSK Medical Governance approval is granted (as described below),', 'Ethics and/or IRB approval is obtained, if required, and', 'Separate consent for treatment restart/rechallenge is signed by the participant', 'If GSK Medical Governance approval to restart/rechallenge participant with study', 'treatment is not granted, then participant must permanently discontinue study treatment', 'and may continue in the study for protocol-specified follow up assessments.', '8.2.3.', 'QTc Interval Stopping Criteria', 'If a participant that meets the corrected QT (QTc) interval duration criteria below, study', 'treatment(s) will be withheld.', ""QT interval corrected for heart rate by Fridericia's formula (QTcF = QT"", '/', 'RR 0.33) > >530 msec', 'OR', '68']"
68,page_69,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Increase of QTcF by >60 msec from baseline', 'Based on average QTcF value of triplicate electrocardiograms (ECGs) to include', 'manual over-read. For example, if an ECG demonstrates a prolonged QT interval,', 'obtain 2 additional ECGs over a brief period (e.g., within approximately 10 minutes', 'of the abnormal ECG, if possible, and approximately 10 minutes apart from each', 'other), and then use the averaged QTc values of the 3 ECGs to determine whether', 'the participants should have study treatment(s) withheld. The QTc should be based', 'on single or averaged QTc values of triplicate electrocardiograms obtained over a', 'brief (e.g., 5-10 minute) recording period.', ""The QT interval should be corrected for heart rate by Fridericia's formula (QTcF)."", '8.2.4.', 'Left Ventricular Ejection Fraction (LVEF) Stopping Criteria', 'Echocardiography must be performed at Screening. If an ECHO is done at any point', 'during the study, the following stopping criteria are to be employed. Participants who', 'have an asymptomatic absolute decrease of > 10% in LVEF and the ejection fraction is', ""below the institution's lower limit of normal (LLN) should temporarily discontinue study"", 'treatment and have a repeat evaluation of LVEF within 1 week. Echocardiogram', '(ECHO) should be repeated every 1 to 2 weeks for 4 weeks or until LVEF recovery to', 'above institutional LLN and within 10% of baseline.', 'If the LVEF recovers (defined as institutional LLN and absolute decrease', '<10% compared with baseline) at any time during the next 4 weeks, after', 'consultation with and approval from the GSK medical monitor, the participant', 'may be restarted on GSK2857916 at a reduced dose. For such participants,', 'monitoring of LVEF will be performed 2 and 4 weeks after re-challenge, then', 'every 4 weeks for a total of 16 weeks.', 'If repeat LVEF does not recover within 4 weeks, treatment must be permanently', 'discontinued. Ejection fraction must be monitored every 4 weeks for a total of', '16 weeks or until resolution (whichever occurs first).', 'Participants with Grade 3 or 4 (symptomatic) left ventricular systolic dysfunction must', 'interrupt treatment with GSK2857916. Ejection fraction must be monitored every 4', 'weeks for a total of 16 weeks or until resolution. If recovery occurs (LVEF', '>', 'institutional LLN and symptom resolution) within 4 weeks, then treatment with', 'GSK2857916 may be restarted at a reduced dose in consultation with the medical', 'monitor.', '8.2.5.', 'Corneal Event Stopping Criteria', 'All GSK2857916 dose modifications and stopping criteria are to be based on the GSK', 'Scale for GSK2857916 Corneal Events (Appendix 9). Corneal events will be graded', 'according to both CTCAE criteria for eye disorders (see Section 9.2) and the guidelines', 'provided in Appendix 9. The treating physician or ophthalmologist (or optometrist, if an', 'ophthalmologist is not available) must discuss the participants who develop a Grade 4', 'corneal event according to the GSK scale with the GSK Medical Monitor or a GSK', 'ophthalmologist to determine whether the participant can be allowed to restart treatment', '69']"
69,page_70,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'with GSK2857916 or whether GSK2857916 should be permanently discontinued. The', 'decision will be documented in study files, together with individual assessment of risk-', 'benefit. For details on re-start guidance (Table 13).', '8.2.6.', 'Infusion-Related Reaction Management and Stopping Criteria', 'Premedication is not required prior to infusion unless deemed medically appropriate by', 'the investigator following evaluation of infusion related reactions. Premedication should', 'be considered in any participant who experienced an infusion related reaction at first or', 'any subsequent infusion with GSK2857916.', 'IRRs should be managed by guidelines provided in Table 11. A participant that', 'experiences a Grade 4 IRR should be permanently withdrawn from the study.', '8.2.7.', 'Allergic and Anaphylactic Reaction Stopping Criteria', 'All participants will be monitored carefully for evidence of allergic response. A', 'participant that exhibits signs or symptoms of severe hypersensitivity or anaphylaxis will', 'receive appropriate medical treatment and be permanently withdrawn from the study', 'treatment.', '8.3.', 'Withdrawal from the Study', 'A participant may withdraw from the study at any time at his/her own request,', 'or may be withdrawn at any time at the discretion of the investigator for safety,', 'behavioral, compliance or administrative reasons.', 'If the participant withdraws consent for disclosure of future information, the', 'sponsor may retain and continue to use any data collected before such a', 'withdrawal of consent.', 'If a participant withdraws from the study, he/she may request destruction of any', 'samples taken and not tested, and the investigator must document this in the site', 'study records.', 'Refer to the SOA for data to be collected at the time of study discontinuation', 'follow-up and for any further evaluations that need to be completed.', '8.4.', 'Lost to Follow Up', 'The following actions must be taken in relation to a participant who fails to attend the', 'clinic for a required study visit:', 'The site must attempt to contact the participant and re-schedule the missed visit', 'as soon as possible.', 'The site must counsel the participant on the importance of maintaining the', 'assigned visit schedule and ascertain whether or not the participant wishes to', 'continue or if the investigator believes that the participant should continue in the', 'study.', '70']"
70,page_71,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'In cases where the participant is deemed ""lost to follow up\', the investigator or', 'designee must make every effort to regain contact with the participant (where', ""possible, 3 telephone calls and if necessary a certified letter to the participant's"", 'last known mailing address or local equivalent methods). These contact', ""attempts should be documented in the participant's medical record."", 'Should the participant continue to be unreachable, only then will he/she be', 'considered to have withdrawn from the study with a primary reason of ""Lost to', 'Follow-up.""', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', 'A signed, written informed consent form must be obtained from the participant prior to', 'any study-specific procedures or assessments being performed. The timing of each', 'assessment is listed in the Schedule of Activities (Table 1).', 'A list of clinical laboratory tests is displayed in Table 14.', 'Whenever vital signs, 12-lead electrocardiograms (ECGs) and blood draws are scheduled', 'for the same nominal time, the assessments must occur in the following order: 12-lead', 'ECG, vital signs, blood draws. The timing of the assessments must allow the blood draw', 'to occur at the exact nominal time. Detailed procedures for obtaining each assessment', 'are provided in the SRM.', 'Study procedures and their timing are summarized in the SOA (Table 1 - Table', '3).', 'Protocol waivers or exemptions are not allowed.', 'Demographic and baseline assessments will include year of birth, sex, race, and', 'ethnicity.', 'Medical/medication/family history will be assessed as related to the', 'inclusion/exclusion criteria listed in Section 6.1 and Section 6.2.', 'Immediate safety concerns must be discussed with the sponsor immediately', 'upon occurrence or awareness to determine if the participant should continue or', 'discontinue study treatment.', 'Adherence to the study design requirements, including those specified in the', 'SOA, is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that', 'potential participants meet all eligibility criteria. The investigator will maintain', 'a screening log to record details of all participants screened and to confirm', 'eligibility or record reasons for screening failure, as applicable.', ""Procedures conducted as part of the participant's routine clinical management"", '(e.g., blood count) and obtained before signing of ICF may be utilized for', 'screening or baseline purposes provided the procedure met the protocol-', 'specified criteria and was performed within the time frame defined in the SOA.', '71']"
71,page_72,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Survival follow-up can be conducted by phone call.', 'Baseline disease assessments must be completed with 21 days prior to dosing', 'start unless otherwise specified. Refer to SOA.', 'Screening assessments performed within the permitted time do not need to be', 'repeated on C1D1 unless otherwise specified.', 'Safety labs completed within 72 hours of first dose do not need to be repeated', 'on C1D1.', 'Pregnancy testing must be completed within 72 hours prior to first dose.', 'ECHO must be completed within 35 days prior to first dose.', 'Imaging must be completed within 30 days prior to first dose.', 'On-study visits have a +3-day window', 'PFS follow-up visits have a +7-day window.', 'Survival follow-up visits have a +14-day window.', '72']"
72,page_73,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 14', 'List of Clinical Laboratory Tests', 'Hematology1', 'Platelet Count', 'RBC Indices:', 'Automated WBC', 'Differential:', 'Red blood cell (RBC) Count', 'MCV', 'Neutrophils', 'White blood cell (WBC)', 'MCH', 'Lymphocytes', 'Count (absolute)', 'Reticulocyte Count', 'MCHC', 'Monocytes', 'Hemoglobin', 'Eosinophils', 'Hematocrit', 'Basophils', 'Clinical Chemistry1', 'Blood urea nitrogen (BUN)', 'Potassium', 'Aspartate aminotransferase', 'Total and direct', '(AST)', 'bilirubin', 'Creatinine', 'Chloride', 'Alanine aminotransferase', 'Uric Acid', '(ALT)', 'Glucose', 'Total bicarbonate', 'Gamma glutamyl transferase', 'Albumin', '(GGT)', 'Sodium', 'Calcium', 'Alkaline phosphatase', 'Total Protein', 'Magnesium', 'Phosphorous', 'Creatine kinase (CK)', 'LDH', 'eGFR', 'Spot urine (albumin /', 'creatinine ratio)5,', 'Urine¹', 'Routine Urine Dipstick (Urinalysis required if blood or protein is detected by dipstick)', 'Specific gravity', 'pH, glucose, protein, blood and ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other Safety', 'C-reactive protein (CRP)', 'Troponin |5', 'B-type natriuretic peptide (BNP)5', 'Follicle stimulating hormone (FSH) and estradiol (as needed in women of non-child bearing potential only) (screening)', 'Pregnancy Test (urine or blood- per local practice)¹', 'Hepatitis B surface antigen (HBsAg)¹', 'Hepatitis B core antibody (HBcAb)1', 'Hepatitis C (Hep C antibody)1', 'Note: Hep C RNA testing is optional but may be done to determine participant eligibility if Hep C antibody positive).', 'Participants with positive Hepatitis C antibody due to prior resolved disease may be offered hepatitis C RNA testing to', 'determine eligibility.', '73']"
73,page_74,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 14', 'List of Clinical Laboratory Tests (cont.)', 'PK/ADA', 'Pharmacokinetics (PK)2,3', 'Anti-Drug Antibodies (ADA2,', '3', 'Optional Testing', 'PGx²', 'Optional tissue sample at PD for BCMA (BM aspirate clot, or fresh tissue, or tissue block from', 'extramedullary tumor)2', 'Disease Evaluation Laboratory Tests', 'Urine Protein', 'urine Immunofixation²', '24-hour urine collection', 'Calcium corrected for', 'Electrophoresis (UPEP)2', 'for M-protein²', 'albumin (serum) 2', 'Serum Protein', 'Serum M-protein', 'Serum Immunofixation²', 'Beta2 microglobulin²', 'Electrophoresis (SPEP)2', 'calculation 2', 'Serum Kappa, lambda free', 'IgG, IgA, IgM,', 'LC, FLC ratio²', 'lgD4), IgE42²', 'Bone Marrow Aspiration/Biopsy', 'Bone marrow for MRD testing2', 'Bone marrow (aspirate preferred) for disease assessment¹', 'Bone marrow biopsy to confirm sCR by IHC1,7', 'Bone marrow for FISH testing5,6', 'Bone marrow aspirate for BCMA IHC assessment²', 'Biomarker Measurements', 'Soluble BCMA (sBCMA)', 'cfDNA (plasma)2', '(Serum)2', '1. To be performed at local laboratory.', '2. To be performed at central laboratory.', '3. Not needed at screening', '4. Only for participants with lgD/E myeloma', '5. If not available from local laboratory, it can be performed at central laboratory.', '6. FISH testing at least for: t(4;14), t(14;16), 17p13del. BM samples from within 60 days prior to first dose are', 'acceptable for FISH analysis. If not available from local laboratory, a bone marrow aspirate can be sent to central', 'lab for analysis. If the participant is known to have high risk disease from previous FISH tests regardless of', 'timing (i.e.: t(4;14), or t(14;16) they should be stratified as High Risk for the purpose of enrollment.', '7. Results from tests to confirm sCR will be collected and stored by third party vendor and reviewed by IRC.', '8. Obtained from first void', '9.1.', 'Efficacy Assessments', 'Standard disease assessments for RRMM will include the following assessments:', 'UPEP, Urine Immunofixation, 24 hr. collection for urine M-protein', 'SPEP, Serum M-protein, serum immunofixation', 'Calcium corrected for albumin', 'IgG, IgM, IgA', 'IgD, IgE (only in participants with IgD or IgE myeloma)', 'Serum Kappa, lambda free LC, FLC ratio', '74']"
74,page_75,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Bone marrow (aspirate preferred) at screening and to confirm CR. Additional', 'BM testing for MRD testing in case of VGPR or CR is achieved, and BM biopsy', 'for immunohistochemistry (IHC) to confirm sCR.', 'Imaging of extramedullary disease (in participants with extramedullary disease)', 'Germany: Only MRI is allowed to be used as imaging modality for', 'participants with extramedullary disease.', 'PET/CT is required upon achieving CR or sCR', 'Germany: no PET/CT to confirm CR or sCR will be performed until approval', 'by the German Federal Office for Radiation Protection until further notice.', 'Skeletal surveys at screening', 'Germany: Only MRI is allowed to be used as imaging modality of bones for', 'lytic lesions.', 'Response evaluation will be performed according to the IMWG Uniform Response', 'Criteria for Multiple Myeloma [Kumar, 2016].', 'Baseline serum/urine disease assessment will be completed during screening period', '(within 21 days prior to the first dose of study treatment) and baseline imaging within 30', 'days prior to the first dose of study treatment. On study serum and urine based', 'assessments (M-protein, FLC, immunofixation) will be performed every 3 weeks.', 'Details for the preparation and shipment of samples for central laboratory assessments', 'will be provided in the SRM.', 'In participants with extramedullary myeloma, the disease assessments must include', 'imaging (e.g., CT, MRI, or PET-CT scans- the same method should be used throughout', 'the study) and physical examination (as indicated for palpable/superficial lesions).', 'For participants who are followed by imaging for extramedullary disease the imaging', 'must be performed as described in the SOA (Section 2).', 'All assessments on study must be performed on a calendar schedule and must not be', 'affected by dose interruptions/delays. For post-baseline assessments, a window of', '+3 days is permitted to allow for flexible scheduling.', 'For participants who are discontinuing IP due to PD the confirmation must be performed', 'from a different blood collection performed either on the same day, or within 14 days of', 'the original disease progression, preferably before initiation of any new anti-myeloma', 'therapy.', 'The assessments may be performed during End of Treatment Visit (Table 3) for the', 'Schedule of Activities of anti-cancer activity', 'If the last imaging assessment was greater than or equal to 8 weeks prior to the', ""participant's discontinuation from study treatment and progressive disease has not been"", 'documented, a new disease assessment must be obtained at the time of discontinuation', 'from study treatment.', '75']"
75,page_76,"['2017N330177_04', 'CONFIDENTIAL', '205678', '9.1.1.', 'Independent Review Committee', 'An Independent Review Committee (IRC) will be utilized to assess efficacy endpoints of', 'the study. All laboratory parameters and lesion measurements used to assess participant', 'response will be shared with the IRC. Additional information can be found in Appendix', '3 and in the IRC Charter.', '9.2.', 'Adverse Events', 'The definitions of an AE or SAE can be found in Appendix 4.', 'Adverse events will be coded using the standard MedDRA and grouped by system organ', 'class. Adverse events will be graded by the investigator according to the NCI-CTCAE,', '(version 4.03). Corneal events associated with GSK2857916 will also be graded', 'according to the GSK corneal event scale provide in Appendix 9. Dose modifications as', 'a result of corneal events will be based on the GSK scale for corneal events (Table 22).', 'The investigator and any designees are responsible for detecting, documenting, and', 'reporting events that meet the definition of an AE or SAE and remain responsible for', 'following up AEs that are serious, considered related to the study treatment or the study,', 'or that caused the participant to discontinue the study treatment (see Section 8).', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', 'All SAEs will be collected from the start of treatment until 45 days following', 'discontinuation of study treatment regardless of initiation of a new cancer', 'therapy or transfer to hospice at the time points specified in the SOA (Table 1,', 'Table 2, and Table 3). However, any SAEs assessed as related to study', 'participation (e.g., study treatment, protocol-mandated procedures, invasive', 'tests, or change in existing therapy) or related to a GSK product will be recorded', 'from the time a participant consents to participate in the study up to and', 'including any follow-up.', 'All AEs will be collected from the start of treatment until 45 days following', 'discontinuation of study treatment regardless of initiation of a new cancer', 'therapy or transfer to hospice at the time points specified in the SOA.', 'Medical occurrences that begin before the start of study treatment but after', 'obtaining informed consent will be recorded on the Medical History/Current', 'Medical Conditions section of the electronic case report form (eCRF) not the AE', 'section.', 'All SAEs will be recorded and reported to the sponsor or designee immediately', 'and under no circumstance should this exceed 24 hours, as indicated in', 'Appendix 4. The investigator will submit any updated SAE data to the sponsor', 'within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'participants. However, if the investigator learns of any SAE, including a death,', 'at any time after a participant has been discharged from the study, and he/she', '76']"
76,page_77,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'considers the event to be reasonably related to the study treatment or study', 'participation, the investigator must promptly notify the sponsor.', 'The method of recording, evaluating, and assessing causality of AEs and SAEs', 'and the procedures for completing and transmitting SAE reports are provided in', 'Appendix 4.', '9.2.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AEs and SAEs. Open-ended and', 'non-leading verbal questioning of the participant is the preferred method to inquire about', 'AE occurrence.', '9.2.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All SAEs, and non-serious AEs of clinical', 'interest, will be followed until the event is resolved, stabilized, otherwise explained, or', 'the participant is lost to follow-up (as defined in Section 8.4). Further information on', 'follow-up procedures is given in Appendix 4.', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to the sponsor of a SAE is essential so', 'that legal obligations and ethical responsibilities towards the safety of', 'participants and the safety of a study treatment under clinical investigation are', 'met.', 'The sponsor has a legal responsibility to notify both the local regulatory', 'authority and other regulatory agencies about the safety of a study treatment', 'under clinical investigation. The sponsor will comply with country-specific', 'regulatory requirements relating to safety reporting to the regulatory authority,', 'Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and', 'investigators.', 'Investigator safety reports must be prepared for suspected unexpected serious', 'adverse reactions (SUSAR) according to local regulatory requirements and', 'sponsor policy and forwarded to investigators as necessary.', 'An investigator who receives an investigator safety report describing a SAE or', 'other specific safety information e.g., summary or listing of SAE) from the', ""sponsor will review and then file it along with the Investigator's Brochure and"", 'will notify the IRB/IEC, if appropriate according to local requirements.', '9.2.5.', 'Cardiovascular and Death Events', 'The Death CRF is provided immediately after the occurrence or outcome of death is', 'reported. Initial and follow-up reports regarding death must be completed within one', 'week of when the death is reported.', '77']"
77,page_78,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'For any cardiovascular events detailed in Appendix 4 and all deaths, whether or not they', 'are considered SAEs, specific Cardiovascular (CV) and Death sections of the eCRF will', 'be required to be completed. These sections include questions regarding cardiovascular', '(including sudden cardiac death) and non-cardiovascular death.', 'The CV eCRFs are presented as queries in response to reporting of certain CV MedDRA', 'terms. The CV information must be recorded in the specific cardiovascular section of the', 'eCRF within one week of receipt of a CV Event data query prompting its completion.', '9.2.6.', 'Disease-Related Events and/or Disease-Related', 'Disease progression does not need to be reported as a serious adverse event (SAE).', 'Death due to disease under study is to be recorded on the Death electronic case report', 'form (eCRF). However, if the underlying disease (i.e., progression) is greater than that', 'which would normally be expected for the participant, or if the investigator considers that', 'there was a causal relationship between treatment with study treatment(s) or protocol', 'design or procedures and the disease progression, then this must be reported as a SAE.', '9.2.7.', 'Adverse Events of Special Interest', 'Adverse events of special interest (AESI) for GSK2857916 are corneal events,', 'thrombocytopenia and infusion related reactions. The severity of all AESI will be graded', 'utilizing the National Cancer Institute- Common Toxicity Criteria for Adverse Events.', 'Severity of corneal events will also be graded using the GSK scale for corneal events', 'provided in Table 22. Guidelines for dose modifications and interruptions for', 'management of common toxicities associated with the study treatment(s) are provided in', 'Table 11. Dose modifications for GSK2857916 corneal events will be based on the GSK', 'scale for corneal events in Table 22.', '9.2.8.', 'Pregnancy', 'Do not collect pregnancy information for female participants known to be pregnant', 'during the screening phase or before exposure to study.', 'The need for a screening pregnancy test depends on whether a female participant is of', 'childbearing potential or non-childbearing potential.', 'If a female participant is of childbearing potential, she must have a serum ß-human', 'chorionic gonadotropin (B-HCG) pregnancy test performed within 72 hours prior to the', 'first dose of study treatment. Participants with positive pregnancy test result must be', 'excluded from the study. Participants with negative pregnancy test result must agree to', 'use an effective contraception method as described below during the study until 80 days', 'following the last dose of study treatment.', 'Details of all pregnancies in female participants and female partners of male', 'participants will be collected after the start of study treatment and until', 'approximately 80 days.', 'If a pregnancy is reported, the investigator must inform GSK within 24', 'hours of learning of the pregnancy and must follow the procedures outlined', 'in Appendix 5.', '78']"
78,page_79,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death,', 'stillbirth, congenital anomalies, and ectopic pregnancy) are considered', 'SAE.', '9.2.9.', 'Ocular Examinations and Procedures', 'A full baseline ophthalmic examination for all participants must include, but is not', 'limited to:', '1.', 'Best corrected visual acuity', '2.', 'Documentation of manifest refraction used to obtain best corrected visual acuity', '3.', 'Current glasses prescription (if applicable)', '4.', 'Pupillary exam', '5.', 'Extraocular muscle movements (graded from one to four with (+) sign', 'indicating over action, (-) sign indicating under action and 0 representing normal', 'movements', ""6. Tear film examination: Schirmer's test with anesthesia and tear breakup time"", '7.', 'Intraocular pressure measurement & time checked', '8.', 'Full anterior segment examination including fluorescein staining of the cornea:', '9.', 'Anterior segment exam (slit lamp) includes: orbit/lids/adnexa, conjunctiva,', 'sclera, cornea, anterior chamber, iris, lens and anterior vitreous', '10. Anterior segment photography of a fluorescein stained cornea', '11. Dilated funduscopic exam: fundus photography with interpretation.', '12. Pachymetry', 'The on treatment and follow-up ophthalmic exam must include everything except:', 'dilated funduscopic exam /, including fundus photography, anterior segment', 'photography, extraocular muscle movements, (which must be performed as clinically', 'indicated) and current glasses prescription (if applicable). The last follow-up ophthalmic', 'visit should also include anterior segment photography of a fluorescein stained cornea.', 'Representative images will be collected and stored centrally.', 'The end of study treatment visit ophthalmic exam should match the baseline (screening)', 'exam.', 'Additional examinations should be performed at the discretion of the treating eye', 'specialist.', '9.2.10.', 'Ocular Sub-Study Examinations', 'Refer to Table 4 for the schedule of assessments for ocular sub-study of participants', 'Although ocular corticosteroids have been used in both published studies (Tannir, 2014;', 'Moskowitz, 2015; Thompson, 2015; Reardon, 2016; Macsai, 2016) and BMA117159 to', 'ameliorate the frequency and severity of MMAF-associated corneal events, this has yet to', '79']"
79,page_80,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'be investigated systematically. Furthermore, the effect of MMAF-conjugated ADCs on', 'the eye has not been fully delineated in studies to date. Therefore, Study 205678 will', 'include a sub-study of approximately 30 participants (~15 participants each dose) to', 'evaluate the effect of ophthalmic topical corticosteroids on GSK2857916-associated', 'corneal findings and to further characterize these findings. This sub-study of participants', 'will be recruited at selected investigational sites associated with ophthalmologists with', 'subspecialty training/expertise in the cornea. These participants will undergo additional', 'ophthalmic examinations during the first 4 cycles of treatment at a minimum or as', 'clinically indicated as determined by the treating ophthalmologist. A separate informed', 'consent (in addition to the main study ICF) will be obtained from these participants.', '9.2.10.1. Monocular prophylaxis', 'Figure 4 summarizes the prophylaxis administration schedule in the ocular sub-study of', 'participants.', 'The treating ophthalmologist, but not the participant, will be blinded as to which eye has', 'received the prophylactic steroid treatment.', 'Randomization will be done within each treatment arm centrally using a randomization', 'schedule, which will assign participants in a 1:1 ratio to:', 'receive topical corticosteroids in right eye only', 'receive topical corticosteroids in left eye only.', 'The participants of the sub-study will administer prophylactic corticosteroid eye drops', '(prednisolone acetate 1%, prednisolone phosphate 1%, dexamethasone 0.1%, or', 'equivalent, 1 drop four times daily starting one day prior to dosing for a total of 7 days).', 'They will be instructed to administer the steroid drops in only one eye.', 'Corticosteroid treated eye', 'Participant should administer 1 drop of topical corticosteroid followed by 1 drop of', 'preservative-free artificial tears 5-10 minutes later, four times daily. This should start', 'one day prior to dosing for a total of 7 days.', 'Other Eye', 'Participants should administer 1 drop of preservative-free artificial tears followed by', 'another 1 drop of preservative-free artificial tears 5-10 minutes later, 4-8 times daily.', 'This should start one day prior to dosing for a total of 7 days. Outside the 7-day', 'prophylaxis period, preservative-free artificial tears should be administered in each', 'eye at least 4-8 times daily as needed (See Appendix 9, Section 12.9).', '80']"
80,page_81,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Figure 4', 'Ocular prophylaxis schematic', 'Prophylaxis', 'Randomization: Right/Left Eye', 'Topical', 'Drops', 'Preservative Free', 'Matched in', 'Corticosteroids QID', 'Frequency', 'Artificial Tears QID', 'Wait 5 minutes', 'Wait 5 minutes', 'Preservative Free', 'Preservative Free', 'Artificial Tears QID', 'Artificial Tears QID', 'Next Dosing', '9.2.10.2.', 'Monocular treatment', 'If a participant in the ocular sub-study develops a corneal event outside the 7-day', 'prophylaxis period, steroid eye drops may be restarted in only one eye at the discretion of', 'the treating ophthalmologist. If steroid treatment is started in only one eye refer to Table', '13 and treat the contralateral eye with an equal number of preservative-free artificial', 'tears.', 'Alternatively, the treating ophthalmologist may start topical corticosteroid treatment in', 'both eyes at any time if clinically indicated and beneficial to the participant (Table 13).', 'If such decision is made at any time between treatment cycles 1 to 4, the participant will', 'receive further prophylaxis and treatment as any other participant on the study according', 'to Section 9.2.9 but will continue to undergo additional imaging as described below.', 'The treating ophthalmologist may unblind themselves at any time if they believe it to be', 'in the best interest of the participant. This may be done by asking the clinical site staff.', 'After Cycle 4, monocular steroid treatment will be performed at the discretion of the', 'treating ophthalmologist', '9.2.10.3.', 'Sub-Study Exams', 'Participants will be assessed by the treating ophthalmologist at baseline, every 3 weeks or', 'prior to each dose, and on Day 10 of Cycles 1, 2, 3, and 4. After Cycle 4, the Day 10', 'exam may be omitted.', 'In addition to the full ophthalmic exam (Section 9.2.9), the participants at these selected', 'sites will undergo the following additional studies during screening (baseline), at the first', '81']"
81,page_82,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'instance of corneal changes attributable to GSK2857916, end of study treatment visit, last', 'follow-up visit and as clinically indicated by the treating ophthalmologist:', '1.', 'Anterior segment OCT (optical coherence tomography)', '2.', 'Anterior segment/corneal slit lamp photography', '3.', 'Confocal microscopy (if available at the site)', '4.', 'Lissamine green staining', 'Given that these evaluations are exploratory, the treating ophthalmologist has the', 'discretion to perform them more frequently as they believe appropriate for the optimal', 'care of the individual participant. Representative images will be collected and stored', 'centrally.', '9.3.', 'Treatment of Overdose', 'There is no specific antidote for an overdose of GSK2857916. GSK does not recommend', 'a specific treatment for an overdose of GSK2857916.', 'In the event of an overdose of GSK2857916, the investigator must:', 'contact the GSK Medical Monitor immediately', 'monitor the participant closely for AEs/ SAEs and laboratory abnormalities until', 'GSK2857916 can no longer be detected systemically (at least 3 months).', '9.4.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SOA (Table 1).', '9.4.1.', 'Physical Examinations', 'At screening, on dosing days, and at end of study treatment visit a full physical', 'examination will include assessments of the head, eyes, ears, nose, throat, skin, thyroid,', 'lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities. Height', '(once at screening only) and weight must also be measured and recorded.', '9.4.2.', 'ECOG Performance Status', 'Participant performance status will be assessed at Screening, every 3 weeks starting at', 'Week 4 and End of Treatment using the Eastern Cooperative Oncology Group (ECOG)', 'scale, provided in Appendix 8.', '9.4.3.', 'Vital Signs', 'Vital sign measurements must include systolic and diastolic blood pressure, temperature,', 'and pulse rate. Vital signs must be measured after resting for at least 5 minutes. Vital', 'signs must be measured more frequently if warranted by the clinical condition of the', '82']"
82,page_83,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'participant. On days where vital signs are measured multiple times, temperature does not', 'need to be repeated unless clinically indicated.', '9.4.3.1.', 'First Infusion', 'Monitoring intervals: Vital signs must be monitored at designated time points related to', 'drug infusion as specified in the Schedule of Activities (Section 2). In general,', 'participants must also be monitored for at least 1 hour after the completion of the first', 'infusion and may be discharged if considered clinically stable and all other study', 'procedures have been completed.', '9.4.3.2.', 'Subsequent Infusions', 'Monitoring intervals: Vital signs must be monitored at designated time points related to', 'drug infusion as specified in the Schedule of Activities (Section 2). Participants may be', 'discharged after the infusion has been completed if considered clinically stable and all', 'other study procedures have been completed.', '9.4.4.', 'Electrocardiogram', '12-lead electrocardiogram (ECGs) must be obtained in triplicate at designated time points', 'specified in the Schedule of Activities (Section 2). The ECG machine must automatically', 'calculate the heart rate and measure PR, QRS, QT, and corrected QT (QTc) intervals. At', 'each assessment, a 12-lead ECG must be performed by qualified personnel at the site', 'after the participant has at least a 10-minute rest.', 'At each time point at which triplicate ECGs are required, 3 individual ECG tracings', 'should be obtained as closely as possible in succession, but no more than 2 minutes apart.', 'The full set of triplicate ECGs should be completed in 4 minutes or less.', ""The QT interval must be corrected for heart rate by Fridericia's formula (QTcF). Refer to"", 'Section 8.3 for QTc withdrawal criteria. Refer to the SRM for details regarding ECG', 'procedures.', '9.4.5.', 'Echocardiogram', 'Echocardiograms (ECHOs) must be performed at baseline to assess cardiac ejection', 'fraction for the purpose of study eligibility, as specified in the SOA. The evaluation of', 'the echocardiographer must include an evaluation for left ventricular ejection fraction', '(LVEF). If an ECHO is performed on study the results must be documented in the e-', 'CRF.', '9.4.6.', 'Laboratory Assessments', 'All protocol-required laboratory assessments, as defined in Table 14, must be performed', 'according to the SOA (Section 2). Details for the preparation and shipment of samples', 'for central laboratory assessments will be provided in the SRM.', 'The investigator must review the laboratory report, document this review, and record any', 'clinically relevant changes occurring during the study in the AE section of the CRF. The', '83']"
83,page_84,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'laboratory reports must be filed with the source documents. Clinically significant', 'abnormal laboratory findings are those which are not associated with the underlying', 'disease, unless judged by the investigator to be more severe than expected for the', ""participant's condition."", 'All laboratory tests with values that are significantly abnormal during participation in the', 'study or within 45 days after the last dose of study treatment must be repeated until the', 'values return to normal or baseline.', 'If such values do not return to normal within a period judged reasonable by the', 'investigator, the etiology must be identified and the sponsor notified.', 'Hematology, clinical chemistry, urinalysis, and additional parameters to be tested are', 'listed, with detailed instructions and timing, in the SRM.', '9.4.7.', 'Patient-Reported Outcome Version of the Common Term Criteria', 'for Adverse Events (PRO-CTCAE)', 'The Patient-Reported Outcomes Version of the Common Terminology Criteria for', 'Adverse Events (PRO-CTCAE) is a patient-reported outcome measure developed to', 'evaluate symptomatic toxicity in patients on cancer clinical trials [Basch, 2014]. The', 'PRO-CTCAE was designed to be used as a companion to the Common Terminology', 'Criteria for Adverse Events (CTCAE), the standard lexicon for adverse event reporting in', 'cancer trials. The PRO-CTCAE includes an item library of 124 items representing 78', 'symptomatic toxicities drawn from the CTCAE. PRO-CTCAE provides a systematic yet', 'flexible tool for descriptive reporting of symptomatic treatment side effects in cancer', 'clinical trials. In the present study, a sub-study of items selected from the PRO-CTCAE', 'Version 1.0 Item library will be administered. The PRO-CTCAE will be administered to', 'participants in different regions based on the availability of translated versions.', '9.4.8.', 'Visual Function Questionnaires', 'The impact of potential ocular toxicity on function and health-related quality-of-life will', 'be assessed with the use of two visual function questionnaires, the NEI-VFQ-25 and', 'OSDI. All participants will use the Self-Administered version of the questionnaires,', 'unless their vision prevents them from being able to complete the questionnaire on their', 'own. Participants who are not able to complete the questionnaire on their own and', 'require assistance must use an Interviewer Administered format. If the Interviewer', 'Administered format is being used, it must be read to the participants verbatim, and', 'participant responses must be recorded directly without any interpretation. For any', 'additional assessments conducted via telephone (either during participation in the', 'treatment period or during Follow-up), the Interviewer Administered format must be', 'used.', 'The NEI-VFQ-25 and OSDI will be administered to participants in different regions', 'based on the availability of translated versions.', '84']"
84,page_85,"['2017N330177_04', 'CONFIDENTIAL', '205678', '9.4.8.1.', 'National Eye Institute Visual Function Questionnaire-25', 'The NEI-VFQ-25 consists of a base set of 25 vision-targeted questions representing 11', 'vision-related constructs, plus an additional single-item general health rating question', '[Orr, 2011; Kirwan, 2012; Mangione, 2001]. These include a global vision rating (1', 'item); difficulty with near vision activities (3 items); difficulty with distance vision', 'activities (3 items); limitations in social functioning due to vision (2 items); role', 'limitations due to vision (2 items); dependency on others due to vision (3 items); mental', 'health symptoms due to vision (4 items); driving difficulties (3 items); limitations with', 'peripheral vision (1 item), limitations with color vision (1 item); and Ocular pain (2', 'items). In addition to the core items from the NEI-VFS-25, select questions from the', 'Appendix of Optional Additional Questions will also be administered to further assess the', 'impact of ocular toxicity on visual function.', '9.4.8.2.', 'The Ocular Surface Disease Index', 'The Ocular Surface Disease Index (OSDI) is a 12-item questionnaire designed to assesses', 'both the frequency of dry eye symptoms and their impact on vision-related functioning', '[Schiffman, 2000; Dougherty, 2011]. The OSDI has demonstrated good reliability,', 'validity, sensitivity, and specificity, and can be used as a complement to other clinical', 'and subjective measures of dry eye disease by providing a quantifiable assessment of dry', 'eye symptom frequency and the impact of these symptoms on vision-related functioning.', '9.5.', 'Pharmacokinetics', '9.5.1.', 'Blood Sample Collection for Pharmacokinetics', 'Blood samples for pharmacokinetic (PK) analysis of GSK2857916 (ADC and total', 'antibody) and cys-mcMMAF will be collected at the time points indicated in the', 'Schedule of Activities table (Section 2). Each PK sample must be collected as close as', 'possible to the planned time relative to the dose (which is 0 h) administered to the', 'participant on PK days. The actual date and time of each blood sample collection will be', 'recorded.', 'Details on PK blood sample collection, processing, storage, and shipping procedures are', 'provided in the SRM.', '9.5.2.', 'Pharmacokinetic Sample Analysis', 'Plasma analysis will be performed under the control of GSK Platform Technology and', 'Sciences (PTS)-Bioanalysis Immunogenicity and Biomarkers (BIB) group, the details of', 'which will be included in the SRM. Concentrations of GSK2857916 (ADC and total', 'antibody) and cys-mcMMAF will be determined in plasma samples using the currently', 'approved bioanalytical methodology. Raw data will be archived at the bioanalytical site', '(detailed in the SRM).', 'Once the plasma has been analyzed for GSK2857916 (ADC and total antibody) and cys-', 'mcMMAF, any remaining plasma may be analyzed for other compound-related', 'metabolites and the results reported under a separate GSK PTS-BIB protocol.', '85']"
85,page_86,"['2017N330177_04', 'CONFIDENTIAL', '205678', '9.6.', 'Immunogenicity', 'Immunogenicity sample analysis will be performed under control of GSK PTS BIB', 'group, the details of which will be included in the SRM.', 'Serum samples for determination of anti-GSK2857916 antibodies will be taken from all', 'participants in this study at the time-points specified in the SOA. Details of sample', 'preparation, storage, and analysis will be provided in the SRM.', 'Samples will be analyzed for the presence of anti-GSK2857916 antibodies by a validated', 'electrochemiluminescent immunoassay. First, all samples will be tested in a screening', 'assay to identify potentially positive samples. Next, samples that screen positive will be', 'further characterized for specificity in a confirmation assay, and, finally, for samples that', 'test positive in the confirmation assay, the antibody titer values will be determined. For', 'each participant, immunogenicity results, including the incidence and titers, will be', 'reported. Raw data will be archived at the bioanalytical site (detailed in the SRM).', '9.7.', 'Translational Research', 'See Section 9.9.', '9.8.', 'Genetics', 'Participation in this part of the study is optional and all enrolled participants will be given', 'the opportunity to contribute samples. Participation may be declined without effect on', 'medical care during the clinical study. Separate consent signature is required for', 'participation in genetic research.', 'Information regarding genetic research is included in Appendix 6. In approving the', 'clinical protocol, the IEC/IRB and, where required, the applicable regulatory agency, are', 'also approving the genetic research described in Appendix 6 unless otherwise indicated.', 'Where required by regulatory authorities, approval of the genetic assessments can occur', 'after approval is obtained for the rest of the study. In that case, written approval will', 'indicate that approval of the genetic assessments is being deferred and the study, except', 'for genetic assessments, can be initiated. If genetic assessments are not approved, they', 'will not be conducted.', '9.9.', 'Tumor Biomarker Analysis', '9.9.1.', 'sBCMA Sample Analysis', 'The BCMA receptor undergoes gamma-secretase mediated cleavage, leading to release', 'of the BCMA extracellular domain as soluble BCMA (sBCMA) into the circulation', '[Laurent, 2015].', 'Samples will be collected to measure concentrations of sBCMA at the time points', 'specified in the SOA using a validated assay. Details of sample preparation, storage, and', 'analysis will be provided in the SRM.', '86']"
86,page_87,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Serum analysis for sBCMA will be performed under control of GSK PTS-BIB group, the', 'details of which will be included in the SRM. Raw data will be archived at the', 'bioanalytical site (detailed in the SRM).', '9.9.2.', 'Potential Tumor Related Biomarkers', 'While BCMA expression is present in multiple myeloma, there is some variability in its', 'expression, as well as its membranous/cytosolic expression pattern. Therefore, it is', 'important to determine if there is any association between the expression levels of', 'BCMA on multiple myeloma cells and clinical responses.', 'Additionally, any blood, serum, and bone marrow samples collected during this study', 'may be used to measure novel biomarkers to identify factors associated with the', 'biological and clinical responses to GSK2857916. If relevant, this approach may be', 'extended to include the identification of biomarkers associated with AEs. Unless stated', 'otherwise, these investigations may be performed irrespective of whether a response to', 'GSK2857916 is observed.', 'Samples will be collected at the time points indicated in the SOA. The sample collection', 'strategy may be adjusted on the basis of emerging data from this study or other studies', 'involving GSK2857916 in order to ensure optimal evaluation of any potential', 'biomarkers. Additionally, novel biomarkers may also be incorporated, as data warrants.', 'These analyses may include but not be limited to:', 'Bone marrow BCMA expression by IHC performed on bone marrow aspirate', 'Measurements of the serum levels of soluble BCMA (sBCMA)', 'Soluble factors, including circulating plasma cell-free DNA (cfDNA).', '9.10.', 'Evaluation of Anti-Cancer Activity', 'Response will be assessed according to the IMWG criteria, [Kumar, 2016] by the', 'Investigator and by an IRC.', 'Standard disease assessments for MM will include serum and urine laboratory tests, bone', 'marrow biopsy at the time of CR (IHC), and MRD testing at the time of VGPR, CR, and', 'baseline. Evaluation will follow the guidance of International Myeloma Working Group', '(IMWG) Uniform Response Criteria for Multiple Myeloma 2016.', 'Clinical efficacy measured as Overall Response Rate (ORR), which is defined as the', 'percentage of participants with confirmed stringent complete response (sCR),', 'complete response (CR), very good partial response (VGPR), or partial response', '(PR) as assessed by 2016 recommendation of the IMWG Panel I [Kumar, 2016].', 'Other efficacy measures of interest (see Section 9.1)', 'The percentage of participants achieving MRD negativity.', 'Disease assessment will include laboratory testing and physical examination (as indicated', 'for palpable/superficial lesions), or imaging CT, MRI, PET CT, or X-ray (as indicated).', '87']"
87,page_88,"['2017N330177_0', 'CONFIDENTIAL', '205678', 'Laboratory-based disease assessments will be completed within 21 days prior to the first', 'dose of GSK2857916 then testing will be performed every 3 weeks from Cycle 1 Day 1', '(C1D1). The imaging will be performed up to 30 days prior to the first dose and will be', 'repeated as indicated in the SOA table. See the SOA for the Schedule of Activities of', 'anti-cancer activity.', 'Assessments must be performed on a calendar schedule and must not be affected by dose', 'interruptions/delays', 'MRD negativity rate (defined as the percentage of participants who are MRD negative by', 'clonoSEQ). Testing will be performed at: Screen for all participants; and at the time of', 'achieving VGPR or CR. The testing will be repeated 6 months and 12 months after', 'achieving VGPR or CR.', '9.11.', 'Health-Related Quality-of-Life', 'Three Health-Related Quality-of-Life (HRQoL) assessments will be performed in this', 'study. More details about all patient questionnaires can be found in the SRM.', 'The following assessments will be administered to participants in different regions based', 'on the availability of translated versions.', '9.11.1.', 'European Organization for Research and Treatment of Cancer', 'Quality of Life Questionnaire 30-item Core module (EORTC QLQ-', 'C30)', 'The EORTC QLQ-C30 is a 30-item questionnaire containing both single- and multi-item', 'measures [Aaronson, 1993]. These include five functional scales (Physical, Role,', 'Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and', 'Nausea/Vomiting), a Global Health Status/QoL scale, and six single items (Constipation,', 'Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). Scores for each', 'scale and single-item measure are averaged and transformed linearly to a score ranging', 'from 0-100. A high score for functional scales and for Global Health Status/QoL', 'represent better functioning ability or HRQoL, whereas a high score for symptom scales', 'and single items represents significant symptomatology [Proskorovsky, 2014].', '9.11.2.', 'European Organization for Research and Treatment of Cancer', 'Quality of Life Questionnaire 20-item Multiple Myeloma module', '(EORTC QLQ-MY20)', 'The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in patients', 'with multiple myeloma [Aaronson, 1993; Cocks, 2007]. The module comprises 20', 'questions that address four myeloma-specific HRQoL domains: Disease Symptoms, Side', 'Effects of Treatment, Future Perspective, and Body Image. Three of the four QLQ-', 'MY20 domains are multi-item scales: Disease Symptoms (includes bone aches or pain,', 'back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity);', 'Side Effects of Treatment (includes drowsiness, thirst, feeling ill, dry mouth, hair loss,', 'upset by hair loss, tingling hands or feet, restlessness/agitation, acid', 'indigestion/heartburn, and burning or sore eyes); and Future Perspective (includes worry', '88']"
88,page_89,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'about death and health in the future, and thinking about illness). The Body Image scale is', 'a single-item scale that addresses physical attractiveness. As with the QLQ-C30, QLQ-', 'MY20 domain scores are averaged and transformed linearly to a score ranging from 0-', '100. A high score for Disease Symptoms and Side Effects of Treatment represents a high', 'level of symptomatology or problems, whereas a high score for Future Perspective and', 'Body Image represents better outcomes [Proskorovsky, 2014].', '9.11.3.', 'Qualitative Telephone Interviews (Patient Interviews)', 'To further evaluate disease and treatment related symptoms and associated impacts on', 'function and health-related quality of life, participants will participate in qualitative', 'interviews conducted via telephone. The interview will be conducted by a trained', ""interviewer in the participant's native language and will be audio recorded for"", 'transcription and analysis.', 'The patient interview (PRO) should be conducted via telephone within 21(+7 days) days', 'following Day 1 of the fourth treatment cycle (C4D1). The PRO interview should also be', 'conducted within 21 days (+7 days) of the participants end of treatment visit, unless the', 'participant has already completed their interview following C4D1 within the prior 30', 'days.', '10.', 'STATISTICAL CONSIDERATIONS', '10.1.', 'Hypothesis Testing', 'This is a two-arm study. The primary objective of this study is to establish the efficacy of', 'BCMA over historical control with respect to ORR for participants with RRMM for each', 'of the two dose levels (frozen liquid solution) studied.', 'The study is designed to provide evidence with respect to ORR to either support the null', 'hypothesis, Ho: ORR 15%, or reject Ho in favor of the alternative hypothesis,', 'H1: ORR>33%. The hypothesis testing will be performed within each arm separately.', 'No hypothesis testing for comparing ORR between the two arms will be performed.', 'All randomized participants will be included in the final analysis to test the hypotheses of', 'interest regardless of length of follow-up or whether or not they receive the treatment or', 'whether or not they have a post-baseline assessment (i.e., participants will not be', 'replaced).', 'An interim analysis (IA) will be conducted after approximately 25 randomized', 'participants per arm are evaluable (i.e., received at least two doses of study treatment and', 'have completed at least one disease assessment after the second dose, or progressed or', 'died or discontinued treatment due to reasons other than PD).', 'The Final analysis will be performed based on a data cutoff 6 months after the last', 'participant (in the frozen liquid solution) is randomized in the study to allow sufficient', 'data maturity of all efficacy endpoints. Time from first-subject-first visit (FSFV) to', 'primary ORR analysis will be approximately 12 months. The timeline is subject to', 'change based on the actual enrollment rate.', '89']"
89,page_90,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'An updated analysis for os will be performed at end of study as defined in Section 5.3.', '10.2.', 'Sample Size Determination', 'The sample size calculation was initially performed using East 6.4 software as a starting', 'point, based on the ORR comparison between the GSK2857916 arm and the historical', 'control in order to choose a final refined study design. The following assumptions were', 'made in the estimation of the required sample size:', 'Normal approximation of binomial proportion', 'A response rate of >33% in the BCMA arm and <15% for the historical control', 'A 1.25%, one-sided risk of erroneously claiming superiority of the BCMA arm, in', 'the presence of no true underlying improvement', 'A ~90% chance of rejecting the null hypothesis when the alternative hypothesis is', 'true', 'An IA after approximately 38% of information is available (i.e., approximately after 25', 'participants out of originally planned 65 participants per arm are evaluable for IA), with a', 'futility rule based on a gamma spending function.', 'The operating characteristics were refined using simulation to account for both within', 'arm futility rule and the comparative futility rule. Based on the simulation results with the', 'originally planned sample size of 65 participants per arm, there is 86.90% power to reject', 'the null hypothesis within each arm with a 1-sided type I error of 1.23%.', 'Due to over enrollment, it is estimated that approximately 200 participants (~100 per', 'arm) will be randomized to the frozen liquid solution. At the Final analysis, the null', 'hypothesis will be rejected if the lower bound of 2-sided 97.5% exact C.I. exceeds the', 'historical control rate of 15%.', 'With no change to planned IA (i.e., approximately after 25 participants/arm are evaluable', 'for IA, and same futility boundary), simulation results show that there is 92.38% power', 'to reject the null hypothesis within each arm with a 1-sided type I error of 0.97% for 100', 'participants per arm as specified in Section 10.3 and Section 10.5.', 'The study will also include an independent cohort of approximately 25 additional', 'participants who will receive the lyophilized configuration of GSK2857916. The sample', 'size for this cohort was chosen based on feasibility in order to gain clinical experience', 'with the lyophilized configuration. The probability of observing a >=20% RR was', 'retrospectively calculated. If the true RR is 33% there is a 95% probability of observing', 'at least a 20% RR with 25 participants. This cohort will be analyzed separately from', 'participants enrolled to the frozen liquid solution formulation.', '10.3.', 'Sample Size Sensitivity', 'Table 15 shows the various power scenarios at the final ORR analysis under different', 'assumption of the ORR given the sample size of 65, and 100 participants per arm and', 'stopping rules based on group sequential design as specified in Section 10.5.9.1.', '90']"
90,page_91,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 15', 'Statistical Power Scenarios', 'ORR', 'Number of', 'BCMA', 'Participants per', 'Power (%)', 'Historical Data (%)', 'arm', 'Monotherapy (%)', '40', '15', '65', '96.05', '35', '15', '65', '91.52', '30', '15', '65', '75.13', '25', '15', '65', '43.18', '20', '15', '65', '12.81', '40', '15', '100', '96.50', '35', '15', '100', '94.62', '30', '15', '100', '85.08', '25', '15', '100', '55.21', '20', '15', '100', '15.92', 'Note: The power for each arm is calculated based on 10,000,000 simulations using R, assuming both arms have the', 'same assumptions of ORR', '10.4.', 'Populations for Analysis', 'Six specific populations have been defined for this study, as shown in Table 16.', 'Table 16', 'Analysis Populations Defined for the Study', 'Population', 'Description', 'All Screened', 'The All Screened Population will consist of all participants who sign the ICF to participate in the', 'clinical trial. Participants in this population will be used for screen failure summary.', 'Intent-to-Treat', 'ITT Population will consist of all randomized participants whether or not randomized treatment', '(ITT)', 'was administered. This population will be based on the treatment to which the participant was', 'randomized and will be the primary population for the analysis of efficacy data. Any participant', 'who receives a treatment randomization number will be considered to have been randomized.', 'Efficacy', 'Efficacy population will consist of first 130 randomized participants whether or not randomized', 'treatment was administered. This population will be based on the treatment to which the', 'participant was randomized and will be used for sensitivity analysis of primary and selected', 'secondary efficacy endpoints.', 'Safety', 'The Safety population will consist of all participants who receive at least 1 dose of study', 'treatment. This population will be used for the analysis of clinical safety data', 'Evaluable', 'The Evaluable Population will consist of all participants who have at least two doses of study', 'treatment and have completed at least one disease assessment after the second dose. This', 'population will be the primary population for summarizing ORR to compare with stopping', 'boundaries in interim analysis only. Refer to IDMC charter for more details.', 'Pharmacokinetic', 'The Pharmacokinetic Population will consist of those participants in Safety Population from whom', 'at least one PK sample has been obtained and analyzed. This population will be the primary', 'population for PK analyses.', '10.5.', 'Statistical Analyses', 'Statistical analyses (both interim and final) will be performed by the sponsor or under the', 'authority of the sponsor. A general description of the statistical methods to be used to', '91']"
91,page_92,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'analyze the efficacy and safety data is outlined below. Specific details will be provided', 'in the RAP.', '10.5.1.', 'Efficacy Analyses', 'Primary analysis of the primary endpoint ORR will be based on the responses assessed by', 'the Independent Review Committee (IRC). Investigator-assessed ORR will also be', 'reported. Analysis of secondary endpoints will include TTR, DoR, TTP, and PFS as', 'assessed by both investigator and IRC.', 'Primary analysis for all efficacy endpoints will be based on the ITT population.', 'In addition, sensitivity analysis for ORR, DoR, and TTR as assessed by both investigator', 'and IRC will be performed using efficacy population; other endpoint-specific sensitivity', 'analyses will be described in the RAP. At interim analysis, investigator-assessed ORR', 'will be analyzed based on the Evaluable Population. In case that one dose arm is dropped', 'based on interim analysis (IA), and some participants in that arm switch to the remaining', 'dose arm, a sensitivity analysis of ORR based on participants who did not switch may be', 'performed.', 'Appropriate subgroup analyses may be performed if data permits, e.g. the primary', 'endpoint ORR may be analyzed by age (<65 years, >=65 years), gender (Female, Male),', 'ethnicity (Hispanic, non-Hispanic) and race groups (American Indian or Alaskan Native,', 'Asian, Black, Native Hawaiian or Other Pacific Islander, White, Mixed Race), prior anti-', 'cancer therapy and other baseline characteristics. The estimates along with 95% exact', 'confidence interval (CI) will be provided. In subgroup analyses, no hypothesis testing', 'will be performed.', 'The analytical methods planned for each endpoint are described in Table 17.', 'Table 17', 'Statistical Analysis Methods for Efficacy Enppoints', 'Endpoint', 'Statistical Analysis Methods', 'Primary', 'Overall Response Rate is the primary endpoint of this study; it is defined as the percentage of', 'participants with a confirmed PR or better (i.e., PR, VGPR, CR and sCR), according to the IMWG', 'Response Criteria [Kumar, 2016].', 'The number and percentage of participants in the following response categories will be presented', 'sCR, CR, VGPR, PR, MR, SD, PD, and NE', 'sCR+CR+VGPR+PR for ORR', 'The corresponding 97.5% exact CI for ORR will also be provided. Participants with unknown or', 'missing response will be treated as non-responders, i.e., these participants will be included in the', 'denominator when calculating percentages of response.', 'The null hypothesis related to ORR against a historical control will be tested by comparing the', 'number of responders with the pre-specified stopping boundaries in the ITT and efficacy', 'population. The boundaries will be adjusted as needed based on the final sample size.', 'ORR will be analyzed at interim and final analysis. A participant with best confirmed response of', 'PR or better will be considered as a responder.', 'ORR at final analysis will be based on the confirmed responses from IRC assessment in both ITT', '92']"
92,page_93,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Endpoint', 'Statistical Analysis Methods', 'and Efficacy population. In addition, ORR based on confirmed response from investigator', 'assessment will be performed in both ITT and Efficacy population.', 'ORR at IA will be analyzed based on investigator-assessed confirmed responses if available.', 'However, in case a participant has achieved a response of PR or better at data cut, which was not', 'confirmed due to the time constraints (too short timeframe for the next assessment) but with a', 'potential to be confirmed through subsequent assessments after interim, the participant will also', 'be considered as a responder. More details will be provided in the RAP.', 'Secondary', 'Secondary efficacy endpoints of this study are CBR, DoR, TTR, PFS, TTP, and OS.', 'CBR, TTR, and DoR as assessed by IRC and investigator will be analyzed using both ITT and', 'Efficacy population. Other TTE endpoints will be analyzed using ITT population only.', 'CBR is defined as the percentage of participants with a confirmed minimal response (MR) or', 'better, according to the IMWG Response Criteria [Kumar, 2016]. CBR at interim and final will', 'be', 'summarized in the same way as the primary endpoint ORR. No hypothesis testing will be', 'performed for CBR', 'DoR is defined as the time from first documented evidence of PR or better until the earliest date of', 'disease progression (PD) per IMWG, or death due to PD among participants who achieve a', 'response (i.e., confirmed PR or better). Responders without disease progression will be censored', 'at the censoring time point for TTP.', 'DoR will be analyzed at the time of final ORR analysis.', 'TTR is defined as the time between the date of randomization and the first documented evidence', 'of response (PR or better), among participants who achieve a response (i.e., confirmed PR or', 'better).', 'TTR will be analyzed at the time of final ORR analysis.', 'PFS is defined as the time from randomization until the earliest date of PD per IMWG, or death', 'due to any cause. Determination of dates of PFS event and dates for censoring will be described', 'in the RAP.', 'PFS will be analyzed at the time of final ORR analysis, also at study close out if applicable.', 'TTP is defined as the time from randomization until the earliest date of PD per IMWG, or death', 'due to PD. Determination of dates of TTP event and dates for censoring will be described in the', 'RAP.', 'TTP will be analyzed at the time of final ORR analysis, also at study close out if applicable.', 'os is defined as the time from randomization until death due to any cause. Participants who', 'withdraw consent from the study or are lost to follow-up will be censored at the time of withdrawal', 'or lost to follow-up. Participants who are still alive at the clinical cut-off date for the analysis will be', 'censored at the last known alive date or last contact date. The last contact date will be', 'determined by the maximum collection/assessment date from among selected data domains', 'within the clinical database. OS, including 12- and 18-month survival rates, will be analyzed for', 'the safety population.', 'An os analysis will be performed at the time of final ORR analysis if there is a sufficient number', 'of', 'death events. An updated os analysis will be performed at the end of study as defined in Sec 5.3', 'of the protocol.', 'For all the TTE endpoints described above, median TTE with 95% CI will be estimated employing', 'the Kaplan-Meier method. A Kaplan-Meier survival curve will be generated. The number and', 'percentage of participants who had the event or were censored will also be reported. In addition,', 'the survival rate with 95% CI at', '12 and 18 months will be estimated using Kaplan-Meier methods for the os endpoint.', '93']"
93,page_94,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Endpoint', 'Statistical Analysis Methods', 'MRD negative rate is defined as the proportion of participants who are negative for MRD at any', 'Exploratory', 'time point after first dose as determined by the protocol defined testing procedure. For analysis', 'purposes, participants in the safety population without MRD assessment will be considered as', 'having positive MRD.', 'The MRD negative rate will be calculated based on the ITT population. The corresponding 95%', 'exact CI will be provided.', 'Other exploratory endpoints will be described in the reporting and analysis plan (RAP)', 'CBR: clinical benefit rate; Cl: confidence interval; CR: complete response; DoR: duration of response; Minimal', 'Response MR; SD: stable disease; MRD: Minimal Residual Disease; NE: non-evaluable; ORR: overall response rate;', 'OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; RAP: report', 'analysis plan; sCR: stringent complete response; TTP: time-to-progression; TTR: time-to-response; VGPR: very good', 'partial response.', '10.5.2.', 'Safety Analyses', 'All safety analyses (Table 18) will be performed on the Safety Population.', 'Table 18', 'Statistical Analysis Methods for Safety Enpoints', 'Enppoint', 'Statistical Analysis Methods', 'Secondary', 'Adverse Events: All adverse events whether serious or non-serious, will be reported from the start', 'of treatment until 45 days after the last dose of study treatment, until the participant withdraws', 'consent for study participation, or until the participant starts subsequent anticancer therapy,', 'whichever occurs first. AEs will be recorded using standard medical terminology and graded', 'according to the NCI-CTCAE, Version 4.03. For AE reporting, the verbatim term used in the CRF', 'by investigators to identify adverse events will be coded using the latest version of MedDRA', 'coding dictionary [NCI, 2010].', 'Adverse events will be summarized by frequency and proportion of total participants, by system', 'organ class and preferred term. Separate summaries will be given for all AEs, treatment-related', 'AEs, SAEs, and AEs leading to discontinuation of study treatment. Adverse events, if listed in the', 'NCI-CTCAE (version 4.03,) will be summarized by the maximum grade.', 'Characteristics (e.g., number of occurrences, action taken, grade, etc.) of the following AEs of', 'clinical interest will be summarized separately:', 'The incidence of deaths and the primary cause of death will be summarized.', 'Clinical Laboratory Evaluation: The evaluation of clinical laboratory tests will focus on', 'selected laboratory analytes from the hematology and blood chemistry panel.', 'Descriptive statistics (mean, standard deviation, median, and range) will be used to', 'summarize observed laboratory values and change from baseline in observed value at', 'each scheduled visit or worst-case post baseline, as appropriate.', 'The worst-case-toxicy grade in hematology and chemistry result during the treatment', 'will be summarized.', 'Corneal events associated with GSK2857916 will be summarized using the GSK scale', 'Other Safety Measures: Data for vital signs, electrocardiograms (ECGs), echocardiograms', '(ECHOs), and ophthalmic examination findings will be summarized. For continuous variables,', 'these summaries will include sample size, mean, median, standard deviation, minimum, and', 'maximum. For categorical variables, the summaries will include frequencies and corresponding', 'percentages. Further details will be provided in the Reporting and Analysis Plan (RAP).', 'Exploratory', 'Exploratory analyses will be described in the RAP', '94']"
94,page_95,"['2017N330177_04', 'CONFIDENTIAL', '205678', '10.5.3.', 'Analyses of Health-Related Quality of Life Data', 'Descriptive statistics will be used to summarize scores derived from different', 'questionnaires and change from baseline at each scheduled visit. Additional details will', 'be provided in the reporting and analysis plan.', '10.5.4.', 'Pharmacokinetic Analyses', '10.5.4.1.', 'Pharmacokinetic Data Analyses', 'Concentration-Time Data: Linear and semi-logarithmic individual concentration-time', 'profiles and mean and median profiles (when appropriate) will be plotted for', 'GSK2857916 (ADC and total mAb) and cys-mcMMAF. Concentrations of', 'GSK2857916 (ADC and total mAb) and cys-mcMMAF will be listed for each participant', 'and summarized (when appropriate) by planned time point and dose level.', 'Derived Pharmacokinetic Parameters: Pharmacokinetic analyses will be the', 'responsibility of Clinical Pharmacokinetics/Modelling and Simulation, GSK.', 'Plasma GSK2857916 (ADC, total mAb) and cys-mcMMAF concentration-time data will', 'be analyzed by non-compartmental methods using WinNonlin. Calculations will be', 'based on the actual sampling times recorded during the study. From the plasma', 'concentration-time data, the following PK parameters will be determined for', 'GSK2857916 (ADC and total mAb) as data permit, for each participant after each dose of', 'GSK2857916:', 'maximum observed plasma concentration (Cmax), time to Cmax (tmax), predose', 'plasma concentration (Ctrough)', 'For Cycle 1 and Cycle 3: area under the plasma concentration-time curve [AUC(0-', 't), AUC (0-tau) and/or AUC(0-00) last time point where the concentration is above', 'the limit of quantification (tlast), systemic clearance (CL), volume of distribution at', 'steady state (Vss), terminal phase elimination rate constant (1z), terminal phase half-', 'life (t1/2)', 'For cys-mcMMAF, Cmax, tmax, AUC [AUC(0-t), AUC (0-tau) and/or AUC(0-00), tlast,', 'NZ, and t¹/2 will be computed at Cycle 1 and Cycle 3, as data permit.', 'Plasma GSK2857916 concentration-time data may be combined with data from other', 'studies and will be analyzed using a population pharmacokinetic approach. A nonlinear', 'mixed effects model will be used to determine population pharmacokinetic parameters', '(clearances, CL and volumes of distribution, V) and identify important covariates (e.g.,', 'age, weight, or disease-related covariates). Summary exposure measures (e.g., Cmax,', 'AUC) will also be computed. For the data from the lyophilized configuration, individual', 'pharmacokinetic parameters may be obtained using a Bayesian approach and the', 'population PK model. Results of this analysis may be provided in a separate report.', '95']"
95,page_96,"['2017N330177_04', 'CONFIDENTIAL', '205678', '10.5.4.2. Statistical Analysis of Pharmacokinetic Data', 'Statistical analyses of the pharmacokinetic (PK) parameters data will be the responsibility', 'of Clinical Statistics, GSK.', 'GSK2857916 (ADC and total mAb) and cys-mcMMAF concentration-time data will be', 'listed for each participant and summarized by descriptive statistics at each time point', '(when appropriate) by planned time point and dose level as needed.', 'Pharmacokinetic parameters will be listed and summarized descriptively (mean, standard', 'deviation, median, minimum, maximum, geometric mean, and the standard deviation,', 'CV%, and 95% CI of log-transformed parameters) by cycle, dose level, and', 'configuration.', '10.5.5.', 'Pharmacokinetic/Pharmacodynamic Analyses', 'If deemed appropriate and if data permit, exposure-response relationships between', 'GSK2857916 exposure (e.g., dose, dose intensity, concentration, Cmax, or AUC) and', 'clinical activity and/or toxicity (e.g., response, corneal event, AESIs) may be explored', 'using population methods. If data permit, the effects of covariates may be explored.', 'Results of this analysis may be provided in a separate report.', '10.5.6.', 'Translational Research Analyses', 'The results of translational research investigations will be reported either within or', 'separately from the main clinical study report (CSR). All endpoints of interest from all', 'comparisons will be descriptively and/or graphically summarized as appropriate to the', 'data.', 'Further details on the translational research analyses will be addressed in the RAP.', '10.5.6.1. Analysis of Novel Biomarker Data', 'The results of these biomarker investigations may be reported separately from the main', 'clinical study report. All endpoints of interest from all comparisons will be descriptively', 'and/or graphically summarized as appropriate to the data.', 'Additional exploratory analyses may be performed to further characterize the novel', 'biomarker.', '10.5.6.2.', 'Analysis of Genetic Data', 'Further details on genetic analyses are addressed in Appendix 6.', '10.5.6.3. Exploratory Analyses of DNA and Protein Data', 'Exploratory analyses may be performed on remaining study samples for analyses of', 'DNA, RNA and protein to understand changes in response to the combination treatment', 'with GSK2857916.', '96']"
96,page_97,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'The results of exploratory investigations will be reported separate from the main CSR.', 'All endpoints of interest from all comparisons will be descriptively and/or graphically', 'summarized as appropriate to the data.', '10.5.7.', 'Analyses of Immunogenicity Data', 'For each participant, the results and titers of anti-GSK2857916 binding antibodies will be', 'listed for each assessment time point, along with the time-matched GSK2857916 plasma', 'concentration. The frequency and percentage of participants with positive and negative', 'results will be summarized for each assessment time and overall for each participant by', 'dose cohort. The detailed information will be included in the RAP.', '10.5.8.', 'Other Analyses', 'Participant disposition, treatment status, demographics, medical history, prior and', 'concomitant medications, prior anti-cancer therapies, and study treatment exposure will', 'be summarized descriptively and listed by participant.', '10.5.9.', 'Interim Analyses', '10.5.9.1.', 'Futility Stopping Rule Based on Group Sequential Design', 'For each arm (2.5 mg/kg or 3.4 mg/kg of frozen liquid solution), one single futility IA is', ""planned for ORR based on investigator's assessment, after approximately 25 participants"", '(~38% information fraction of initially planned 65 participants) per arm are evaluable. A', 'user-defined gamma spending function (y=1.1) [Hwang, 1990] was used as a beta-', 'spending function to determine the non-binding futility boundary (as implemented in East', '6.4). With this ß-spending function, the stopping boundary in IA is identified as 0.16 on', 'the proportion scale (4 responders out of 25 participants), which is close to the historical', 'control of 0.15. The spending function and associated boundary were chosen to ensure', 'good operating characteristics, specifically, the type 1 error and power are well', 'controlled.', 'A two-step approach is used to identify the futility stopping rule based on a group', 'sequential design under the assumption of exact binomial distribution.', 'First, as described in Section 10.2, an initial design based on the assumption of normal', 'approximation of binomial proportion is identified by East 6.4.', 'The interim futility and final efficacy analysis boundaries were then converted to number', 'of responders needed in 25 participants who are evaluable at IA and the 65 participants', 'initially planned at the final analysis.', 'With a total sample size of 100 participants per arm and an IA with approximately 25', 'participants per arm, the same futility boundary (< 4 responders out of 25 participants)', 'will still apply with a user-defined gamma spending function (y=5.4). For the final', 'analysis, the boundary for claiming efficacy is the minimum number of responders', 'required for the lower bound of the two-sided 97.5% C.I. to exceed 15% (i.e. 24', 'responders for sample size of 100 per arm).', '97']"
97,page_98,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Statistical properties of the group sequential design with sample sizes of 65, and 100 per', 'arm are summarized in Table 19.', 'Table 19', 'Probabilities of Crossing Boundaries at the Interim or Final ORR', 'Analysis based on Group Sequential Design', 'Sample', 'Boundaries', 'Cumulative Boundary Crossing', 'Size (per', 'Probabilities', 'Look', 'arm)', '# of Responders', 'Under Ho', 'Under H1', 'Interim (futility)', '25', '<4', '68.21%', '4.96%', 'Final (Efficacy)', '65', '>17', '1.23%', '88.00%', '100', '>24', '0.97%', '93.70%', 'Note: The Cumulative Boundary Crossing Probabilities are calculated based on exact binomial distribution', 'theoretically.', '10.5.9.2. Additional Comparative Futility Stopping Rule Based on Bayesian', 'Approach', 'If both arms pass the futility boundaries based on group sequential design described', 'above, posterior probability of observing a better RR in one arm relative to the other will', 'be calculated. If such a probability is at least 97.5%, then the treatment arm with lower', 'RR will be dropped due to lack of efficacy. This additional guidance was put in to allow', 'for dropping an arm with substantially inferior response rates (e.g. absolute difference', '>', '28%).', 'To calculate the posterior probability, a non-informative Beta prior (0.025, 0.1) will be', 'used for each arm. Details about calculating the posterior probabilities are provided in', 'Appendix 12.', 'Statistical properties for different scenarios based on both futility rules are summarized in', 'Table 20.', 'Table 20', 'Probabilities of Stopping for Futility at the Interim or Claiming', 'Efficacy at the Final ORR Analysis based on Both Futility Rules', 'Futility Stopping', 'Probabilities of', 'Response Rate', 'Boundary Crossing', 'Claiming Efficacy at', 'Scenario', 'Participant', 'Probabilities at IA [1]', 'Final [1]', 'S', 'S per arm', 'Arm 1 [2]', 'Arm 2 [2]', 'Arm 1 [2]', 'Arm 2 [2]', 'Arm 1 [2]', 'Arm 2 [2]', '1', '65', '33%', '60%', '53.59%', '0.01%', '44.83%', '99.99%', '2', '65', '33%', '45%', '16.95%', '0.47%', '77.94%', '99.49%', '3 [3]', '65', '33%', '33%', '6.33%', '6.33%', '86.90%', '86.92%', '4', '65', '33%', '25%', '5.09%', '23.83%', '87.89%', '42.39%', '5', '65', '33%', '20%', '4.97%', '44.59%', '87.98%', '12.52%', '6', '65', '33%', '15%', '4.96%', '69.99%', '87.99%', '1.20%', '7', '65', '33%', '10%', '4.96%', '90.85%', '87.99%', '0.01%', '98']"
98,page_99,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Futility Stopping', 'Probabilities of', 'Response Rate', 'Boundary Crossing', 'Claiming Efficacy at', 'Scenario', 'Participant', 'Probabilities at IA [1]', 'Final [1]', 'S', 'S per arm', 'Arm 1 [2]', 'Arm 2 [2]', 'Arm 1 [2]', 'Arm 2 [2]', 'Arm 1 [2]', 'Arm 2 [2]', '8 [4]', '65', '15%', '15%', '68.22%', '68.22%', '1.23%', '1.24%', '9', '100', '33%', '60%', '53.59%', '0.01%', '46.11%', '99.99%', '10', '100', '33%', '45%', '16.95%', '0.47%', '82.09%', '99.53%', '11[3]', '100', '33%', '33%', '6.33%', '6.33%', '92.38%', '92.39%', '12', '100', '33%', '25%', '5.09%', '23.83%', '93.57%', '53.93%', '13', '100', '33%', '20%', '4.97%', '44.59%', '93.68%', '15.46%', '14', '100', '33%', '15%', '4.96%', '69.99%', '93.70%', '0.94%', '15', '100', '33%', '10%', '4.96%', '90.85%', '93.70%', '0.003%', '16 [4]', '100', '15%', '15%', '68.22%', '68.22%', '0.97%', '0.97%', 'Note:', '[1] The Boundary Crossing Probabilities are calculated based on 10,000,000 simulations using R program.', '[2] Arm 1 and Arm 2 in the table just represent two different treatment arms and are not necessarily refers to 3.4', 'mg/kg and 2.5 mg/kg, respectively.', '[3]', 'The power is shown in Scenario 3, and 11 as 86.90% and 92.38% for sample size of 65, and 100 respectively.', '[4] The type I error is shown in Scenario 8, and 16 as 1.23%, and 0.97% for sample size of 65, and 100 respectively.', 'The IA to assess futility will be reviewed by an Independent Data Monitoring Committee', '(IDMC). Additional details of the IA are provided in Section 10.5.9 and will be provided', 'in an IDMC Charter. The stopping rules described above are guidelines for decision-', 'making and the totality of the data will be considered when making a final decision.', 'Participants will continue to be enrolled, dosed, and followed as planned at the time of', 'IA.', '99']"
99,page_100,"['2017N330177_04', 'CONFIDENTIAL', '205678', '11.', 'REFERENCES', 'Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The', 'European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life', 'instrument for use in international clinical trials in oncology. J Natl Cancer Institute.', '1993 Mar 3;85(5):365-76.', 'Afifi S, Michael A, Lesokhin A. Immunotherapy: A New Approach to Treating Multiple', 'Myeloma with Daratumumab and Elotuzumab. Ann Pharmacother. 2016;50(7):555-68', 'Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, et al. The', 'pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther.', '2009;330(3):932-8.', 'Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al.', ""Development of the National Cancer Institute's patient-reported outcomes version of the"", 'common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst.', '2014;106(9).', 'Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is', 'critical for plasmablast survival in the bone marrow and poorly expressed by early-life', 'bone marrow stromal cells. Blood. 2008;111(5):2755-64.', 'Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E, et al. An international field study', 'of the reliability and validity of a disease-specific questionnaire module (the QLQ-', 'MY20) in assessing the quality of life of patients with multiple myeloma. European', 'Journal of Cancer. 2007 Jul 31;43(11):1670-8.', 'Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, et al., editors.', 'B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells', '(CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I', 'Study. Abstract 1147. American Society of Hematology (ASH) 58th Annual Meeting &', 'Exposition December 3rd to 6th, 2016; 2016 05December 2016; San Diego, CA.', 'https://ash.confex.com/ash/2016/webprogram/Paper92775.html.', 'DARZALEX (daratumumab) injection, for intravenous use Full Prescription Information.', 'In: Janssen Biotech I, editor.', 'ittps://wwwdarzalexhcpcom/shared/product/darzalex/darzalex-prescribing-', 'informationpdf. Horsham, PA 19044 2017. p. 9.', 'de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al.', 'Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of', 'multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-8', 'Dougherty BE, Nichols JJ, Nichols KK. Rasch analysis of the Ocular Surface Disease', 'Index (OSDI). Invest Ophthalmol Vis Sci. 2011;52(12):8630-5.', 'GSK2857916 IB [GlaxoSmithKline Document Number 2013N175128_04 Report Date', '26-APRIL-2018', '100']"
100,page_101,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, et al. A randomized', 'phase III study of carfilzomib VS low-dose corticosteroids with optional', 'cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia.', '2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176.', 'Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error', 'probability spending functions. Stat Med. 90;9(12):1439-45.', 'Janssen-Cilag International NV. Darzalex (daratumumab) summary of Product', 'Characteristics. In: Janssen-Cilag International NV, editor.', 'tp://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-', '-', 'Product_Information/human/004077/WC500207296pdf. B-2340 Beerse, Belgium 2016.', 'Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD. B cell maturation antigen', 'deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J', 'Immunol. 2011;186(11):6136-47.', ""Kirwan C, Lanigan B, O'Keefe M. Vision-related quality of life assessment using the"", 'NEI-VFQ-25 in adolescents and young adults with a history of congenital cataract.', 'J', 'Pediatr Ophthalmol Strabismus. 2012;49(1):26-31.', 'Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy.', 'Annu Rev Immunol. 2013; 31:51-72.', 'Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P.', 'Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer.', '2012;12(12):860-75.', 'Kumar S, et al. International Myeloma Working Group consensus criteria for response', 'and minimal residual disease assessment in multiple myeloma. The Lancet Oncology.', '2016;17: e328-e346.', 'Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, et al. Response', 'rate, durability of response, and survival after thalidomide therapy for relapsed multiple', 'myeloma. Mayo Clin Proc. 2003;78(1):34-9.', 'Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of', 'progression and survival in multiple myeloma relapsing after therapy with IMiDs and', 'bortezomib: a multicenter international myeloma working group study. Leukemia.', '2012;26(1):149-57.', 'Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al.', 'Improved survival in multiple myeloma and the impact of novel therapies. Blood.', '2008;111(5):2516-20.', 'Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al.', 'Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc.', '2004;79(7):867-74.', '101']"
101,page_102,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, et al.', 'gamma-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat', 'Commun. 2015; 6:7333.', 'Macsai M, Nariani A, Gan H, Lassman A, Merrell R, Gomez E, et al. Corneal Toxicity of', 'ABT-414 in Glioblastoma (GBM): Clinical Manifestations, Ophthalmological Findings', 'and Management. Investigative Ophthalmology & Visual Science. 2016 Sep', '26;57(12):269-269.', 'Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. Development', 'of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol.', '2001;119(7):1050-8.', 'Moskowitz CH, Fanale MA, Shah BD, Advani RH, Chen R, Kim S, Kostic A, et al. A', 'phase 1 study of denintuzumab mafodotin (SGN-CD19A) in Relapsed/Refractory B-', ""lineage non-hodgkin's lymphoma. Blood. 2015; 126:182."", 'NCCN (2016). Multiple Myeloma. Version 3.2017 - November 28, 2016. NCCN', 'Clinical Practice Guidelines in Oncology (NCCN Guidelines), 58.', 'NCI (2010) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.', 'In: Health NIo, editor. https://evs.nci.nih.gov/ftpl/CTCAE/CTCAE_4.03_2010-06', '14_QuickReference_5x7.pdf U.S. Department of Health and Human Services.', 'Neuenschwander B, Branson M and Gsponer T. Critical aspects of the Bayesian approach', 'to Phase I cancer trials. Statistics in Medicine 2008; 27:2420-39.', 'Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al.', 'Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for', 'growth and survival. Blood. 2004;103(2):689-94', 'NYHA. The Criteria Committee of the New York Heart Association. Nomenclature and', 'Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. Boston, Mass:', 'Little, Brown & Co. 1994:253-256.', 'Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, et al. Validation of', 'the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related', 'macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(6):3354-9.', 'Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Boyd MR, Hamel E, et al.', 'Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des.', '1998;13(4):243-77', 'Proskorovsky I., P. Lewis, C. D. Williams, K. Jordan, C. Kyriakou, J. Ishak, F. E. Davies.', 'Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple', 'myeloma. Health Qual Life Outcomes. 2014 Mar 11; 12:35.', '102']"
102,page_103,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al.', 'International Myeloma Working Group updated criteria for the diagnosis of multiple', 'myeloma. The Lancet Oncology. 2014;15: e538-e548.', 'Rajkumar SV, Richardson P, San Miguel JF. Guidelines for the determination of the', 'number of prior lines of therapy in multiple myeloma. Blood. 2015; 126:921-922.', 'Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and', 'management. Am J Hematol. 2011 Jan;86(1):57-65. doi: 10.1002/ajh.21913', 'Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma.', 'Am Soc Clin Oncol Educ Book. 2016;35: e418-23.', 'Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, et al.', 'Efficacy and safety results of ABT-414 in combination with radiation and temozolomide', 'in newly diagnosed glioblastoma. Neuro-oncology. 2016; 19:965-975.', 'Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al.', 'Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and', 'refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123:1826-1832;', 'doi: https://doi.org/10.1182/blood-2013-11-538835', 'Sanchez E, Li M, Kitto A, LiJ, Wang CS, Kirk DT, et al. Serum B-cell maturation', 'antigen is elevated in multiple myeloma and correlates with disease status and survival.', 'Br J Haematol. 2012;158(6):727-38', 'Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and', 'validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615-21.', 'Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of', 'single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory', 'multiple myeloma. Blood. 2012;120(14):2817-25.', 'Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-', '30.', 'Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma.', 'Immunotherapy. 2015;7(11):1187-99', 'Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, et al. Role of B-cell-activating', 'factor in adhesion and growth of human multiple myeloma cells in the bone marrow', 'microenvironment. Cancer Res. 2006;66(13):6675-82.', 'Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, et al.', 'Phase I dose-escalation study of SGN-75 in patients with CD70-positive', 'relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.', 'Investigational new drugs. 2014 Dec 1;32(6):1246-57', '103']"
103,page_104,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Thompson JA, Motzer R, Molina AM, Choueiri TK, Heath EI, Kollmannsberger CK, et', 'al. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced', 'refractory renal cell carcinomas (RRCC). J. Clin. Oncol. 2015; 33:2503.', 'Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy', 'of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory', 'multiple myeloma. Blood. 2016;128(1):37-44.', 'Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, et al.', 'APRIL-deficient mice have normal immune system development. Mol Cell Biol.', '2004;24(3):997-1006.', 'Weisel K, San Miguel JF, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. MM-', '003 phase 3 study of pomalidomide in combination with low-dose dexamethasone (Pom', '+ LoDex) VS high-dose dexamethasone (Hi-Dex) in relapsed/refractory multiple myeloma', '(RRMM): Pom + LoDex is beneficial for elderly patients (>65 years of age). Blood.', '2013; 122:3198.', '104']"
104,page_105,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.', 'APPENDICES', '12.1.', 'Appendix 1: Abbreviations and Trademarks', 'ADA', 'Anti-drug antibodies', 'ADC', 'Antibody drug conjugate', 'ADCC', 'Antibody dependent cellular cytotoxicity', 'ADL', 'Activities of daily living', 'AE', 'Adverse Event', 'AESI', 'Adverse events of special interest', 'ALP', 'Alkaline phosphatase', 'ALT', 'Alanine aminotransferase', 'ANC', 'Absolute neutrophil count', 'Anti-CD38', 'Anti-CD38 antibody', 'APRIL', 'A proliferation-inducing ligand', 'AST', 'Aspartate aminotransferase', 'AUC', 'Area under the curve', 'AV', 'Atrioventricular', 'BAFF', 'B-cell-activating factor belonging to the TNF family', 'BCMA', 'B-cell maturation antigen', 'BCVA', 'Best corrected visual acuity', 'BIB', 'Bioanalysis Immunogenicity and Biomarkers', 'BiTe', 'Bispecific antibodies', 'BLRM', 'Bayesian Logistic Regression Model', 'BM', 'Bone marrow', 'BNP', 'B-type natriuretic peptide', 'BP', 'Blood Pressure', 'BUN', 'Blood urea nitrogen', 'C1D1', 'Cycle 1 Day 1', 'CAR-T', 'Chimeric antigen receptor T-Cell', 'CBR', 'Clinical Benefit Rate', 'cfDNA', 'Circulating cell-free deoxyribonucleic acid', 'CFR', 'Code of Federal Regulations', 'CI', 'Confidence interval', 'CIOMS', 'Council of International Organizations of Medical Sciences', 'CK', 'Creatine kinase', 'CL', 'Clearance', 'Cmax', 'Maximum observed concentration', 'CO2', 'Carbon dioxide', 'CONSORT', 'Consolidated Standards of Reporting Trials', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'CPK', 'Creatine phosphokinase', 'CR', 'Complete Response', 'CRF', 'Case Report Form', 'CRP', 'C-reactive protein', 'CSR', 'Clinical study report', '105']"
105,page_106,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'CT', 'Computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CV', 'Coefficient of variation', 'DAMPs', 'Danger-associated molecular patterns', 'DCs', 'Dendritic cells', 'DICOM', 'Digital Imaging and Communications in Medicine', 'DILI', 'Drug-induced liver injury', 'DLT', 'Dose limiting toxicities', 'DNA', 'Deoxyribonucleic acid', 'DOR', 'Duration of Response', 'EC', 'Ethics committee', 'ECG', 'Electrocardiogram', 'ECHO', 'Echocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'Electronic case report form', 'eGFR', 'Estimated glomerular filtration rate', 'EORTC', 'European Organization for Research and Treatment of Cancer', 'EOT', 'Endo of treatment', 'EQ-5D-5L', 'EuroQOL Group EQ-5D 5 Level', 'FISH', 'Fluorescence in situ hybridization', 'FLC', 'Free light chain', 'FSFV', 'First subject first visit', 'FSH', 'Follicle stimulating hormone', 'FTIH', 'First Time in Human Trial', 'GCP', 'Good Clinical Practice', 'GFR', 'Glomerular filtration rate', 'GGT', 'Gamma glutamyl transferase', 'GSK', 'GlaxoSmithKline', 'HBV', 'Hepatitis B', 'HCV', 'Hepatitis C virus', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'HIV', 'Human Immunodeficiency Virus', 'HLA', 'Human leukocyte antigen', 'HR', 'Hazard ratio', 'HRT', 'Hormone replacement therapy', 'HSCT', 'Hematopoietic stem cell transplantation', 'IB', 'Investigator Brochure', 'ICD', 'Immunogenic cell death', 'ICH', 'International Conference on Harmonization', 'IDMC', 'Independent Data Monitoring Committee', 'IEC', 'Institutional Ethics Committee', 'IgA', 'Immunoglobulin A', 'IgG', 'Immunoglobulin G', 'IgM', 'Immunoglobulin M', 'IHC', 'Immunohistochemistry', 'IMiD', 'Immunomodulatory drugs', '106']"
106,page_107,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'IMWG', 'International Myeloma Working Group', 'INR', 'International normalization ratio', 'IP', 'Investigational product', 'IRB', 'Institutional review board', 'IRC', 'Independent Review Committee', 'IRR', 'Infusion related reaction', 'IRT', 'Interactive Response Technology', 'IUD', 'Intra-uterine device', 'IUS', 'Intrauterine hormone-releasing system', 'IV', 'Intravenous', 'LC', 'Light chain', 'LDH', 'Lactate dehydrogenase', 'LLN', 'Lower limit of normal (range)', 'LSFV', ""Last subject's first visit"", 'LVEF', 'Left ventricular ejection fraction', 'mAb', 'Monoclonal antibody', 'MDRD', 'Modified diet in renal disease', 'MM', 'Multiple myeloma', 'MMAF', 'Monomethyl auristatin-F', 'MOA', 'Mechanism of Action', 'MR', 'Minimal Response.', 'MRD', 'Minimal residual disease', 'MRI', 'Magnetic resonance imaging', 'MSDS', 'Material Safety Data Sheet', 'NCI', 'National Cancer Institute', 'NE', 'Not evaluable', 'NEI-VFQ-25', 'National Eye Institute 25-Item Visual Function Questionnaire', 'NGS', 'Next Generation Sequencing', 'NYHA', 'New York Heart Association', 'ORR', 'Overall Response Rate', 'OS', 'Overall survival', 'OSDI', 'Ocular Surface Disease Index', 'PCR', 'Polymerase chain reaction', 'PD', 'Progressive disease', 'PET', 'Positron Emission Tomography', 'PFS', 'Progression Free Survival', 'PI', 'Principal Investigator', 'PK', 'Pharmacokinetics', 'PR', 'Partial response', 'PRO', 'Patient reported outcome', 'PRO-CTCAE', 'Patient-Reported Outcome Version of the Common Term Criteria for', 'Adverse Events', 'PTS', 'Platform Technologies and Science', 'Q21D', 'Once every 21 days', 'Q3W', 'Once every 3 weeks', 'QID', 'Four times a day', '107']"
107,page_108,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'QLQ-C30', 'Quality of Life Questionnaire 30-item Core module', 'QLQ-MY20', 'Quality of Life Questionnaire 20-item Multiple Myeloma module', 'QTc', 'Corrected QT interval (ECG)', 'QTcF', 'Corrected QT interval Fridericia', 'RAMOS', 'Registration and Medication Ordering System', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cell', 'RNA', 'Ribonucleic acid', 'RP2D', 'Recommended Phase II Dose', 'RRMM', 'Relapsed / refractory multiple myeloma', 'SAE', 'Serious adverse event', 'sCR', 'Stringent Complete Response', 'SCT', 'Stem cell transplant', 'SD', 'Stable disease', 'SOA', 'Schedule of activities', 'SOI', 'Start of infusion', 'SOP', 'Standard operating procedure', 'SPD', 'Sum of the products of the maximal perpendicular diameters of', 'measured lesions', 'SPEP', 'Serum Protein Electrophoresis', 'SRM', 'Study Reference Manual', 'SUSAR', 'Suspected Unexpected Serious Adverse Reaction', 'SUV', 'Standardized uptake value', 't¹/2', 'Terminal phase half-life', 'TCR', 'T-Cell receptor', 'TLS', 'Tumor Lysis syndrome', 'tmax', 'Time of maximum observed concentration', 'TNF', 'Tumor necrosis factor', 'TTP', 'Time to progression', 'TTR', 'Time to (best) Response', 'TTR', 'Time to response', 'UK', 'United Kingdom', 'ULN', 'Upper limit of normal', 'UPEP', 'Urine protein electrophoresis', 'US', 'United States', 'USP', 'United States Pharmacopeia', 'V', 'Volume of distribution', 'VGPR', 'Very good partial response', 'WBC', 'White blood cell', 'WFI', 'Sterile water for injection', 'WOCBP', 'Woman of Childbearing Potential', 'ß-HCG', 'Beta human chorionic gonadotropin', '108']"
108,page_109,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'NONE', 'None', '109']"
109,page_110,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.2.', 'Appendix 2: Clinical Laboratory Tests', 'The tests detailed in Table 14 are identified as being performed at either local or', 'central laboratory.', 'For response assessments, local laboratory results are only required in the event', 'that the central laboratory results are not available in time for response', 'evaluation. If a local sample is required, it is important that the sample for', 'central analysis is obtained at the same time.', 'Protocol-specific requirements for inclusion or exclusion of participants are', 'detailed in Section 6 of the protocol.', 'Additional tests may be performed at any time during the study as determined', 'necessary by the investigator or required by local regulations.', 'Pregnancy testing (see Section 6.1 [Inclusion Criteria] for screening pregnancy', 'criteria)', 'Pregnancy testing (urine or serum as required by local regulations) should be', 'conducted at monthly intervals during intervention', 'Pregnancy testing (urine or serum as required by local regulations) should be', 'conducted at the end of relevant systemic exposure plus an additional 30 days', 'and correspond with the time frame for female participant contraception in', 'Section 6.1 (Inclusion Criteria).', '110']"
110,page_111,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.3.', 'Appendix 3: Study Governance Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with:', 'Consensus ethical principles derived from international guidelines', 'including the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical', 'Guidelines', 'Applicable ICH Good Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other', 'relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by', 'the investigator and reviewed and approved by the IRB/IEC before the study is', 'initiated.', 'Any amendments to the protocol will require IEC/IRB approval before', 'implementation of changes made to the study design, except for changes', 'necessary to eliminate an immediate hazard to study participants.', 'The investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC', 'annually or more frequently in accordance with the requirements, policies,', 'and procedures established by the IRB/EC', 'Notifying the IRB/IEC of SAE or other significant safety findings as', 'required by IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 CFR, ICH guidelines, the IRB/IEC, European', 'regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', 'Financial Disclosure', 'Investigators and sub-investigators will provide the sponsor with sufficient, accurate', 'financial information as requested to allow the sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate regulatory authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study.', 'Informed Consent Process', 'The investigator or his/her representative will explain the nature of the study to', 'the participant or his/her legally authorized representative and answer all', 'questions regarding the study.', '111']"
111,page_112,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Participants must be informed that their participation is voluntary. Participants', 'or their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', ""A copy of the ICF(s) must be provided to the participant or the participant's"", 'legally authorized representative.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', 'Committees Structure', 'An IRC will be utilized to assess response and progression and primary endpoint of', 'the study. GSK will require the site to send electronic files (typically in DICOM', 'format) with acquired imaging for independent review. Details on scan acquisition', 'and image transferal are provided in the Scanning Reference Manual. Further details', 'on the IRC process will be defined in the IRC charter Results from the IRC will not', 'be provided to the investigative sites during the study.', 'Participant data to be shared with the IRC may include the following:', 'Scans (CT, MRI, or PET CT- whichever applicable)', 'SPEP, UPEP, M-protein in 24 hr. urine collection immunoelectrophoresis-', 'urine and serum, serum calcium, and albumin (unless reported as albumin', 'corrected),', 'Serum kappa, serum lambda FLC, FLC Ratio', 'MRD results', '112']"
112,page_113,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with', 'International Committee of Medical Journal Editors authorship requirements.', 'Dissemination of Clinical Study Data', 'For studies conducted in the EU under Regulations EU 536/2014: Consider whether', 'submission of results of the clinical study will be delayed more than one year after the', 'end of trial and provide substantiated reasons. Provide justification if a single summary of', 'results report will not be submitted for all study treatments used in the clinical study.', 'Disclosure of CSRs, periodic safety reports, and clinical study summary reports', 'after review by regulatory authorities. This includes access to CSRs from studies', 'with negative outcomes and from terminated development programs.', 'The posting of company-sponsored study information and tabular study results', ""on the US National Institutes of Health's website www.ClinTrials.gov and other"", 'publicly-accessible sites.', 'Publication planning and other activities related to non-promotional, peer-', 'reviewed publications, to ensure the scientific integrity and credibility of', 'publication activities performed by or on behalf of the company. The granting of', 'access to analyzable datasets from clinical studies through a secure system,', 'following an independent assessment of the scientific merit of a rigorously', 'defined research question from a third party.', 'Where required by applicable regulatory requirements, an investigator signatory', 'will be identified for the approval of the clinical study report. The investigator', 'will be provided reasonable access to statistical tables, figures, and relevant', 'reports and will have the opportunity to review the complete study results at a', 'GSK site or other mutually-agreeable location.', 'GSK will also provide the investigator with the full summary of the study', 'results. The investigator is encouraged to share the summary results with the', 'study participants, as appropriate.', 'The procedures and timing for public disclosure of the results summary and for', 'development of a manuscript for publication will be in accordance with GSK', 'Policy.', '113']"
113,page_114,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'A manuscript will be progressed for publication in the scientific literature if the', 'results provide important scientific or medical knowledge.', 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic', 'CRF unless transmitted to the sponsor or designee electronically (e.g.,', 'laboratory data). The investigator is responsible for verifying that data entries', 'are accurate and correct by physically or electronically signing the CRF.', 'The investigator must maintain accurate documentation (source data) that', 'supports the information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the CRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the investigator for 25 years from the issue of the final', 'Clinical Study Report (CSR)/ equivalent summary or as locally agreed unless', 'local regulations or institutional policies require a longer retention period. No', 'records may be destroyed during the retention period without the written', 'approval of the sponsor. No records may be transferred to another location or', 'party without written notification to the sponsor.', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', ""investigator's site."", 'Data entered in the eCRF that are transcribed from source documents must be', 'consistent with the source documents or the discrepancies must be explained.', 'The investigator may need to request previous medical records or transfer', 'records, depending on the study. Also, current medical records must be', 'available.', 'Definition of what constitutes source data can be found in SRM.', '114']"
114,page_115,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed.', 'The investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the sponsor or investigator may include', 'but are not limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', ""IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines"", 'Inadequate recruitment of participants by the investigator', 'Discontinuation of further study treatment development', '115']"
115,page_116,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', 'Definition of AE', 'AE Definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of a study treatment, whether or not considered related to the', 'study treatment.', 'Note: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study treatment.', 'Events Meeting the AE Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)', 'or other safety assessments (e.g., ECG, radiological scans, vital signs', 'measurements), including those that worsen from baseline, considered clinically', 'significant in the medical and scientific judgment of the investigator (i.e., not related', 'to progression of underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study treatment administration even', 'though it may have been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'treatment or a concomitant medication. Overdose per se will not be reported as an', 'AE/SAE unless it is an intentional overdose taken with possible suicidal/self-', 'harming intent. Such overdoses must be reported regardless of sequelae.', '""Lack of efficacy"" or ""failure of expected pharmacological action"" per se will not be', 'reported as an AE or SAE. Such instances will be captured in the efficacy assessments.', 'However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy', 'will be reported as AE or SAE if they fulfill the definition of an AE or SAE.', 'Events NOT Meeting the AE Definition', 'Any clinically significant abnormal laboratory findings or other abnormal safety', 'assessments which are associated with the underlying disease, unless judged by the', ""investigator to be more severe than expected for the participant's condition."", 'The disease/disorder being studied or expected progression, signs, or symptoms of', 'the disease/disorder being studied, unless more severe than expected for the', '116']"
116,page_117,"['2017N330177_04', 'CONFIDENTIAL', '205678', ""participant's condition."", 'Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that', 'leads to the procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or', 'convenience admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Definition of SAE', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious', 'conditions are met (e.g., hospitalization for signs/symptoms of the disease under study,', 'death due to progression of disease).', 'A SAE is defined as any untoward medical occurrence that, at any dose:', 'Results in death', 'Is life-threatening', 'The term ""life-threatening\' in the definition of \'serious\' refers to an event in which the', 'participant was at risk of death at the time of the event. It does not refer to an event,', 'which hypothetically might have caused death, if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization', 'In general, hospitalization signifies that the participant has been detained (usually', 'involving at least an overnight stay) at the hospital or emergency ward for observation', ""and/or treatment that would not have been appropriate in the physician's office or"", 'outpatient setting. Complications that occur during hospitalization are AE. If a', 'complication prolongs hospitalization or fulfills any other serious criteria, the event is', 'serious. When in doubt as to whether ""hospitalization"" occurred or was necessary, the', 'AE must be considered serious.', 'Hospitalization for elective treatment of a pre-existing condition that did not worsen from', 'baseline is not considered an AE.', 'Results in persistent disability/incapacity', ""The term disability means a substantial disruption of a person's ability to conduct"", 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,', 'and accidental trauma (e.g., sprained ankle) which may interfere with or prevent', 'everyday life functions but do not constitute a substantial disruption.', '117']"
117,page_118,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Is a congenital anomaly/birth defect', 'Other situations:', 'Medical or scientific judgment must be exercised in deciding whether SAE reporting', 'is appropriate in other situations such as important medical events that may not be', 'immediately life-threatening or result in death or hospitalization but may jeopardize', 'the participant or may require medical or surgical intervention to prevent one of the', 'other outcomes listed in the above definition. These events must usually be', 'considered serious.', 'Examples of such events include invasive or malignant cancers, intensive treatment', 'in an emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', 'Is associated with liver injury and impaired liver function defined as:', 'ALT >3 X ULN and total bilirubin* >2 x ULN (>35% direct), or', 'ALT: >3 X ULN and INR', '>1.5.', '* Serum bilirubin fractionation should be performed if testing is available; if unavailable,', 'measure urinary bilirubin via dipstick. If fractionation is unavailable and ALT >3 x ULN', 'and total bilirubin >2 X ULN, then the event is still to be reported as an SAE.', '** INR testing not required per protocol and the threshold value does not apply to', 'participants receiving anticoagulants. If INR measurement is obtained, the value is to be', 'recorded on the SAE form.', 'Refer to Appendix 7 for liver chemistry follow-up procedures.', 'Definition of Cardiovascular Events', 'Cardiovascular Events (CV) Definition:', 'Investigators will be required to fill out the specific CV event page of the CRF for the', 'following AEs and SAEs:', 'Myocardial infarction/unstable angina', 'Congestive heart failure', 'Arrhythmias', 'Valvulopathy', 'Pulmonary hypertension', 'Cerebrovascular events/stroke and transient ischemic attack', 'Peripheral arterial thromboembolism', '118']"
118,page_119,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Deep venous thrombosis/pulmonary embolism', 'Revascularization', 'Recording AE and SAE', 'AE and SAE Recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (e.g., hospital progress notes, laboratory, and diagnostics reports)', 'related to the event.', 'The investigator will then record all relevant AE/SAE information in the CRF.', ""It is not acceptable for the investigator to send photocopies of the participant's"", 'medical records to GSK in lieu of completion of the GSK/AE/SAE CRF page.', 'There may be instances when copies of medical records for certain cases are', 'requested by GSK. In this case, all participant identifiers, with the exception of the', 'participant number, will be redacted on the copies of the medical records before', 'submission to GSK.', 'The investigator will attempt to establish a diagnosis of the event based on signs,', 'symptoms, and/or other clinical information. Whenever possible, the diagnosis (not', 'the individual signs/symptoms) will be documented as the AE/SAE.', 'Assessment of Intensity', 'The investigator will make an assessment of intensity for each AE and SAE reported', 'during the study and assign it to 1 of the following categories:', 'Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations', 'only; intervention not indicated.', 'Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-', 'appropriate instrumental ADL*', 'Grade 3: Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care', 'ADL **', 'Grade 4: Life-threatening consequences; urgent intervention indicated.', 'Grade 5: Death related to AE.', '*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money,', 'etc.', '**Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not', 'bedridden.', '119']"
119,page_120,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Assessment of Causality', 'The investigator is obligated to assess the relationship between study treatment and', 'each occurrence of each AE/SAE.', 'A ""reasonable possibility"" of a relationship conveys that there are facts, evidence,', 'and/or arguments to suggest a causal relationship, rather than a relationship cannot', 'be ruled out.', 'The investigator will use clinical judgment to determine the relationship.', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other', 'risk factors, as well as the temporal relationship of the event to study treatment', 'administration will be considered and investigated.', ""The investigator will also consult the Investigator's Brochure (IB) and/or Product"", 'Information, for marketed products, in his/her assessment.', 'For each AE/SAE, the investigator must document in the medical notes that he/she', 'has reviewed the AE/SAE and has provided an assessment of causality.', 'There may be situations in which an SAE has occurred and the investigator has', 'minimal information to include in the initial report to GSK. However, it is very', 'important that the investigator always make an assessment of causality for', 'every event before the initial transmission of the SAE data to GSK.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information and send an SAE follow-up report with the updated causality', 'assessment.', 'The causality assessment is one of the criteria used when determining regulatory', 'reporting requirements.', 'Follow-up of AE and SAE', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as medically indicated or as requested by GSK to', 'elucidate the nature and/or causality of the AE or SAE as fully as possible. This may', 'include additional laboratory tests or investigations, histopathological examinations,', 'or consultation with other health care professionals.', 'New or updated information will be recorded in the originally completed CRF.', 'The investigator will submit any updated SAE data to GSK within 24 hours of', 'receipt of the information.', '120']"
120,page_121,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Reporting of SAE to GSK', 'SAE Reporting to GSK via Electronic Data Collection Tool', 'The primary mechanism for reporting SAE to GSK will be the electronic data', 'collection tool.', 'If the electronic system is unavailable, then the site will use the paper SAE data', 'collection tool (see next section) in order to report the event within 24 hours.', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', 'The investigator or medically-qualified sub-investigator must show evidence within', 'the eCRF (e.g., check review box, signature, etc.) of review and verification of the', 'relationship of each SAE to IP/study participation (causality) within 72 hours of SAE', 'entry into the eCRF.', 'After the study is completed at a given site, the electronic data collection tool will be', 'taken off-line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated', 'data on a previously reported SAE after the electronic data collection tool has been', 'taken off-line, then the site can report this information on a paper SAE form (see', 'next section).', 'Contacts for SAE reporting can be found in SRM.', 'SAE Reporting to GSK via Paper CRF', 'Facsimile transmission of the SAE paper CRF is the preferred method to transmit', 'this information to the SAE coordinator. Details provided in the SRM.', 'In rare circumstances and in the absence of facsimile equipment, notification by', 'telephone is acceptable with a copy of the SAE data collection tool sent by overnight', 'mail or courier service.', 'Initial notification via telephone does not replace the need for the investigator to', 'complete and sign the SAE CRF pages within the designated reporting time frames.', 'Contacts for SAE reporting can be found in the SRM.', '121']"
121,page_122,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below).', 'If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle', 'cannot be confirmed before first dose of study intervention, additional evaluation should', 'be considered.', 'Women in the following categories are not considered WOCBP', '1', 'Premenarchal', '2', 'Premenopausal females with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', 'For individuals with permanent infertility due to an alternate medical cause', 'other than the above, (e.g., mullerian agenesis, androgen insensitivity),', 'investigator discretion should be applied to determining study entry.', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3', 'Postmenopausal females', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, confirmation with', 'more than one FSH measurement is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-estrogen hormonal highly effective contraception methods if', 'they wish to continue their HRT during the study. Otherwise, they must', 'discontinue HRT to allow confirmation of postmenopausal status before study', 'enrollment.', '122']"
122,page_123,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Contraception Guidance', 'CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDE:', 'Highly Effective Methodsb That Have Low User Dependency', 'Implantable progestogen-only hormone contraception associated with inhibition of ovulation', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)c', 'Bilateral tubal occlusion', 'Vasectomized partner', 'Note: Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole', 'sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used. Spermatogenesis cycle is', 'approximately 90 days.', 'Highly Effective Methodsb That Are User Dependent', 'Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of', 'ovulation', 'oral', 'intravaginal', 'transdermal', 'injectable', 'Progestogen-only hormone contraception associated with inhibition of ovulation°', 'oral', 'injectable', 'Sexual abstinence', 'Note: Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study intervention. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the', 'preferred and usual lifestyle of the participant', 'a.', 'Contraceptive use by men or women should be consistent with local regulations regarding the use of', 'contraceptive methods for those participating in clinical studies.', 'b.', 'Failure rate of <1% per year when used consistently and correctly. Typical use failure rates differ from those when', 'used consistently and correctly.', 'C.', 'Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with Clinical', 'Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those which inhibit', 'ovulation as the primary mode of action.', 'Note: Periodic abstinence (calendar, sympto-thermal, post-ovulation methods), withdrawal (coitus interruptus),', 'spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception for this', 'study. Male condom and female condom should not be used together (due to risk of failure with friction)', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', ""Investigator will attempt to collect pregnancy information on any male participant's"", 'female partner of a male study participant who becomes pregnant while participating', 'in this study. This applies only to male participants who receive study intervention.', '123']"
123,page_124,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'After obtaining the necessary signed informed consent from the pregnant female', 'partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'The female partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure.', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', ""24 hours of learning of a participant's pregnancy."", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy for medical reasons will be', 'reported as an AE or SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study intervention by the investigator, will be reported to', 'GSK as described in Appendix 4. While the investigator is not obligated to actively', 'seek this information in former study participants, he or she may learn of an SAE', 'through spontaneous reporting.', 'Any female participant who becomes pregnant while participating will discontinue study', 'intervention.', '124']"
124,page_125,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.6.', 'Appendix 6: Genetics', 'USE/ANALYSIS OF DNA', ""Genetic variation may impact a participant's response to therapy, susceptibility,"", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a 6-mL blood sample will be collected from participants who have consented', 'to participate for DNA analysis.', 'DNA samples will be used for research related to GSK2857916 or Multiple', 'Myeloma and related diseases. They may also be used to develop tests/assays', 'including diagnostic tests related to GSK2857916 or study treatments of this drug', 'class, and Multiple Myeloma. Genetic research may consist of the analysis of one or', 'more candidate genes or the analysis of genetic markers throughout the genome or', 'analysis of the entire genome (as appropriate).', 'DNA samples will be analyzed for described planned analyses. Additional analyses', 'will be conducted if it is hypothesized that this may help further understand the', 'clinical data.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to GSK2857916 or study treatments of this class. The', 'results of genetic analyses may be reported in the clinical study report or in a', 'separate study summary.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on GSK2857916 (or study treatments of', 'this class) or Multiple Myeloma continues but no longer than 15 years after the last', 'subject last visit or other period as per local requirements.', '125']"
125,page_126,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments and Study Treatment Rechallenge Guidelines', 'Phase I/II liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event etiology.', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'ALT-absolute', 'ALT >5xULN', 'ALT Increase', 'ALT >3xULN persists for >4 weeks', 'Bilirubin1,2', 'ALT >3xULN and bilirubin >2xULN (>35% direct bilirubin)', 'INR²', 'ALT >3xULN and INR >1.5, if INR measured', 'Cannot Monitor', 'ALT >3xULN and cannot be monitored weekly for 4 weeks', 'Symptomatic³', 'ALT >3xULN associated with symptoms (new or worsening) believed to be related', 'to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments following ANY Liver Stopping Event', 'Actions', 'Follow Up Assessments', 'Report the event to GSK within 24 hours', 'Viral hepatitis serology4', 'Complete the liver event CRF and complete', 'Only in those with underlying chronic hepatitis B at', 'an SAE data collection tool if the event also', 'study entry (identified by positive hepatitis B', 'meets the criteria for an SAE²', 'surface antigen) quantitative hepatitis B DNA and', 'Perform liver event follow up assessments', 'hepatitis delta antibody5.', 'Monitor the participant until liver chemistries', 'Blood sample for pharmacokinetic (PK) analysis, if', 'resolve, stabilize, or return to within baseline', 'it can be obtained within 45 days after last dose', '(see MONITORING below)', 'Serum creatine phosphokinase (CPK) and lactate', 'Do not restart/rechallenge participant with', 'dehydrogenase (LDH).', 'study treatment unless allowed per protocol', 'Fractionate bilirubin, if total bilirubin>2xULN', 'and GSK Medical Governance approval is', 'granted (refer to language within this', 'Obtain complete blood count with differential to', 'Appendix)', 'assess eosinophilia', 'If restart/rechallenge not allowed per', 'Record the appearance or worsening of clinical', 'protocol or not granted, permanently', 'symptoms of liver injury, or hypersensitivity, on the', 'discontinue study treatment and may', 'AE report form', 'continue participant in the study for any', 'Record use of concomitant medications on the', 'protocol specified follow up assessments', 'concomitant medications report form including', 'MONITORING:', 'acetaminophen, herbal remedies, other over the', 'counter medications', 'For bilirubin or INR criteria:', 'Record alcohol use on the liver event alcohol', 'Repeat liver chemistries (include ALT, AST,', 'intake case report form', '126']"
126,page_127,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'alkaline phosphatase, bilirubin) and perform', 'For bilirubin or INR criteria:', 'liver event follow up assessments within 24', 'hrs', 'Anti-nuclear antibody, anti-smooth muscle', 'antibody, Type 1 anti-liver kidney microsomal', 'Monitor participants twice weekly until liver', 'antibodies, and quantitative total immunoglobulin', 'chemistries resolve, stabilize or return to', 'G (lgG or gamma globulins).', 'within baseline', 'Serum acetaminophen adduct HPLC assay', 'A specialist or hepatology consultation is', '(quantifies potential acetaminophen contribution to', 'recommended', 'liver injury in participants with definite or likely', 'For All other criteria:', 'acetaminophen use in the preceding week', '[James, 2009]) Note: not required in China', 'Repeat liver chemistries (include ALT, AST,', 'alkaline phosphatase, bilirubin) and perform', 'Liver imaging (ultrasound, magnetic resonance, or', 'liver event follow up assessments within 24-', 'computerized tomography) and /or liver biopsy to', '72 hrs', 'evaluate liver disease complete Liver Imaging', 'and/or Liver Biopsy CRF forms.', 'Monitor participants weekly until liver', 'chemistries resolve, stabilize or return to', 'within baseline', '1.', 'Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that participant if ALT >3xULN and bilirubin >2xULN.', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT >3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT >3xULN and INR>1.5, if INR', ""measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding"", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (lgM); Hepatitis C', 'RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain', 'heterophile antibody or monospot testing); Hepatitis E IgM antibody', '5.', 'If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus', '(where needed) [Le Gal, 2005].', '6.', 'Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to', ""blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the participant's best"", 'approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in', 'the time period indicated above, do not obtain a PK sample.', '127']"
127,page_128,"['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Phase I/II Oncology liver chemistry increased monitoring criteria with continued', 'therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'ALT >3xULN but <5xULN and', 'Notify the GSK medical monitor within 24 hours of', 'learning of the abnormality to discuss participant', 'bilirubin <2xULN, without symptoms believed', 'safety.', 'to be related to liver injury or hypersensitivity', 'and who can be monitored weekly for 4 weeks', 'Participant can continue study treatment', 'Participant must return weekly for repeat liver', 'chemistries (ALT, AST, alkaline phosphatase,', 'bilirubin) until they resolve, stabilize or return to', 'within baseline', 'If at any time participant meets the liver chemistry', 'stopping criteria, proceed as described above', 'If, after 4 weeks of monitoring, ALT <3xULN and', 'bilirubin <2xULN, monitor participants twice monthly', 'until liver chemistries normalize or return to within', 'baseline.', '12.7.1.', 'Liver Safety Drug Restart or Re-Challenge Guidelines', 'If participant meets liver chemistry stopping criteria do not restart/re-challenge', 'participant with study treatment unless all the following conditions are met:', 'GSK Medical Governance approval is granted (as described below)', 'IRB/IEC approval is obtained, if required', 'Separate consent for treatment restart/re-challenge is signed by the participant', 'If GSK Medical Governance approval to restart/re-challenge participant with study', 'treatment is not granted, then participant must permanently discontinue study treatment', 'and may continue in the study for protocol-specified follow up assessments.', '12.7.1.1. Re-challenge Following Liver Stopping Events that are Possibly', 'Related to Study Treatment', 'Re-challenge refers to resuming study treatment following drug-induced liver injury', '(DILI). Because of the risks associated with re-challenge after DILI, this should only be', 'considered for a participant for whom there is compelling evidence of benefit from a', 'critical or life-saving medicine, there is no alternative approved medicine available, and', 'a', 'benefit: risk assessment of re-challenge is considered to be favorable.', 'Following DILI, drug re-challenge is associated with a 13% mortality across all drugs in', 'prospective studies [Andrade, 2009]. Clinical outcomes vary by drug with nearly 50%', '128']"
128,page_129,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'fatality with halothane re-administered within 1 month of initial injury. However, some', 'drugs seldom result in recurrent liver injury or fatality.', 'Risk factors for a fatal drug re-challenge outcome include the following:', 'Hypersensitivityl with initial liver injury (e.g., fever, rash, eosinophilia)', 'Jaundice or bilirubin >2 X ULN with initial liver injury (direct bilirubin >35% of', 'total)', 'Participant currently exhibits severe liver injury defined by ALT >3 X ULN, bilirubin', '>2 x ULN (direct bilirubin >35% of total), or INR >1.5', 'SAE or fatality has been observed with drug rechallenge [Papay, 2009; Hunt, 2010]', 'Evidence of drug-related preclinical liability (e.g., reactive metabolites;', 'mitochondrial impairment) [Hunt, 2010]', 'Approval by GSK for re-challenge with study treatment can be considered under the', 'following conditions:', 'Investigator requests consideration of re-challenge with study treatment for a', 'participant who is receiving compelling benefit with study treatment that exceeds', 'risk, and no effective alternative therapy is available.', 'IRB/IEC approval for re-challenge with study treatment must be obtained, as', 'required.', 'If the re-challenge is approved by GSK Medical Governance in writing, the', 'participant must be provided with a clear description of the possible benefits and', 'risks of study treatment administration including the possibility of recurrent, more', 'severe liver injury or death.', 'The participant must also provide signed informed consent specifically for the', 're-challenge with study treatment. Documentation of informed consent must be', 'recorded in the study chart.', 'Study treatment must be administered at the dose specified by GSK.', 'Participants approved by GSK Medical Governance for re-challenge with study', 'treatment must return to the clinic twice a week for liver chemistry tests until stable', 'liver chemistries have been demonstrated and then standard laboratory monitoring', 'may resume as per protocol.', 'If after study treatment re-challenge, participant meets protocol-defined liver', 'chemistry stopping criteria, study treatment must be permanently discontinued.', 'GSK medical monitor, and the IRB/IEC as required, must be informed of the', ""participant's outcome following study treatment re-challenge."", 'GSK must be notified of any AEs as per Section 9.2.4.', '129']"
129,page_130,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.7.1.2. Re-challenge Following Transient Liver Stopping Events Not Related to', 'Study Treatment', 'Restart refers to resuming study treatment following liver stopping events in which there', 'is a clear underlying cause (other than DILI) of the liver event (e.g., biliary obstruction,', 'pancreatic events, hypotension, and acute viral hepatitis). Furthermore, there should be', 'no evidence of alcoholic hepatitis or hypersensitivity, and the study treatment should not', 'be associated with human leukocyte antigen (HLA) markers of liver injury.', 'Approval by GSK for study treatment restart can be considered under the following', 'conditions:', 'Investigator requests consideration for study treatment restart if liver chemistries', 'have a clear underlying cause (e.g., biliary obstruction, hypotension and liver', 'chemistries have improved to normal or are within 1.5 X baseline and ALT', '<3 X ULN).', 'Possible study treatment-related liver injury has been excluded by the investigator', 'and the study team. This includes the absence of markers of hypersensitivity', '(otherwise unexplained fever, rash, eosinophilia). Where a study treatment has an', 'identified genetic marker associated with liver injury (e.g., lapatinib, abacavir,', 'amoxicillin/clavulanate), the presence of the marker should be excluded. If study', 'treatment-related liver injury cannot be excluded, the guidance on re-challenge in', 'Section 12.7.1.1 will apply.', 'There is no evidence of alcoholic hepatitis.', 'IRB/IEC approval of study treatment restart must be obtained, as required.', 'If restart of study treatment is approved by GSK Medical Governance in writing, the', 'participant must be provided with a clear description of the possible benefits and', 'risks of study treatment administration including the possibility of recurrent, more', 'severe liver injury or death.', 'The participant must also provide signed informed consent specifically for the study', 'treatment restart. Documentation of informed consent must be recorded in the study', 'chart.', 'Study treatment must be administered at the dose specified by GSK.', 'Participants approved by GSK Medical Governance for restarting study treatment', 'must return to the clinic once a week for liver chemistry tests until stable liver', 'chemistries have been demonstrated and then laboratory monitoring may resume as', 'per protocol.', 'If after study treatment restart, participant meets protocol-defined liver chemistry', 'stopping criteria, follow usual stopping criteria instructions.', 'GSK medical monitor, and the IRB/IEC as required, must be informed of the', ""participant's outcome following study treatment restart."", 'GSK must be notified of any AEs, as per Section 9.2.4.', '130']"
130,page_131,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.7.2.', 'References', 'Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the', 'attractive hazard. Expert Opin Drug Saf. 2009;8:709-714.', 'Hunt, CM. Mitochondrial and immunoallergic injury increase risk of positive drug', 'rechallenge after drug-induced liver injury: A systematic review. Hepatol. 2010;52:2216-', '2222.', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', 'Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, Gault E. Quantification', 'of Hepatitis Delta Virus RNA in Serum by Consensus Real-Time PCR Indicates', 'Different Patterns of Virological Response to Interferon Therapy in Chronically Infected', 'Patients. J Clin Microbiol. 2005;43(5):2363-2369.', 'Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM. Drug-induced liver', 'injury following positive drug rechallenge. Regul Tox Pharm. 2009;54:84-90.', '131']"
131,page_132,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.8.', 'Appendix 8: ECOG Performance Status', 'Grade', 'Descriptions', '0', 'Normal activity. Fully active, able to carry on all pre-disease performance without restriction.', '1', 'Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able', 'to carry out work of a light or sedentary nature (e.g., light housework, office work).', '2', 'In bed <50% of the time. Ambulatory and capable of all self-care, but unable to carry out any', 'work activities. Up and about more than 50% of waking hours.', '3', 'In bed >50% of the time. Capable of only limited self-care, confined to bed or chair more than', '50% of waking hours.', '4', '100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to bed', 'or chair.', '5', 'Dead.', 'Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of', 'the Eastern Cooperative Oncology Group. American journal of clinical oncology. 1982 Dec 1;5(6):649-56.', '132']"
132,page_133,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.9.', 'Appendix 9: GSK Corneal Event Severity Scale and', 'Mitigation Strategy for GSK2857916 Treatment-Related', 'Corneal Events', 'In order to minimize corneal events associated with GSK2857916, participants must', 'receive steroid eye drops as prophylaxis (such as: prednisolone acetate 1%, prednisolone', 'phosphate 1%, dexamethasone 0.1% or equivalent) 1 drop QID starting 1 day prior to', 'each GSK2857916 infusion, and continuing for a total of consecutive 7 days. Omission', 'or discontinuation of prophylactic steroid eye drops may be allowed under certain', 'circumstances (e.g., in the setting of intolerability, contraindication, or toxicity secondary', 'to steroid eye drops) upon discussion with the Medical Monitor.', 'Prophylactic preservative-free artificial tears should be administered in each eye at least 4', 'to 8 times daily beginning on Cycle 1 Day 1 until the EOT. Allow at least 5-10 minutes', 'between administration of artificial tears and steroid eye drops. In the event of ocular', 'symptoms (e.g., dry eyes), the use of artificial tears may be increased up to every 2 hours', 'as needed.', 'While not yet clinically demonstrated, it is theoretically possible that the application of a', 'cooling eye mask during GSK2857916 administration, and in the first few hours after', 'infusion may subsequently decrease ocular side effects. On the day of infusion at the', 'discretion of the participant and the investigator, the following may be considered:', 'Beginning with the start of each GSK2857916 infusion, participants may apply', 'cooling eye masks to their eyes for approximately 1 hour or as much as tolerated.', 'Participants may continue using the cooling eye mask beyond the first hour for up to', ""4 hours. Further use beyond 4 hours is at the participant's discretion."", 'Participants must avoid the use of contact lenses during the study.', 'An ophthalmology (or optometry, if ophthalmology is not available) consult is required', 'for all participants who develop signs or symptoms of corneal events or require steroid', 'eye drops for more than 7 days.', 'Following discussions with regulatory agencies, GSK developed a grading scale for', 'corneal events to capture both corneal findings and visual acuity changes in participants', 'treated with GSK2857916. This GSK scale is different from CTCAE criteria for eye', ""disorders which relies mainly on patient's symptoms and patient's ability to attend to"", ""'activities of daily living' for grading of events."", 'A summary of prophylactic interventions for corneal events associated with', 'GSK2857916 is provided in Table 21. In addition to reporting eye disorders using', 'CTCAE 4.03 criteria, corneal events associated with GSK2857916 must be graded', 'according to the guidelines provided in Table 22. Additional guidance on visual acuity', 'changes is provided in Table 23.', 'In the FTIH study (BMA117159), eye examinations showed that most participants', 'continued to receive GSK2857916 dose when either a GSK Scale Grade 2 corneal', 'examination finding or a 2-3-line decrease in visual acuity was reported. With this dosing', '133']"
133,page_134,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'paradigm, participants generally showed improvement in both corneal examination', 'findings and visual acuity over time. Therefore, the dosing guideline has been adjusted to', 'allow dosing with GSK2857916 if only one component on the GSK corneal event scale', 'indicates Grade 2 corneal event.', 'Table 21', 'Prophylactic Measures for Corneal Events Associated with', 'GSK2857916 a, b', 'Prophylactic', 'Measurea', 'Dose and Administration', 'Timing', 'Steroid eye dropsb', 'Prednisolone acetate 1.0%,', 'Begin 1 day prior to each dose of', 'Prednisolone phosphate 1%, or', 'GSK2857916 infusion, and continuing', 'dexamethasone 0.1%, or', 'for a total of consecutive 7 days', 'equivalent, 1 drop QID', 'Preservative-free', 'Administer in each eye at least 4', 'Administer daily beginning on Cycle 1', 'artificial tears', 'to 8 times daily', 'Day 1 until EOT. Allow 5-10 minutes', 'between administration of artificial tears', 'and steroid eye drops', 'Cooling eye mask', 'May apply cooling eye mask to', 'During GSK2857916 infusion', 'both eyes for approximately', 'administration in the first hour for up to 4', '1 hour or as much as tolerated', 'hours, as tolerated', 'a.', 'Dose modifications and treatment for ocular toxicities are discussed in Section 7.2', 'b', 'Omission or discontinuation of prophylactic steroid eye drops may be allowed under certain circumstances (e.g., in', 'the setting of intolerability, contraindication, or toxicity secondary to steroid eye drops) upon discussion with the', 'Medical Monitor.', 'Table 22', 'GSK Scale for Corneal Events Associated with GSK2857916a', 'Measure', 'Grade 1 per', 'Grade 2 per GSK', 'Grade 3 per GSK', 'Grade 4 per', 'GSK Scale', 'Scale', 'Scale', 'GSK Scale', 'Ophthalmic', 'Mild superficial', 'Moderate punctate', 'Severe punctate', 'Corneal ulcer', 'exam', 'keratopathy', 'keratopathy', 'keratopathy', 'findings', '(change from', 'and/or', 'and/or', 'baseline)', 'Mild/patchy microcysts', 'Diffuse microcysts', 'and/or', 'and/or', 'Mild/patchy Epithelial', 'Diffuse Epithelial or', 'or stromal edema', 'stromal edema', 'and/or', 'and/or', 'Sub-epithelial haze', 'Sub-epithelial haze', '(peripheral)', '(central)', 'and/or', 'and/or', 'Active stromal opacity', 'Active stromal opacity', '(peripheral)', '(central)', 'Visual', 'Change of 1 line', 'Change of 2-3 lines', 'Change of more than 3', 'Worse than', 'Acuity b,c', 'from baseline', 'from baseline and not', 'lines from baseline and', 'Vision 20/200b', 'worse than 20/200b', 'not worse than 20/200b', '134']"
134,page_135,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Note: Standardized guidance for grading ophthalmic findings associated with GSK2857916 is provided to sites in the', ""ophthalmology SRM. Ophthalmic exam findings as described must be present in a participant to utilize GSK's"", 'scale.', 'a.', 'Grading is based on most severe finding. If eyes differ in severity, GSK grading should be based on the more', 'severe eye.', 'b.', 'Change in visual acuity should be due to corneal events. If change in vision is for reason other than corneal', 'events, ophthalmic exam findings will drive event grading.', 'C.', 'See Table 23 for additional guidance on how to grade changes in visual acuity depending on baseline vision. If a', 'participant has a baseline visual acuity of 20/200 or worse in an eye, ophthalmic exam findings will drive event', 'grading.', 'Table 23', 'Guidance on GSK Scale Grading Based on Changes in Visual Acuity', 'Baseline Vision', 'Grade 1 per', 'Grade 2 per GSK', 'Grade 3 per GSK', 'Grade 4 per GSK', '(best corrected)', 'GSK scale', 'scale', 'scale', 'scale', '20/20', '20/25', '20/30 - 20/40', '20/50-20/200', 'Worse than 20/200', '20/25', '20/30', '20/40 - 20/50', '20/60-20/200', 'Worse than 20/200', '20/30', '20/40', '20/50 - 20/60', '20/70-20/200', 'Worse than 20/200', '20/40', '20/50', '20/60 - 20/70', '20/80 - -20/200', 'Worse than 20/200', '20/50', '20/60', '20/70 - 20/80', '20/100 - 20/200', 'Worse than 20/200', '20/60', '20/70', '20/80 - 20/100', '20/125 - 20/200', 'Worse than 20/200', '20/70', '20/80', '20/100 - 20/125', '20/200', 'Worse than 20/200', '20/80', '20/100', '20/125 - 20/200', 'N/A', 'Worse than 20/200', '20/100', '20/200', '20/200', 'N/A', 'Worse than 20/200', '135']"
135,page_136,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.10.', 'Appendix 10: Modified Diet in Renal Disease (MDRD)', 'Formula', 'The MDRD formula for calculating the estimated glomerular filtration rate (eGFR) is as', 'follows:', 'eGFR (mL/min/1.73 m²) = 175 X (Scr) -1.154 X (Age) -0.203 X (0.742 if female) X (1.212 if', 'African American)', 'GFR is expressed in mL/min/1.73 m², , Scr is serum creatinine expressed in mg/dL, and', 'age is expressed in years.', 'The link below will auto-calculate the creatinine clearance: http://nephron.org/cgi-', 'bin/MDRD_GFR/cgi', '136']"
136,page_137,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.11.', 'Appendix 11: Protocol Amendment History', 'The Protocol Amendment Summary of Changes Table for the current amendment is', 'located directly before the Table of Contents (TOC).', 'Amendment 2: 04-SEP-2018', 'Overall Rationale for the Amendment:', 'The protocol has been amended to address feedback from regulatory agencies, EC/IRB,', 'and investigators. The updates include the addition of Exclusion Criteria defining the', 'use of high dose steroids, clarification of specific timeframe from last treatment required', 'for systemic anti-myeloma therapy, and increase of QTcF criteria. Additional PK', 'sampling timepoints were added to capture the Cmax of the free cytotoxic drug (cys-', 'mcMMAF) and to better define the kinetics of cys-mcMMAF and the elimination phase', 'of ADC and cys-mcMMAF. Soluble BCMA collection timepoints were also added to', 'capture the effect of GSK2857916 administration on soluble BCMA concentrations over', 'time as a marker of pharmacodynamic effect. The dose modifications guidelines for', 'GSK2857916 related Corneal Events clarify dose adjustments for GSK Scale Grade 2', 'events.', 'DOCUMENT HISTORY', 'Document', 'Date of Issue', 'Amendment 2 (Republishing)', '04-Sep-2018', 'Amendment 2', '30-Aug-2018', 'Amendment 1', '02-Apr-2018', 'Original Protocol 18-Jan-2018', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'All Sections', 'Replaced ophthalmologist with', 'To allow for either an', 'ophthalmologist (or an optometrist if an', 'optometrist or ophthalmologist', 'ophthalmologist is not available)', 'to perform eye examinations.', 'Updated Investigator Brochure Version', 'Section 1 Synopsis', 'Changed text in Synopsis to reflect', 'See below for all significant', 'changes to the text of the protocol', 'changes', 'Section 2 Schedule of', 'Table 1-Table 3: Footnote numbering', 'Administrative changes and', 'Activities (SOA)', 'corrected and text made applicable for', 'clarifications of timepoints', 'each schedule', 'Table 1-Table 3: Abbreviations updated', 'Acceptability of positive results', 'Table 1: Screening SOA - addition of', 'for high risk abnormalities by', '137']"
137,page_138,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'FISH results that are classified as high', 'FISH have been extended', 'risk beyond the 60-day timepoint.', 'beyond 60-days, as those are', 'Table 2: Clarifications of timings for', 'myeloma defining abnormalities', 'vital sign, ECG collections and PK', 'and do not change in the course', 'of the disease.', 'sample collection,', 'Table 2: Triplicate ECG measurements', 'Additional ECG timepoints', 'added to assess at the Cmax of', 'changed from 5 minutes apart to 2', 'minutes apart; additional timepoints', 'the free cytotoxic drug (cys-', 'added', 'mcMMAF) and to detect any', 'delayed effects on QTc.', 'Table 2: Additional PK timepoints', 'added', 'Additional PK timepoints added', 'to capture the Cmax of the free', 'Table 2 & Table 3: Clarifications of', 'cytotoxic drug (cys-mcMMAF)', 'timings for imaging added', 'and to better define the kinetics', 'Table 2 & Table 3: Clarifications of', 'of cys-mcMMAF and the', 'serum and urine immunofixation added', 'elimination phase of ADC and', 'cys-mcMMAF.', 'Table 2: Removed requirement for', 'German MRI collection for skeletal', 'Additional sBCMA timepoints', 'survey', 'added to capture the effect of', 'GSK2857916 administration on', 'Table 2: Additional sBCMA sample', 'soluble BCMA concentrations', 'collection timepoints added', 'over time as a marker of', 'Table 4: Removed requirement for', 'pharmacodynamic effect.', 'mandatory exams in ocular substudy', 'Section 3.4.2 Corneal', 'Added CTCAE grading', 'Provides clarity that CTCAE', 'Events', 'scale was utilized to report all', 'corneal events in the FTIH', 'study.', 'Section 4 Objectives', 'Secondary endpoint for Clinical benefit', 'Resolves Discrepancy and', 'and Endpoints', 'rate added to align with Section 1,', 'aligns section to Synopsis', 'synopsis', 'Secondary endpoint for Time to', 'Align with Section 10, which', 'Response, Progression Free Survival,', 'states all randomized', 'Time to Progression and Overall', 'participants will be included in', 'Survival updated to align with Section', 'analyses', '1, Synopsis and Section 10, Statistical', 'Considerations.', 'Plasma concentrations of GSK2857916', 'clarified as ADC, total mAb, and cys-', 'mcMMAF.', '138']"
138,page_139,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Exploratory Endpoint for MRD', 'negativity testing clarified', 'Clarification on how analyses', 'will be performed', 'Section 5 Study Design', 'Study Schema revised to remove', 'Lyophilized cohort will not open', 'description of start of lyophilized', 'until the drug configuration is', 'cohort.', 'available and the enrollment is', 'complete under the frozen', 'configuration.', 'Section 5.5 Dose', 'Added CTCAE grading', 'Aligned with Section 3.4.2 to', 'Justification', 'clarify that the CTCAE scale', 'was utilized in the FTIH study', 'Section 6.1 Inclusion', 'Changed i.e. to e.g. for prior lines', 'Clarification and Prior Lines of', 'Criteria', 'Table 9 footnote cross-reference', 'therapy updated to clarify it is', 'corrected', 'any proteasome inhibitor or', 'IMiD.', 'Section 6.2 Exclusion', 'Systemic anti-myeloma therapy', 'Exclusion Criteria #1 -', 'Criteria', 'clarified as excluded if administered', 'Clarification of timeframe', 'within 14 days or 5 half-lives,', 'required from last treatment of', 'whichever is shorter', 'systemic anti-myeloma therapy', 'Added Exclusion criteria #2 for high', 'dose steroids', 'Exclusion Criteria #2 added to', 'Modified Exclusion criteria #12 to', 'define high dose steroid usage', 'accept malignancy of non-melanoma', 'that may have anti myeloma', 'skin cancers', 'activity though not given to treat', 'the disease', 'QTcF increase to 480 msec from 470', 'msec', 'Exclusion Criteria #13 - QTcF', 'increased to align with GSK', 'internal standards for oncology', 'trials determined by GSK', 'Cardiac Safety Panel.', 'Section 7 Treatments', 'Removed Infusion Time', 'Administrative change', '139']"
139,page_140,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 7.2 Dose', 'Table edited for clarity.', 'Changes to dose modifications', 'Modifications, Table 13', 'GSK Scale for corneal events', 'guidelines for GSK2857916', 'Dose Modification', 'related Corneal Events further', 'incorporated and Dosing modifications', 'Guidelines for', 'amended', 'clarify dose modifications based', 'GSK2857916', 'on the visual acuity or findings', 'Treatment-Related', 'on ophthalmic examination', 'Corneal Events', 'Section 7.2.2 Dose', 'Dosing delay and restarting language', 'Updated to allow for restart prior', 'Reductions for Toxicity', 'added', 'to next cycle in cases where the', 'treating physician feels it is', 'necessary for participants well-', 'being.', 'Section 7.2.3 Corneal', 'Clarified that corneal supportive care is', 'To provide consistency and', 'Supportive Care', 'based on GSK Corneal Scale (Table', 'alignment throughout the', 'Guidelines', '22)', 'protocol.', 'Section 7.7.2 Prohibited', 'Caution statement for CYP', 'For alignment with IB version', 'Medications', 'inhibitors/inducers added', '05, Section 6.4', 'Section 7.8 Treatment', 'Cross-reference corrected from Table 1', 'Administrative change', 'after the End of Study', 'to Table 3', 'Section 8.1', 'Pregnancy added to the list of reasons', 'To align with Section 9.2.8 and', 'Discontinuation of Study', 'for discontinuation', 'Appendix 5 as animal', 'Treatment', 'reproductive studies have not', 'been conducted with', 'GSK2857916', 'Section 8.2.5 Corneal', 'Added Clarity on use of GSK scale and', 'Alignment throughout protocol.', 'Event Stopping Criteria', 'CTCAE scale for reporting purposes', 'Both the CTCAE and GSK', 'and dose modifications.', 'Scale are to be utilized for', 'reporting of corneal events and', 'clarify that the GSK scale to be', 'utilized for dose modification', 'decisions.', 'Section 9 Study', 'On study visits and PFS follow-up visits', 'Alignment with Section 2,', 'Assessments and', 'separated to aligned with SOA Tables', 'Schedule of Activities', 'Procedures', 'Table 14 - addition of spot urine', 'instructions; and clarification of FISH', 'results to align with Section 2,', 'Schedule of activities', '140']"
140,page_141,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 9.1 Efficacy', 'Clarified language regarding collection', 'Language modified to allow for', 'Assessments', 'of PD blood sample', 'confirmation sample to occur on', 'the same day as original', 'collection.', 'Section 9.2 Adverse', 'Added clarity on use of GSK Scale and', 'Revised to provide clear', 'Events', 'CTCAE', 'guidance for dose modifications', 'due to GSK2857916 corneal', 'Added clarity that all AEs will be', 'events.', 'graded using CTCAE and that corneal', 'events will also be graded using the', 'CTCAE scale will be utilized to', 'GSK scale. GSK2857916 dosing', 'harmonize data with FTIH study', 'decisions related to GSK2857916', 'results', 'corneal events are to be made using', 'the GSK Scale for corneal events.', 'Section 9.2.1 Time', 'Updated AE reporting timeframe from', 'Revised to align with 5 half-lives', 'Period and Frequency', '30 days to 45 days', 'of GSK2857916', 'for collecting AE and', 'SAE information', 'Section 9.2.6 Disease', 'Clarified disease progression does not', 'Updated to align with GSK', 'Related Events and/or', 'need to be reported as an SAE', 'internal standards for oncology', 'Disease Related', 'trials.', 'Section 9.2.7 Adverse', 'Added that corneal AESI should be', 'Revised to align with Section', 'Events of Special', 'graded by CTCAE and GSK Scale for', '9.2 Adverse Events.', 'Interest', 'corneal events', 'Section 9.2.9 Ocular', 'Added statement to clarify', 'Revised to align with all', 'Exams and Procedures', 'representative images will be collected', 'GSK2857916 protocols', 'and stored centrally.', 'Section 9.2.10.1', 'Preservative free artificial tear', 'Clarification to align with Table', 'Monocular Prophylaxis', 'requirements updated to align with', '21.', 'Table 21, Prophylactic measures for', 'corneal events associated with', 'GSK2857916', 'Section 9.2.10.3 Sub-', 'Clarification of exam requirements', 'Updated information regarding', 'Study Exams', 'confocal exams.', 'Section 9.4.2 ECOG', 'Timepoints updated to perform to align', 'Clarification to align with', 'Performance Status', 'with Section 2, Schedule of Activities', 'Section 2.', 'Section 9.4.4', 'Triplicate ECG measurements changed', 'Allows time for EOI PK sample', '141']"
141,page_142,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Electrocardiogram', 'to 2 minutes apart', 'collection', 'Section 10.2 Sample', 'Update the type-1 error and power due', ""To address EMA's comments"", 'Size Determination', 'to the change in boundary for claiming', 'on maintaining overall type-1', 'efficacy at final ORR analysis.', 'error (1-sided 2.5%) adjusting', 'for multiplicity (two dose arms),', 'the boundary for claiming', 'efficacy at final ORR analysis', 'was modified.', 'Section 10.3 Sample', 'Update scenarios due to change in', ""To address EMA's comments"", 'Size Sensitivity', 'boundary for claiming efficacy at final', 'on maintaining overall type-1', 'ORR analysis.', 'error (1-sided 2.5%) adjusting', 'for multiplicity (two dose arms),', 'the boundary for claiming', 'efficacy at final ORR analysis', 'was modified.', 'Section 10.4', 'Provide reference for detailed definition', 'To ensure consistency with', 'Populations for Analysis', 'of Evaluable Population, which will be', 'IDMC charter', 'used for ORR analysis at interim', 'Section 10.5.1 Efficacy', 'Update language regarding ORR', 'Clarify that the ORR analysis at', 'Analyses', '(confirmed VS. unconfirmed) at interim', 'interim should be based on', 'analysis.', 'confirmed response if available.', 'Section 10.5.2 Safety', 'Addition of summarizing corneal events', 'To clarify that AESI of corneal', 'Analysis', 'using GSK Scale for corneal events', 'events will also be summarized', 'Table 18', 'using the GSK Scale for corneal', 'events.', 'Section', 'Creation of subsections in Section', 'For clarity', '10.5.4. 1Pharmacokinetic', '10.5.4 to separate pharmacokinetic', 'Added noncompartmental', 'Data Analyses', 'and statistical analyses', 'analysis based on revised PK', 'Addition of non-compartmental', 'sampling schedule', 'analysis, data permitting', 'Section 10.5.4.2', 'Creation of subsections in Section', 'For clarity', 'Statistical Analysis of', '10.5.4 to separate pharmacokinetic', 'Pharmacokinetic Data', 'and statistical analyses', 'Section 10.5.9 Interim', 'Modify boundary of claiming efficacy at', ""To address EMA's comments"", 'Analyses', 'final ORR analysis, and associated', 'on maintaining overall type-1', 'operating characteristics.', 'error (1-sided 2.5%) adjusting', 'for multiplicity (two dose arms),', 'the boundary for claiming', '142']"
142,page_143,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'efficacy at final ORR analysis', 'was modified.', 'Section 11 References', 'GSK2857916 IB version updated from', 'Updated to include most recent', '03 to 05', 'version of IB', 'Section 12.5', 'New template language added to', 'Clarifies notification needed ""for', 'Contraception Guidance', 'elective termination description', 'medical reasons""', 'Section 12.7 Liver', 'Removed non-applicable PK sample', 'Comparator language removed', 'Chemistry Stopping', 'statements in footnote 6', 'since monotherapy study', 'Criteria', 'Clarification', 'PK collection interval updated to 5 half-', 'Updated timeframe during', 'lives', 'which drug concentrations', 'should be measured', '12.9 Corneal Event', 'Added clarification that Grading is a', 'To align with Section 9.2', 'Severity Grading and', 'GSK Scale', 'Adverse Events and to indicate', 'Mitigation Strategy', 'the GSK Scale for corneal', 'Footnotes updates', 'Table 22', 'events is not a CTCAE scale', '12.10 Modified Diet in', 'MDRD formula for calculating the', 'Provides instruction for', 'Renal Disease (MDRD)', 'estimated glomerular filtration rate was', 'calculation of eGFR', 'Formula', 'clarified to show superscript values', 'The numbers in the Table 24 in', '12.12 Appendix 12', 'Table 24 clear version inserted', 'previous version were not', 'Modified description of simulation', 'legible.', 'studies for evaluating operating', 'characteristics', 'To clarify the objectives and', 'conduct of simulation studies', 'Throughout', 'Minor editorial and document', 'Minor, therefore have not been', 'formatting revisions', 'summarized', 'Amendment 1: 02 April 2018', 'Overall Rationale for the Amendment:', 'The protocol has been amended to address regulatory agency advice. The original single-', 'arm design with 1 dose level (3.4 mg/kg GSK2857916 Q3W) was amended to an', 'open-label, randomized, 2-arm study with 2 dose levels by including the 2.5 mg/kg Q3W', 'dose. In addition, a new exploratory cohort of 25 participants, who will receive a', 'lyophilized configuration of GSK2857916, has been added to gain clinical experience', '143']"
143,page_144,"['2017N330177_0', 'CONFIDENTIAL', '205678', 'with the lyophilized configuration. To accommodate these main changes, the overall', 'sample size and related analytical methods have been changed.', 'DOCUMENT HISTORY', 'Document', 'Date of Issue', 'Amendment 3', '17-Dec-2018', 'Amendment 2 (Republishing)', '04-Sep-2018', 'Amendment 2', '30-Aug-2018', 'Amendment 1', '02-Apr-2018', 'Original Protocol', '18-Jan-2018', '144']"
144,page_145,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Cover Page', 'Study title updated', 'Title updated to reflect the design', 'A Phase II, Open Label,', 'change (see below)', 'Randomized, Two-Arm Study to', 'Investigate the Efficacy and Safety of', 'Two Doses of the Antibody Drug', 'Conjugate GSK2857916 in', 'Participants with Multiple Myeloma', 'Who Had 3 or More Prior Lines of', 'Treatment, Are Refractory to a', 'Proteasome Inhibitor and an', 'Immunomodulatory Agent and Have', 'Failed an Anti-CD38 Antibody', '(DREAMM 2).', 'Synopsis', 'Changed text of Synopsis to reflect', 'See below for all significant', 'changes to the text of the protocol', 'changes', 'All sections', 'Replaced the word ""patient\' with', '""participant\' and \'subset\' replaced', 'with ""sub-study\'.', 'New references added', 'Section 2 Schedule of', 'Separate schedule tables for', 'The tables have been separated', 'Activities', 'Screening assessments, on study', 'to clarify activities.', ""assessment, 'end of treatment"", 'assessment and follow-up', 'assessment have been included.', 'Deletion of coagulation criteria (INR)', 'Current liver event management', 'for determining adequate organ', 'guidelines do not require INR.', 'system function', 'Flow cytometry is not used in', 'Removal of aspirate for flow', 'IMWG Kumar, 2016.', 'cytometry', 'Based on Kumar, 2016.', 'Added PET/CT to confirm CR, sCR', 'Germany: approval by the', 'German Federal Office for', 'Radiation Protection is required', 'German exceptions to PET/CT', 'prior to PET/CT or other x-rays', 'can be performed.', '145']"
145,page_146,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 3.1 Study', 'Ongoing FTIH study number has', 'Editorial changes', 'Rationale', 'been changed from BMA117158 to', 'BMA117159', 'Section 3.4.2 Corneal', 'Additional information regarding', 'Events', 'corneal toxicity included', 'Included new section', 'To support the additional arm', 'Section 3.4.3', 'Pharmacokinetics', '""Pharmacokinetics; with section', 'that includes dose level 2.5mg/kg', 'number 3.4.3', 'Updated to reflect the change in', 'Section 3.5.3 Overall', 'Overall Benefit-Risk conclusions is', 'study design.', 'Benefit- Risk', 'Conclusions', 'updated to reflect the additional', 'dose.', 'Section 4 Objectives', 'Primary objective has been modified:', 'Updated to reflect the change in', 'and Endpoints,', 'to evaluate the clinical efficacy of 2', 'study design.', 'Primary Objective', 'doses of GSK2857916 in', 'participants with relapsed/refractory', 'multiple myeloma by overall', 'response rate', 'To gain clinical experience with', 'Exploratory Objective', 'the lyophilized configuration.', 'New exploratory endpoint has been', 'included: To assess the safety,', 'efficacy, immunogenicity, and', 'pharmacokinetics of GSK2857916 in', 'a lyophilized configuration (n=25)', 'Number increased to reflect the', 'additional arm and increased', 'Ocular Sub-Study', 'Objective', 'study sample size.', 'Number of participants to evaluate', 'the effect of topical corticosteroids', 'on corneal findings has been', 'increased to 30 (15 in each dose', 'arm).', 'Section 5 Study', 'Study design description and the', 'Language and the schema', 'Design', 'Study Schema revised.', 'modified to clarify changes in', 'study design have been added,', 'including the addition of a second', 'Efficacy and safety results from the', 'arm, change to the total number', 'interim analysis will not be shared', 'of participants, IA to assess', 'with investigators or other study/site', 'futility, IDMC to review IA results,', 'personnel', 'and an additional cohort of', 'participants (n=25) who will', 'receive the lyophilized', 'configuration.', '146']"
146,page_147,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 5.2 Number of', 'Number of participants to be', 'Study design has changed from 1', 'Participants', 'screened has been changed from', 'arm to 2 arms, thus the sample', '100 to 170, to be enrolled changed', 'size is increased. Ocular sub-', 'from 90 to 155 and number of', 'study sample size is increased', 'recruitment centers changed from 30', 'for same reason.', 'to 60 investigational sites. Number of', 'participants in the ocular sub-study', 'increased to 30', 'Section 5.3 Participant', 'Definition of the study-completed', 'Language to offer participants', 'and Study Completion', 'participant has been modified', 'this option was inadvertently', 'omitted.', 'New criteria have been added: If a', 'participant remains on treatment at', 'the time end of study is achieved,', 'they will be offered an option to', 'extend treatment on this or another', 'protocol.', 'Section 5.4: Scientific', 'Scientific rationale and dose', 'Scientific rationale and dose', 'Rationale of Study', 'justification sections are updated.', 'justification updated to address', 'Design', 'new design and additional dose', 'level.', 'Section 5.5: Dose', 'Justification', 'Section 6.2 Exclusion', 'Deletion of exclusion criterion #3', '#3 Per regulatory agency', 'Criteria', 'regarding best corrected visual', 'suggestion, the criterion related', 'acuity', 'to visual acuity limitations', 'New #2 Exclusion criteria for', 'deleted. Requirement for', 'symptomatic amyloidosis, active', 'preexisting conditions has been', '""polyneuropathy, organomegaly,', 'revised according to feedback for', 'endocrinopathy, myeloma protein,', 'regulatory agencies.', ""and skin changes' (POEMS)"", 'New # 2 Included to avoid', 'syndrome, active plasma cell', 'unpredictable toxicity.', 'leukemia at the time of screening', 'and Prior allogeneic stem cell', 'transplant has been added.', 'Section 7 Treatments', 'Table listing the study treatments.', 'To provide details of how the', 'lower dosage form and the', 'lyophilized form are supplied to', 'the sites.', '147']"
147,page_148,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 7.2.2 Dose', 'Permitted dose reductions have', 'Dose reductions updated per', 'Reductions for Toxicity', 'been included. Table 10 updated.', 'design change to 2 dose levels.', 'Table 10', 'Section 7.2.2 Dose', 'Modified grading of corneal events', 'As the AE grading scale is now', 'Reductions for Toxicity', 'by deleting the presence of', 'based on corneal clinical', 'Table 13', 'asymptomatic corneal findings on', 'symptoms and visual acuity, this', 'ophthalmic exam not observed at', 'situation (asymptomatic findings)', 'baseline (grade 1)', 'is no longer applicable as all', 'findings will be considered AEs.', 'Changes made due to regulatory', 'agency recommendations.', 'Editorial changes to clarify that', 'artificial tears are to be increased', 'for other AE grades.', 'Modified management of corneal', 'events, i.e. dosage of preservative', 'free artificial tears has been', 'Editorial changes to reflect prior', 'increased for G4 corneal events.', 'allogenic transplants are now', ""Footnote 'C' regarding patients with"", 'excluded, thus footnote is', 'prior allogenic transplant with', 'unnecessary.', 'corneal toxicity has been deleted:', 'Section 7.3 Method of', 'Section 7.3 updated for', '7.3 changes address', 'Treatment Assignment', 'randomization and stratification', 'randomizing to 2 arms.', 'information for treatment', 'assignment.', 'Section 8.1', 'Deletion of language that allowed', 'Decision made to treat all', 'Discontinuation of', 'participants who have achieved CR', 'patients until PD', 'Study Treatment', 'to discontinue treatment.', 'Section 8.2.5 Corneal', 'Management guidelines for corneal', 'Guidelines updated according to', 'Supportive Care', 'events updated.', 'feedback from regulatory agency.', 'Guidelines', 'Section 8.2.6', 'Language added to reference Table', 'Added to reinforce the actions', '11', 'based on a Grade 4 IRR.', '148']"
148,page_149,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 9 Study', 'Baseline demographic assessment', 'Editorial updates: demographics', 'Assessments and', 'and medical family history', 'and medical history were added.', 'Procedures', 'assessment included', 'Section 9.2 Adverse', 'General language corrections made', 'Events', 'for clarity.', 'Adverse event coding by MedDRA', 'and grading by NCI-CTCAE included', 'Section 9.1 Efficacy', 'IgG, IgM and IgA assessments and', 'To provide additional clarification', 'Assessment', 'additional bone marrow testing', 'included', 'Section 9.2.10 Ocular', 'The language in the Ocular Sub-', 'Language modified to clarify the', 'Sub-Study', 'Study Examinations section has', 'required examinations and', 'Examination', 'been updated for increased clarity', 'palliative treatment for', 'The language in Ocular Sub-study', 'participants in this cohort.', 'Recommendations from', 'examinations now modified to', 'remove confrontation of visual fields,', 'independent corneal experts.', 'evaluation of optic nerve and retina.', 'Tear film examination, anterior', 'segment photography, and', 'pachymetry were added. Fundus', 'and anterior segment photography', 'are now included at baseline, end of', 'study, and last follow-up visit.', '9.2.10.1 Monocular', 'Registration into RAMOS after', 'The section for monocular', 'Prophylaxis', 'assessment completion deleted.', 'prophylaxis has been updated to', 'Additional information and schematic', '9.2.10.2 Monocular', 'clarify the treatment.', 'Treatment', 'for prophylactic eye drops included.', '9.2.10.3 Sub-Study', 'Exams', '9.2.9 (old)', 'The section on assessment of', 'Removed as this information is', 'sentinel events deleted.', 'specific to a GSK process rather', 'than something the sites must', 'do. This will be captured in the', 'SRM.', '149']"
149,page_150,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 9', 'Total carbon dioxide replaced with', 'Editorial changes to reflect the', 'bicarbonate', 'Table 14 List of', 'correct parameter', 'Clinical Laboratory', 'Bone marrow to confirm stringent', 'Tests', 'complete response by flow cytometry', 'Editorial changes to reflect IMWG', 'deleted and an additional footnote', 'criteria 2016.', 'included', '9.9.1 sBCMA Sample', 'Specific assay used for sample', 'Analysis', 'collection, i.e.', 'electrochemiluminescent', 'immunoassay deleted', '9.10 Evaluation of', 'Testing for evaluation of anti-cancer', 'Clarification to state this should', 'Anti-Cancer Activity', 'activity at 6 months included', 'be performed at the 6-month', 'timepoint.', 'Section 10.1', 'The sample size and hypothesis', 'Section updated to reflect revised', 'Hypothesis Testing', 'testing is updated to reflect a 2-arm', 'design and operating', 'study. Updated enrollment duration', 'characteristics based on', 'and number of evaluable participants', 'interactions with regulatory', 'for interim analysis.', 'agency.', 'Section 10.2 Sample', 'Included information on independent', 'Section updated to reflect revised', 'Size Determination', 'cohort for lyophilized configuration.', 'design and operating', 'characteristics based on', 'interactions with regulatory', 'agency.', 'Section 10.3 Sample', 'Updated IA futility stopping rules', 'Section updated to reflect revised', 'Size Sensitivity', 'design and operating', 'characteristics based on', 'Section 10.5.9.1', 'Futility Stopping Rule', 'interactions with regulatory', 'based on Group', 'agency.', 'Sequential Design', 'Section 10.4', 'Safety population has been replaced', 'Population for Analysis', 'with ITT population as a primary', 'Section 10.5.1 Efficacy', 'population of analysis of efficacy', 'Analysis', 'data and safety population updated', 'to be used for analysis of clinical', 'safety data', '150']"
150,page_151,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 10.5.1 Efficacy', 'Updated statistical analysis methods', 'Analysis', 'for efficacy endpoints', 'Section 10.5.9.2', 'New section heading ""Additional', 'Clarification of the posterior', 'Comparative Futility Stopping Rule', 'probability calculations are added', 'Based on Bayesian Approach""', 'added', 'Section 12.4 Adverse', 'AE reporting corrected.', 'Reporting based on CT-CAE', 'Events: Definition and', 'grading.', 'Procedures for', 'Recording, Evaluating,', 'Follow-up and', 'Reporting', 'Section 12.7.1.2', 'Additional relevant references', 'References', 'included', 'Section 12.8', 'Appendix 8 deleted', 'IMWG response criteria are', 'referenced directly. Further', 'interpretation is not needed.', '12.10 Corneal Event', 'Table 21, Table 22 and Table 23', 'Reporting based on CT-CAE', 'Severity Grading and', 'updated', 'grading.', 'Mitigation Strategy', 'Table 22 (Corneal events AE', 'grading scale) is now based on', 'best corrected visual acuity.', '151']"
151,page_152,"['2017N330177_04', 'CONFIDENTIAL', '205678', '12.12.', 'Appendix 12: Statistical Considerations for Section 10.5.9.2', 'Additional Comparative Futility Stopping Rule Based on', 'Bayesian Approach', 'Introduction', 'This document provides details about the additional comparative futility stopping rule', 'based on the Bayesian approach at interim analysis (IA) for Study 205678.', 'As described in Section 10.5.9.2, the additional comparative rule based on the Bayesian', 'approach will be used to further facilitate the decision of early stopping for futility. The', 'arm deemed inferior to the other will be dropped. In practice, if both arms pass the', 'futility boundaries based on group sequential design described above, posterior', 'probability of observing a better RR in one arm relative to the other will be calculated. If', 'such a probability is at least 90%, then the treatment arm with lower RR will be dropped', 'due to lack of efficacy. To calculate the posterior probability, a non-informative beta', 'prior (0.025,0.1) will be used for each arm.', 'Statistical Modeling', 'In the Bayesian approach,', 'let P1 denote the response rate for arm 1; m1 and X1 denote the number of participants and', 'number of responders at IA for arm 1;', 'let P2 denote the response rate for arm 2; m2 and X2 denote the number of participants and', 'number of responders at IA for arm 2;', 'We assume P1 and P2 are independent.', 'We assume the prior distributions of response rates TLy (P1) and follow a', 'beta', 'distribution beta (a,B). The beta distribution represents the prior knowledge or belief', 'R', 'about the efficacy of the new drug. The quantity reflects the prior mean response', 'rate, while the quantity a + B reflects the amount of information contained in the prior.', 'The larger value of a +B, the stronger belief the prior has. In both simulations and actual', 'IA, a non-informative beta prior (0.025,0.1) will be used for each arm.', 'We assume', 'X1/m1.P1 vbinomial (m1,P1) and X2/m2,P2', 'Consequently, the posterior distributions of the response rates P1 and P2 follow beta', 'distributions:', 'P1|x/~beta(a+ X1, B+ m1 - - X1), P2|x2~beta(a+ X2, B+ m2-x2. P1/x1 and P2/x2 are also', 'independent.', 'The comparative futility stopping rules are defined as:', '152']"
152,page_153,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'If the posterior probability P (P1 > P2/X1, X2) > 97.5%, then arm 2 is considered inferior to', 'arm 1 and will stop for futility.', 'If the posterior probability P (P2 > P1|x1, x2) > 97.5% P(P2 > P1/x1,x2) A 90%, then', 'arm 1 is considered inferior to arm 2 and will stop for futility.', '- = *', 'Following the methods of [Dmitrienko, 2006], the posterior probabilities P (P1 >', 'P2/X1,X2) and P (P2>P1/X1,X2) will be computed as', '1', 'Where and are the cumulative distribution functions of B and', 'B', '(2,B2) distributions, respectively. The integral on the right-hand side of this equation', 'was computed using the integrate function in R.', 'Determination of the Cutoff for Posterior Probabilities.', 'The cutoff for posterior probabilities was chosen as 97.5%, to allow for dropping an arm', 'with substantially inferior response rates (e.g absolute difference > 28%). The posterior', 'probabilities of (Arm 1 Response Rate > Arm 2 Response Rate) for all possible scenarios', 'of the comparative rule at IA are shown in Table 24.', 'Table 24', 'Posterior Probabilities of (Arm 1 Response Rate > Arm 2 Response', 'Rate) at Interim Analyses', 'Posterior Probabilities of', 'Arm 1. Number al Responders at IA Resporase Rates)', '(Arm Arm 2 IRR)', '5', '6', '7', 'a', ',', '10', '11', '12', '13', 'H', '15', 'M', '17', '10', '13', '20', '21', '22', '23', '24', '25', '(2062)', '124%)', '(40%)', '144%)', '(48%)', '15251', '(72%)', '18491', '19251', '(100%)', '5', '50.Ch', '63.8x', '75.3b', '30.350', '34.45', '57.05', '100.00', '100.0', '100.0', '100.06', '100.00', '1001', '1001', '100.0', '6 (245)', '362b', '50.0x', '63.0b', '33.7%', '3658', '33.30', '100.00', '100', '100.00', '100.00', '100.00', '100.0', '24.7%', '37.0N', '50.00.', '62.4%', '7325', '68.68', '5625', '50.00', '33.3', '100.00', '100.00', '100.08', '100.0N', '100.000', '100.05', '100.0x', '132x0', '25.36', '37.600', '50.000', '62:050', '72.6x', '00.00', '36.00', '23.00', '33.600', '33.85', '33.20', '100.00', '100.00', '100.00', '100.00', '100.0', '100.0', '50.05', '6175', '33.6', '33 8', '100.00', '100.00', '100.00', '1000', 'sex', '10.7%', '27.4%', '38.350', '61500', '60.7%', '52.500', '57%', '100.00', '100.00', '100.00', '100.06', '100.0', '1(44x)', '30x', '6.3%', '27.0%', '30.550', '50.000', '6130', '67.00', '52.60', '33.7%', '100.05', '100.00', '100.05', '100.0', '12 (480)', '150', '35x', '68b', '11.9m;', '38.75', '50.00', '6136', '80.7%', '36.2%', '102', '33.3%', '33.72', '33.3', '100.00', '100.00', '1001', '(52x)', '0.T%', '18x', '7.2x', '12.30', '282x', '50.00', '613', '7130', '88.0x', '33.2x', '100.00', '100.00', '100.0', 'Arm 2. Number el', '(5800)', '0.30', '0.30', '4.000', '7.4%', '12.45', '20.250', '38.7%', '50.000', '61500', '72.60', '80.EX', '53.7%', '20.75', '33.65', '33.50', '100.05', '100.0', 'Responders - IA', '(60%)', '10h', '7.55', '38.50', '50.0%', '6175', '82.0%', '33.5', '13.8', '100.00', '1000', 'Response Ratea)', '(64x)', 'D.TA', '0.2b:', '0.4b', '10m', '4.TN', '7.40', '38.30', '73.2x', '30.20', '952x', '38.0', '93.50', '100.0', '(68x)', '0.0%', '0.250', '0.4%', '1080', '4.080', '7.2%', '12:08:', '10.7%', '27.400', '50.000', '62.4%', '74.00', '04.00', '50.05', '(72x)', '0.0x', '02%', '040', '100', '200', '11,4%', '10.00', '26.8x', '50.0x', '7522', '33.0x', '100.0', '(76x)', '00x', '00N', 'OTN', '02%', '0.40', '18%', '35%', '6.30', '10.7%', '17.2%', '37.tv', '50.00', '63.76', '76.7x', '87.5%', '54.50', '38.8%', '100.0r', 'DOV', '0.00', 'D.OB', '0.00', 'D.B.', '0.30', '0.7%', '168.', '560', '9.8%', '2480', '36.38', '50.00', '64.80', '70.3%', '50.380', '97.3%', 'BON', '00%', '0.0%', '286', 'MSX', '3528', '59.0%', '65.xx', 'ne', '22', '00x', '00x', '000', '02x', '0.4%', '030', '138', '7.0%', '12.5x', '50.0x', '692x', '87.8%', 'DON', '0.0N', '0.08', '0.00', '0.00', 'ore', '020', '0.SM', '12%', '2.NM', '30.8N', '50.00', '74.8M', '24 (36x)', '000', '0.0x', '0.00', '0.00', '0.00', '000', '0.00', 'DOC', '020', '12x', '17x', '530', '12,4X', '254x', '5000', '34.20', '25 (1000)', '00x', '0.0ng', '0.0x', '0.0%', '0.t%', '02%', '08x', '176', 'Sax', 'Note: For both Arm 1 and Arm 2, the IA sample sizes are assumed to be 25. The green cells represent scenarios with', 'posterior probabilities greater than 97.5%.', '153']"
153,page_154,"['2017N330177_04', 'CONFIDENTIAL', '205678', 'Evaluating Probabilities of Stopping for Futility Using Simulations', 'Simulation studies are conducted to evaluate probabilities of stopping for futility at the', 'interim and claiming efficacy at final using both futility rules (group sequential design', 'and Bayesian approach). Scenarios of simulation studies tested are listed in Table 25.', 'Table 25', 'Scenarios of Simulation Studies to Evaluate Probabilities of', 'Stopping for Futility', 'Response Rate', 'Scenarios', 'Arm 1', 'Arm 2', '1', '33%', '60%', '2', '33%', '45%', '3', '33%', '33%', '4', '33%', '25%', '5', '33%', '20%', '6', '33%', '15%', '7', '33%', '10%', '8', '15%', '15%', 'For each scenario, K=10,000,000 trials are simulated based on the assumed response', 'rates (RR) for each arm (assuming number of responders for both arms follow binomial', 'distribution). IA and final sample sizes are fixed as 25 and 65, respectively. For each', 'simulate trial, the posterior probabilities P(P1 >P2/x1,x2 and P(P2 y P1 *1 *2', ')', 'are', 'compute as specified above. For each simulated trial, both futility rules will be used to', 'determine whether the trial should stop for futility at IA or claim efficacy at final. Such', 'probabilities will be computed based on (=10,000,000 simulated trials. The simulation', 'results are summarized in Table 20 in Section 10.5.9.2.', 'References', 'Dmitrienko A, Wang MD. Bayesian predictive approach to interim monitoring in clinical', 'trials. Statistics in Medicine. 2006 July 5;25(13):2178-2195.', '154']"
